Selective aryl hydrocarbon receptor modulators (sahrms) and methods of using thereof to treat disease

Selective aryl hydrocarbon receptor modulators (SAhRMs) like Compound 101 address the challenge of unpredictable AhR activation effects by selectively modulating AhR activity in specific cells, effectively treating diseases such as PAH and kidney disease with reduced side effects.

WO2026236562A2PCT designated stage Publication Date: 2026-11-12VASCULONICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027195
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing treatments for diseases associated with aryl hydrocarbon receptor (AhR) activation, such as cancer, fibrosis, and chronic kidney disease, lack selectivity and predictability, leading to unpredictable effects on inflammatory and fibrotic mechanisms depending on cell type and signaling context.

Method used

Development of selective aryl hydrocarbon receptor modulators (SAhRMs), like Compound 101, that selectively modulate AhR activity in specific cell types, reducing profibrotic gene expression and oxidative stress, and administering these compounds to treat conditions like pulmonary arterial hypertension and kidney disease.

Benefits of technology

SAhRMs like Compound 101 provide targeted treatment by inhibiting AhR activity in lung and kidney cells while stimulating it in liver cells, reducing disease progression in animal models of PAH and kidney disease with a superior safety profile compared to non-selective antagonists.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000005_0001
    Figure IMGF000005_0001
  • Figure IMGF000005_0002
    Figure IMGF000005_0002
  • Figure IMGF000006_0001
    Figure IMGF000006_0001
Patent Text Reader

Abstract

Disclosed are compounds that can modulate aryl hydrocarbon receptor (AhR) activity in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to reduce AhR pathway gene expression and / or treat a variety of diseases and disorders including cancer, autoimmune diseases and disorders, obesity, fibrosis, oxidative stress, and the progression of kidney disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No. 10877-004W01

[0002] Selective Aryl Hydrocarbon Receptor Modulators (SAhRMs) and Methods of Using Thereof to Treat Disease

[0003] CROSS REFERENCE TO RELATED APPLICATIONS

[0004] This application claims benefit of priority of U. S. Provisional Application No. 63 / 801, 429, filed May 7, 2025, which is hereby incorporated herein by reference in its entirety.

[0005] BACKGROUND

[0006] Aryl hydrocarbon receptor (AhR) plays a critical role in normal homeostasis and pathology of several diseases. AhR is activated by endogenous or exogenous ligands. Upon binding to the AhR ligand, the inactive AhR receptor in association with hsp90, AIP / XAP2 and p23 undergoes nuclear translocation. AhR forms heterodimer complex with the nuclear translocator (ARNT) and interacts with DNA at the xenobiotic consensus response elements (XRE). Depending upon the nature of the nuclear co-transcription factors this interaction leads to the activation or repression of a wide range of gene expression. In addition to this canonical pathway, a non -canonical signaling pathway of AhR involves interaction with several other transcription factors, binding to non-consensus XRE and modulation of different genes.

[0007] AhR plays a critical role in immune modulation, particularly in immune suppression in cancer. High levels of AhR ligands such as kynurenine are produced in several types of cancers which activate AHR. Activated AhR can produce an immunosuppressive effect on cytotoxic CD8+ T cells, regulatory T cells, and upregulating program death (PD-1) expression. Cancer cells escape immune surveillance by activating these immune suppressive pathways within the tumor microenvironment.

[0008] Persistent or overactivation of AhR pathway can also lead to inflammation, fibrosis and oxidative stress in tissues. For example, in the lung, AhR induces pro-inflammatory factors and fibrosis by epithelial-mesenchymal transition of pulmonary epithelial cells through the Wnt / 0-catenin signaling pathway. Other studies have shown that AhR mediates fibrosis via the TGF- P1 / SMAD3) and Wnt / p-catenin pathway.Attorney Docket No. 10877-004W01

[0009] Excessive AhR activation also mediates the generation of reactive oxygen species (ROS) which contribute to organ damage and disease progression. For example, uremic toxins such as indoxyl sulfate (IS) and indole-3-acetic acid (IAA), which are AhR agonists induce endothelial dysfunction, ROS, inflammation and promote chronic kidney disease (CKD) and cardiovascular complications associated with CKD.

[0010] AhR can be modulated by its ligands in a tissue and context dependent manner, and the ligand can act as Selective Aryl hydrocarbon Receptor Modulators (SAhRM). The selectivity of action of SAhRM may be imparted by the recruitment of different coach vator(s) following binding of structurally different agonists and antagonists. Interaction of different AhR ligands can also lead to the activation of canonical and non-canonical signaling pathways. Depending upon the ligand, different cellular responses can be produced. Thus, the nature of the ligand is important to achieve selective response. For example, in liver disease models, AhR activation acts as antifrbrotic. Similarly, AhR activation with an agonist was found cardioprotective in mice, preventing cardiac hypertrophy and reducing the expression of pro-fibrotic genes. Whereas other studies have shown that AhR plays a profibrotic and proinflammatory role and therefore inhibition of AhR is beneficial. Similarly, AhR and its ligands may act as a suppressor or a promoter of tumors. Thus, identification of selective modulators of the signaling pathway and the resulting physiological outcome are critical for targeting AhR for the development of therapeutics.

[0011] / AhR activity is linked to several diseases. In some cases, the presence of high levels of endogenous or exogenous ligands can activate AhR and contribute to disease. For example, high level of AhR is expressed in breast, pancreatic, gliuobalstoma, lung, colon, glioma and other cancers. Blocking AHR is a promising approach to cancer immunotherapy.

[0012] By modulating inflammation, ROS and fibrosis, AhR pathway plays role in the pathogenesis of chronic diseases including cardiovascular diseases, chronic kidney disease, diabetic kidney disease, lung disease, pulmonary arterial hypertension (PAH), pulmonary fibrosis, atopic dermatitis, sarcopenia, metabolic dysfunction, obesity, liver fibrosis and neurological diseases.

[0013] AhR is a critical driver of inflammation and fibrosis and the pathogenesis of PAH in humans and preclinical models. Inhibition of AhR activity may provide a new approach to develop disease modifying therapy for PAH. However, it is important to note that the effectAttorney Docket No. 10877-004W01

[0014] of AhR ligands on inflammatory and fibrosis mechanisms is not predictable and may depend on the cell type and the signaling context. For example, AhR activation induces pro- inflammatory factors and fibrosis by epithelial-mesenchymal transition of pulmonary epithelial cells through the Wnt / p-catenin signaling pathway and apoptosis via the NF-KB pathway. Other studies have shown that AhR activation inhibits fibrosis in the liver and the heart.

[0015] AhR activation plays an important pathological role in various forms of kidney diseases including, diabetic kidney disease, IgA nephropathy and membranous nephropathy. The treatment options for various forms of kidney diseases such as in MN, IgA nephropathy, DKD and various stages of CKD are limited because of different underlying patholo gi cal mechanisms.

[0016] In addition, AHR has been implicated in inflammation and pro-fibrotic processes in multiple tissues, such as liver, dermis, and vascular structures. Thus, compounds modulating AhR pathway may have use in treatment of inflammatory and fibrotic disease including CKD, PAH, COPD, pulmonary fibrosis, obstructive sleep apnea, heart failure, age related fibrosis, skin disease atopic dermatitis, psoriasis, inflammatory bowel disease, and systemic sclerosis an autoimmune disease involving fibrosis in several organs for which there is no effective treatment. AHR agonists also inhibited osteoclastogenesis and bone destruction.

[0017] Through its effect on vascular function, inflammation, generation of reactive oxygen species (ROS), mitochondrial function and smooth muscle cell proliferation, AhR plays an important role in the progression of atherosclerosis, metabolic diseases, including obesity, sarcopenia and fatty liver disease. AhR also plays multiple roles in the brain and in acute ischemic brain injury (stroke) Alzheimer’s, Parkinson’s, traumatic brain injury among others.

[0018] Compounds that have the ability to modulate AhR activity have significant potential as new therapeutic agents to treat these and other disorders.

[0019] SUMMARY

[0020] Described herein are compounds that produce cell and tissue selective modulation of AhR activity. The compounds described herein were unexpectedly found to exhibit cell-selective AhR activity. By way of example, Compound 101 (also referred to as CompoundAttorney Docket No. 10877-004W01

[0021] 101 ) and other compounds described herein were found to inhibit AhR activity in lung cells and kidney cells while stimulating AhR activity in liver cells.

[0022] Unexpectedly, Compound 101 and related compounds were also shown to increase DDAH expression. The DDAH enzyme plays a clinically important role in metabolizing and clearing symmetric dimethyl arginine (ADM A). Tills activity was different as compared to the known AhR inhihbtors such as CH-233191 compound.

[0023] The dual activity of Compound 101 in both Selective Aryl hydrocarbon Receptor Modulation (SAhRM) and ADMA lowering can collectively impact broader disease mechanisms of lung vascular remodeling, mitochondrial energy metabolism, inflammation and fibrosis. As described herein, Compound 101 reduced disease progression in animal models of PAH, kidney disease as well as a model of cardiac fibrosis. The SAhRM activity of Compound 101 can also provide a superior safety profile as compared to, for example, non-selective AhR antagonists. As such, the compounds described herein, including Compound 101, can function as SAhRMs, reducing cellular responses that play role in pathophysiology of in PAH including pulmonary arterial SMC proliferation, oxidative stress, inflammation, and fibrosis.

[0024] Accordingly, described herein are selective Aryl hydrocarbon Receptor Modulators (SAhRMs), including Compound 101, that can modulate AhR activity in a subject. In some embodiments, the compounds described herein can effectively reduce AhR pathway gene expression, fibrosis, oxidative stress, and the progression of PAH and kidney disease in a preclinical models.

[0025] In some embodiments, the compounds described herein can be used to modulate aryl hydrocarbon receptor (AhR) activity in a subject. In some embodiments, the compounds described herein can reduce profibrotic gene and protein expression. Accordingly, the compounds described herein can also be administered to a subject in need thereof to treat or prevent fibrosis / fibrotic conditions. By way of example, the compounds described herein can be administered to a subject in need thereof, for example, to treat obesity, to reduce inflammation and fibrosis associated with diseases such as liver and renal fibrosis, cirrhosis, pulmonary fibrosis, pulmonary arterial hypertension, scleroderma, graft vs host disease, keloids, intestinal fibrosis, Crohn’s disease, idiopathic pulmonary fibrosis, and nonalcoholic hepatic steatosis.

[0026] For example, provided herein are methods for modulating aryl hydrocarbon receptor (AhR) activity in a subject. 'These methods can comprise administering to the subject aAttorney Docket No. 10877-004W01

[0027] composition comprising a therapeutically effective amount of a compound defined by Formula I or Formula II:

[0028]

[0029] or a pharmaceutically acceptable salt or prodrug thereof, wherein

[0030] Q is selected from one of the following:

[0031]

[0032] Z is selected from -CH2-, CH2CH2, and -C(=O)-; A is, individually for each occurrence, selected from N and CH; R1is selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C i-C 4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, a 5-membered heteroaryl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxy carbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, - SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, and the 5-membered heteroaryl ring are each optionally substituted with from 1 to 4 RAgroups, or R1and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R2is selected from halogen, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkoxy, -P(=())R7R'S, and -L-RB, wherein the C1-C4 alkoxy group is optionally substituted with from 1 to 4 RAgroups, or wherein R and R4, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R3is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R3and Rbare independently selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R5and together with the atoms toAttorney Docket No. 10877-004W01

[0033] which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups, or R3is selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R6and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R7and Rsare independently C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R' is C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and Rsand R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8; L is a bivalent linking group comprising from 2 to 10 atoms; RBis selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, Ci- C4 alkylsulfonyl, a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, - S(=())(=NR5)R7, -NH-S(=O)(=NR’)R7, and -P(=())R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, the 5-7 membered aryl ring, the 5-7 membered heteroaryl ring, the 3-7 membered cycloalkyl ring, and the 3-7 membered heterocycloalkyl ring are each optionally substituted with from 1 to 4 RAgroups; n is an integer from 0 to 4; and m is an integer from 0 to 4.

[0034]

[0035] In some embodiments, A is, in each occurrence, CH.

[0036] In some embodiments, R2is a halogen, such as fluoro.

[0037] In some embodiments, R2is hydroxyl.

[0038] In some embodiments, R is one of the followingAttorney Docket No. 10877-004W01

[0039]

[0040] In certain embodiments, R2is one of the following

[0041]

[0042] In some embodiments, R2is -P(=O)R7R8.

[0043] In some embodiments, m is 0. In other embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

[0044] In some embodiments, n is 0.Attorney Docket No. 10877-004W01

[0045] In some embodiments, R1is a cyano group.

[0046] In other embodiments, R1is -P(=O)R7R8.

[0047] In other embodiments, R1is a sulfonamide group, a methanesulfonamido group, a protected amino group, or a carbamate group.

[0048] In other embodiments, R1is a carboxy group, an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0049] In other embodiments, Rlis a C1-C4 alkoxy group substituted with a carboxy group, a sulfonamide group, a methanesulfonamido group, an amino group, a protected amino group (e.g., an alkyloxycarbonylamino group such as -NH-CO-O-tBu), an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0050] In other embodiments, R1is a tetrazole ring.

[0051] In other embodiments, R1is -O-CH2-CO2H, -CH2-NH-SO2Me), -NHSO2Me), -CH2CO2H), or carboxy.

[0052] Also provided herein are methods for modulating aryl hydrocarbon receptor (AhR) activity in a subject. These methods can comprise administering to the subject a composition comprising a therapeutically effective amount of a compound defined by¬ Formula III:

[0053]

[0054] Formula III

[0055] or a pharmaceutically acceptable salt or prodrug thereof, wherein

[0056] R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; m is an integer from 0 to 4;

[0057] Y is selected from a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, each optionally substituted with one or more substituents individually selected from RA; and

[0058] RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8.Attorney Docket No. 10877-004W01

[0059] In some embodiments, m is 0. In other embodiments, m is I and R4is C1-C4 alkyl group, such as a methyl group.

[0060] In some embodiments, Y is a phenyl ring. In certain embodiments, Y is an optionally substituted thiophenyl ring.

[0061] In some embodiments, the methods described herein can comprise a method of treating a fibrotic condition in a subject in need thereof, a method of treating obesity in a subject in need thereof, a method of treating kidney disease in a subject in need thereof, a method of treating pulmonary arterial hypertension (PAH) in a subject in need thereof, a method of treating chronic kidney disease (CKD) in a subject in in need thereof, a method of treating COPD in a subject in need thereof, a method of treating pulmonary fibrosis in a subject in in need thereof, a method of treating liver fibrosis in a subject in in need thereof, a method of treating obstructive sleep apnea in a subject in in need thereof, a method of treating heart failure in a subject in in need thereof, a method of treating skin disease, such as atopic dermatitis and / or psoriasis in a subject in in need thereof, a method of treating colitis in a subject in in need thereof, a method of treating sarcopenia and / or fatty liver disease in a subject in in need thereof, a method of treating acute stroke in a subject in in need thereof, a method of treating Alzheimer’s disease in a subject in in need thereof, a method of treating Parkinson’s disease in a subject in in need thereof, a method of treating traumatic brain injury (TBI) in a subject in in need thereof, a method of treating cancer in a subject, a method of reducing tumor progression in a subject, a method of treating an autoimmune disease in a subject, such as allergic rhinitis and Hashimoto’s thyroiditis, or a combination thereof.

[0062] Also described herein are methods of treating cancer in a subject that comprise administering to the subject a composition comprising a therapeutically effective amount of a compound defined by Formula I or Formula II:

[0063]

[0064] or a pharmaceutically acceptable salt or prodrug thereof, whereinAttorney Docket No. 10877-004W01

[0065] Q is selected from one of the following:

[0066]

[0067] Z is selected from -CH2-, -CH2CH2-, and -C(=O)-; A is, individually for each occurrence, selected from N and CH; R1is selected from halogen, cyano, hydroxyl, amino, C i-C 4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, a 5-membered heteroaryl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH- S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, and the 5-membered heteroaryl ring are each optionally substituted with from 1 to 4 RAgroups, or R1and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R2is selected from halogen, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkoxy, - P(=O)R7R'S, and -L-RB, wherein the C1-C4 alkoxy group is optionally substituted with from 1 to 4 RAgroups, or wherein R2and R4, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R3is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R3and R6are independently selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R5and R6, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups, or R5is selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R6and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R7and R8are independently C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R7is C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R8and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; RAis, independently for each occurrence, selected from halogen, cyano,Attorney Docket No, 10877-004W01

[0068] hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 di alkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8; L is a bivalent linking group comprising from 2 to 10 atoms; RBis selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, Ci- C4 alkylsulfonyl, a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, - S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, the 5-7 membered aryl ring, the 5-7 membered heteroaryl ring, the 3-7 membered cycloalkyl ring, and the 3-7 membered heterocycloalkyl ring are each optionally substituted with from 1 to 4 RAgroups; n is an integer from 0 to 4; and m is an integer from 0 to 4.

[0069] In some embodiments,

[0070]

[0071] In some embodiments, A is, in each occurrence, CH.

[0072] In some embodiments, R2is a halogen, such as fluoro.

[0073] In some embodiments, R2is hydroxyl.

[0074] In some embodiments, R2is one of the followingAttorney Docket No. 10877-004W01

[0075]

[0076] In certain embodiments, R2is one of the following

[0077]

[0078] In some embodiments, R2is -P(=O)R7R8.

[0079] In some embodiments, m is 0. In other embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

[0080] In some embodiments, n is 0.Attorney Docket No. 10877-004W01

[0081] In some embodiments, R1is a cyano group.

[0082] In other embodiments, R1is -P(=O)R7R8.

[0083] In other embodiments, R1is a sulfonamide group, a methanesulfonamido group, a protected amino group, or a carbamate group.

[0084] In other embodiments, R1is a carboxy group, an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0085] In other embodiments, Rlis a C1-C4 alkoxy group substituted with a carboxy group, a sulfonamide group, a methanesulfonamido group, an amino group, a protected amino group (e.g., an alkyloxycarbonylamino group such as -NH-CO-O-tBu), an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0086] In other embodiments, R1is a tetrazole ring.

[0087] In other embodiments, R1is -O-CH2-CO2H, -CH2-NH-SO2Me), -NHSO2Me), -CH2CO2H), or carboxy.

[0088] Also provided herein are methods of heating cancer in a subject that comprise administering to the subject a composition comprising a therapeutically effective amount of a compound defined by Formula III:

[0089]

[0090] Formula III

[0091] or a pharmaceutically acceptable salt or prodrug thereof, wherein R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; m is an integer from 0 to 4; Y is selected from a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, each optionally substituted with one or more substituents individually selected from RA; and RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxy carbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8.

[0092] In some embodiments, m is 0. In other embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group.Attorney Docket No. 10877-004W01

[0093] In some embodiments, Y is a phenyl ring. In certain embodiments, Y is an optionally substituted thiophenyl ring.

[0094] In some embodiments, these methods of treating cancer further comprise co¬ administering an additional anticancer agent to the subject. In some embodiments, the additional anticancer agent comprises a small-molecule chemotherapeutic selected from the group consisting of platinum-based compounds (e.g., cisplatin, carboplatin, oxaliplatin), taxanes (e.g., paclitaxel, docetaxel, cabazitaxel), antimetabolites (e.g., 5 -fluorouracil, capecitabine, gemcitabine, pemetrexed), and anthracyclines (e.g., doxorubicin, epirubicin). In some embodiments, the additional anticancer agent comprises a targeted-therapy agent selected from the group consisting of a tyrosine-kinase inhibitor, a PARP inhibitor, an mTOR inhibitor, a STAT inhibitor, a KRAS inhibitor, and a PI3K inhibitor. In some embodiments, the additional anticancer agent comprises an immunotherapy agent selected from the group consisting of an immune-checkpoint inhibitor (anti-PD-1, anti-PD-Ll, or anti-CTLA-4 antibody), a chimeric-antigen -receptor (CAR) T-cell therapy, a bispecific T-cell engager, an oncolytic virus, a therapeutic cancer vaccine, and a cytokine therapy. In some embodiments, the additional anticancer agent comprises a hormone-therapy agent selected from the group consisting of a selective estrogen-receptor modulator, an aromatase inhibitor, an androgen -receptor antagonist, and a gonadotropin-releasing-hormone agonist or antagonist. In some embodiments, the additional anticancer agent comprises a biologic anticancer agent selected from the group consisting of a naked monoclonal antibody, an antibody-drug conjugate, a fusion protein, a therapeutic cancer vaccine, and a cell-based therapy (e.g., CAR-T, tumor-infiltrating lymphocyte).

[0095] In some embodiments, the compound defined by Formula I, Formula II, or Formula III is administered in an effective amount to inhibit SIN3A expression, thereby reducing immune suppression by T regulatory and Thl7 cells and increasing expression of MHC-1 (HLA-1, HLA-2).

[0096] In some embodiments, the cancer is selected from brain cancer, breast cancer, colorectal cancer, esophageal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, melanoma, pancreatic, prostate and GI cancer

[0097] Also described herein are compounds defined by Formula I or Formula II:Attorney Docket No. 10877-004W01

[0098]

[0099] Formula I Formula II

[0100] or a pharmaceutically acceptable salt or prodrug thereof, wherein

[0101] Q is selected from one of the following:

[0102]

[0103] Z is selected from -CH2-, -CH2CH2-, and -C(=O)-; A is, individually for each occurrence, selected from N and CH; R1is selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, Ci - C4 alkyl sulfonyl, a 5-membered heteroaryl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C i-C 4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, - SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH- S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, and the 5- membered heteroaryl ring are each optionally substituted with from 1 to 4 RAgroups, or R1and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R2is selected from halogen, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkoxy, - P(=O)R7R8, and -L-RB, wherein the C1-C4 alkoxy group is optionally substituted with from 1 to 4 RAgroups, or wherein R2and R4, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R3is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R5and R6are independently selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R5and R6, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups, or R5is selected from hydrogen and C1-C4 alkyl,Attorney Docket No. 10877-004W01

[0104] wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R6and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R7and R8are independently C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R7is C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R8and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 di alkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8; L is a bivalent linking group comprising from 2 to 10 atoms; RBis selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, Ci- C4 alkylsulfonyl, a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, - S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, the 5-7 membered aryl ring, the 5-7 membered heteroaryl ring, the 3-7 membered cycloalkyl ring, and the 3-7 membered heterocycloalkyl ring are each optionally substituted with from 1 to 4 RAgroups; n is an integer from 0 to 4; and m is an integer from 0 to 4; with

[0105] the proviso that when R2is hydroxy, fluoro, or

[0106]

[0107] , R1is not carboxy; and with the provisio that the compound is not the following

[0108]

[0109] In some embodiments, A is CH.

[0110] In some embodiments, R2is a halogen, such as fluoro.

[0111] In other embodiments, R2is hydroxyl.Attorney Docket No. 10877-004W01

[0112] In other embodiments, R2is one of the following

[0113]

[0114] In certain embodiments, R' is one of the following

[0115]

[0116] In other embodiments, R2is -P(=O)R'R8.

[0117] In some embodiments, m is 0.

[0118] In some embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group. In some embodiments, n is 0.Attorney Docket No. 10877-004W01

[0119] In some embodiments, R1is a cyano group.

[0120] In other embodiments, R1is -P(=O)R7R8.

[0121] In other embodiments, R1is a sulfonamido group, a methanesulfonamido group, a protected amino group, or a carbamate group.

[0122] In other embodiments, R1is a carboxy group, an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0123] In other embodiments, Rlis a C1-C4 alkoxy group substituted with a carboxy group, a sulfonamido group, a methanesulfonamido group, an amino group, a protected amino group (e.g., an alkyloxycarbonylamino group such as -NH-CO-O-tBu), an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0124] In other embodiments, R1is a tetrazole ring.

[0125] In other embodiments, R1is -O-CH2-CO2H, YYR-NH-SC Me), -NHSChMe), - ( ’ 11 •( ()■ 11 A or carboxy.

[0126] Also provided herein are compounds defined by Formula III:

[0127]

[0128] Formula III

[0129] or a pharmaceutically acceptable salt or prodrug thereof, wherein R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; m is an integer from 0 to 4; Y is selected from a thiophenyl ring optionally substituted with one or more substituents individually selected from RA; and RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, Ci- C4 alkoxy, alkylsulfinyl, alkylsulfonyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodi alkylami n ocarbony 1.

[0130] In some embodiments, m is 0.

[0131] In some embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group. In some embodiments, Y is a phenyl ring. In other embodiments, Y is an optionally substituted thiophenyl ring.

[0132] In some embodiments, the compound comprises one of the following:Attorney Docket No. 10877-004W01

[0133]

[0134] Attorney Docket No. 10877-004W01

[0135]

[0136] Also provided herein are pharmaceutical compositions comprising the compounds described herein.

[0137] BRIEF DESCRIPTION OF THE DRAWINGS

[0138] Figures 1 A-1B. Compound 101 inhibited AhR activity. Figure shows the inhibition of AhR activity by Compound 101 in cells treated with the indicated concentrations in the presence of known agonist FICZ (10nM) (Figure 1A). AhR promoter activity was determined using XRE-Nanoluciferase transfected cells. Dotted line shows the values with agonist alone. All data are given as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to control. #P < 0.05, ##P < 0.01, ###P < 0.001 as compared to FICZ. Figure 1B shows inhibition of AhR agonist induced CYP1A1 gene expression by Compound 101. CYP1A1 mRNA in was determined by using RT-PCR after 24 hour treatment of cells with Compound 101 in the presence of FICZ.

[0139] Figures 2A-2B. Compound 101 is a selective modulator of AhR pathway. Figure 2 A shows the recruitment of AhR-SRC-P-gal by FICZ or Compound 101 indicating AhR agonist activity of FICZ but no agonist activity in Compound 101. Y axis indicates % maximum signal (% stimulation) generated upon treatment with an agonist. Figure 2B shows the inhibition of AhR-SRC-P-gal recruitment in the presence of 10 nM FICZ andAttorney Docket No. 10877-004W01

[0140] CH-223191 or Compound 101. The known antagonist CH-223191 but not Compound 101 inhibited FICZ induced SRC recruitment.

[0141] Figures 3A-3B. Cell selective action of Compound 101. Figure 3A shows that Compound 101 inhibited FICZ (F) induced CYP1A1 in endothelial cells whereas Compound 101 enhanced CYP1A1 expression in HepG2 cells (Figure 3B). All data are given as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to control. #P < 0.05, ##P < 0.01, ###P < 0.001 as compared to Sugen.

[0142] Figure 4. Illustration that Compound 101 but not the known AhR antagonist CH- 223191 increased DDAH expression in HPASMC. Cells 'ere treated with the compounds for 24 and DDAH-1 expression was determined by Rl’-PCR.

[0143] Figure 5. Illustration of cell selective modulating activity of the compounds described herein. The compounds inhibited activity of AhR agonist in human pulmonary artery smooth muscle cells (HPASMC) whereas the compounds stimulated in HepG2 liver cells. The activity is measured by determination of AhR pathway gene Cyplal changes upon treatment with the compounds.

[0144] Figures 6A-6B. Compound 101 inhibited proliferation and reactive oxygen species (ROS) generation in lung cells. Figure 6A shows the effect of Compound 101 on human pulmonary artery smooth muscle (HPASMC) proliferation and % cell viability (solid square). Inhibition of ROS generation (measured by using DCFDA Cellular ROS detection kit (Ex / Em 485 / 435 nm) by Compound 101 on in HPASMC in response AhR agonist FICZ( F) and FICZ plus Compound 101, (Figure 6B). All data are given as mean ± SD. *P < 0.05, **P < 0.01, *** P < 0.001 as compared to control. #P < 0.05, ##P < 0.01, #P < 0.001 as compared to FICZ.

[0145] Figures 7A-7B. Compound 101 inhibited AhR agonist induced fibrosis gene expression. Figures show' fibrosis pathway protein expression in human pulmonary artery smooth muscle cells (HPASMC) after 24 hour treatment with vehicle control (C), Compound 101 alone, luM FICZ (F) orFICZ+ Compound 101. Cell extracts were analyzed by western blotting using antibodies against CollagenlAl (Figure 7 A) and TGF-p (Figure 7B). by western blotting.

[0146] Figures 8A-8B. Compound 101 improves lung function in rat PAH disease progression model. Treatment in rat Sugen-Hypoxia (Su-Hx) model with vehicle or Compound 101 (30mg / kg bid) was initiated 3 weeks after disease onset. Measurements were made after 6 weeks of treatment. Administration of Compound 101 starting 3 weeksAttorney Docket No. 10877-004W01

[0147] after disease initiation significantly reduced systolic pulmonary pressure (sPAP, Figure 8A) and right ventricular systolic pressure (RVSP, Figure 8B). All data are given as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to control or vehicle.

[0148] Figures 9A-9B. Compound 101 promotes remodeling of lung vessels in Sugen-Hypoxia model. Histology and E& H staining show hyperplasia and occlusion of small and medium size arteries in the lung of vehicle and Compound 101 treated animals. Bar graph shows quantitative image analysis of wall thickness (Figure 9A) and % muscularized vessels (Figure 9B ). All data are given as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to sham or vehicle. All data are given as mean + SD. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to sham or vehicle.

[0149] Figure 10. Compound 101 reduced inflammation in the lung. The images show macrophage F4 / 80 immunostaining in lungs of vehicle and Compound 101 treated animals. Quantification by image analysis shows dramatic reduction in inflammatory macrophages in the lung. All data are given as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to sham or vehicle

[0150] Figure 11. Compound 101 inhibited Indoxyl sulphate activated AhR. Inhibition of AhR agonist indoxyl sulphate activity by Compound 101 in cells transfected with XRE-NanoLuc. All data are given as mean + SEM. *P < 0.05, **P < 0.01, *** P < 0.001.

[0151] Figures 12A-12C. Compound 101 Inhibited reactive oxygen species (ROS) and Fibrosis Genes in Kidney Tubular Cells The generation of reactive oxygen species (ROS) in HK-2 cells was determined after treatment with Compound 101 (20uM) for 18 hours in the presence or absence of IS (200 uM) using the DCFDA Cellular ROS detection assay kit (Figure 12A). Effect on the expression of AhR pathway gene on fibrosis genes TGF- (Figure 12B) and collagenlal (Figure 12C) and in HK-2 cells treated with Compound 101 (20 uM) in the presence or absence of agonist (A, IS (500 uM) was determined by western blotting and quantification. All data are given as mean + SEM. *P < 0.05, **P < 0.01, ***P < 0.001. #P < 0.05 as compared to control.

[0152] Figures 13: Compound 101 reduced CKD progression. Rats were fed 0.25% adenine diet for three weeks and plasma creatinine in control diet (sham) and adenine diet was determined. Rats were then divided into vehicle and Compound 101 treatment groups and continued on 0.25% adenine diet. Changes in plasma creatinine in vehicle (circle) and Compound 101 (square) treated group over 6 weeks (wkl-wk 6, Figure 1). Pre-T indicatesAttorney Docket No. 10877-004W01

[0153] levels prior to treatment. All data are given as mean + SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

[0154] Figures 14A-14C. Compound 101 reduced fibrosis in kidney and heart. At the end of six weeks, the kidneys and hearts were removed and fixed in formalin. Tissue sections from renal cortex (Figure 14A), and heart (Figure 14B) were stained with trichrome for fibrosis and fibrosis area was quantified by image analysis. All data are given as mean + SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Heart sections were stained with trichrome for fibrosis (and quantified by image analysis. All data are given as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

[0155] Figures 15A-15C. Compound 101 reduced AhR activity and inhibited fibrosis gene expression in the kidney of CKD model. Gene expression for AhR pathway gene CYP1 Al (Figure 15A), and fibrosis genes collagenlal (Figure 15B) and TGF- 0 (Figure 15C) was determined by western blotting of tissue extracts from sham, vehicle and Compound 101 treated animals. All data are given as mean + SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0156] Figures 16A-16B. Compound 101 reduced body weight in an animal model. Male (Figure 16A) and female (Figure 16B) rats were treated with 101 (75mg / kg, M) or no treatment control (®) once a day for 7 days. Body weight was determined each day.

[0157] Figure 17. Treatment with Compound 107 reduced fibrosis in mouse liver injury model. Plot shows the percent collagen (y-axis) in liver slices of sham, vehicle and Compound 107 treated groups. For CCL4 liver model, animals received intraperitoneal injection of 5 pl per gram (0.5mL / kg) of 10% CC14 solution twice weekly for 4 weeks. Treatment with Compound 107 was initiated on Day 0 by oral administration twice a day. After 4 weeks liver was perfused with ice-cold PBS, harvested and dissected for homogenization to quantify hydroxyproline and collagen content. A third part of the liver was fixed with 10% neutral buffered formalin, embedded in paraffin, sliced at 5 pm thickness, mounted, stained with Hematoxylin and Eosin (H& E). Another two slices per liver sample will be stained with Sirius Red for collagen quantification and Ishak Scale.

[0158] DETAILED DESCRIPTION

[0159] The compounds, compositions, and methods described herein may be understood more readily by reference to the following detailed description of specific aspects of the disclosed subject matter and the Examples included therein.Attorney Docket No. 10877-004W01

[0160] Before the present compounds, compositions, and methods are disclosed and described, it is to be understood that the aspects described below are not limited to specific synthetic methods or specific reagents, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting.

[0161] Also, throughout this specification, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which the disclosed matter pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

[0162] General Definitions

[0163] In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings.

[0164] Throughout the description and claims of this specification the word “comprise” and other forms of the word, such as “comprising” and “comprises,” means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps.

[0165] As used in the description and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a composition” includes mixtures of two or more such compositions, reference to “an agent” includes mixtures of two or more such agents, reference to “the component” includes mixtures of two or more such components, and the like.

[0166] “Optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0167] Ranges can be expressed herein as from “about” one particular value, and / or to “about” another particular value. By “about” is meant within 5% of the value, e.g., within 4, 3, 2, or 1% of the value. When such a range is expressed, another aspect includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints ofAttorney Docket No. 10877-004W01

[0168] each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

[0169] It is understood that throughout this specification the identifiers “first” and “second” are used solely to aid in distinguishing the various components and steps of the disclosed subject matter. The identifiers “first” and “second” are not intended to imply any particular order, amount, preference, or importance to the components or steps modified by these terms.

[0170] As used herein, by a “subject” is meant an individual. Thus, the “subject” can include domesticated animals e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.), and birds. “Subject” can also include a mammal, such as a primate or a human. Thus, the subject can be a human or veterinary patient. The term “patient” refers to a subject under the treatment of a clinician, e.g., physician.

[0171] The term “inhibit” refers to a decrease in an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This can also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.

[0172] By “reduce” or other forms of the word, such as “reducing” or “reduction,” is meant lowering of an event or characteristic. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reduces AMD A” means reducing the circulating levels of ADMA in a subject relative to a standard or a control.

[0173] A modulator is a compound that can reduce or increase AhR activity depending upon the cell, tissues type or in response to different stimulator or inhibitor. A modulator may produce efficacy in certain diseases by increasing AhR activity such as in liver whereas in other diseases such as PAH, CKD or obesity, it may produce efficacy by reducing AhR activity in lung, kidney or adipose tissue.

[0174] By “prevent” or other forms of the word, such as “preventing” or “prevention,” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that aAttorney Docket No. 10877-004W01

[0175] particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed. For example, the terms “prevent” or “suppress” can refer to a treatment that forestalls or slows the onset of a disease or condition or reduced the severity of the disease or condition. Thus, if a treatment can treat a disease in a subject having symptoms of the disease, it can also prevent or suppress that disease in a subject who has yet to suffer some or all of the symptoms.

[0176] The term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, tliis term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.

[0177] As used herein, “fibrotic condition” refers to a disease or condition involving the formation and / or deposition of fibrous tissue, e.g., excessive connective tissue builds up in a tissue and / or spreads over or replaces normal organ tissue (reviewed in, e.g., Wynn, Nature Reviews 4:583-594 (2004) and Abdel -Wahab, O. etal. (2009) Annu. Rev. Med. 60:233-45, incorporated herein by reference). In certain embodiments, the fibrotic condition involves excessive collagen mRNA production and deposition. In certain embodiments,

[0178] the fibrotic condition is caused, at least in part, by injury, e.g., chronic injury (e.g., an insult, a wound, a toxin, a disease). In certain embodiments, the fibrotic condition is associated with an inflammatory, an autoimmune or a connective tissue disorder. For example, chronic inflammation in a tissue can lead to fibrosis in that tissue. Exemplary fibrotic tissuesAttorney Docket No. 10877-004W01

[0179] include, but are not limited to, biliary tissue, liver tissue, lung tissue, heart tissue, vascular tissue, kidney tissue, skin tissue, gut tissue, peritoneal tissue, bone marrow, and the like. In certain embodiments, the tissue is epithelial tissue.

[0180] The term “therapeutically effective” refers to the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination.

[0181] The term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit / risk ratio.

[0182] The term “prodrug” refers to a compound that, when metabolized in vivo, undergo conversion to a compound having the desired pharmacological activity. Prodrugs can be prepared by replacing appropriate functionalities present in compound of Formula I with "pro-moieties" as described, for example, in H. Bundgaar, Design of Prodrugs (1985). Examples of prodrugs include ester (e.g., alkyl esters, glycyl esters, amino acid esters such as valine esters, PEG esters, glycerol esters, N-methylpiperazino esters, aminocarboxylic acid esters, etc.), ether, amide (e.g., benzamides, carboxamides, amides derived from amino acids residues, etc.), carbonate, carbamate, imine, and phosphate derivatives of the compounds herein, and their pharmaceutically acceptable salts. For further discussions of prodrugs, see, for example, T. Higuchi and V. Stella " Pro-drugs as Novel Delivery Systems," ACS Symposium Series 14 (1975) and E. B. Roche ed., Bioreversible Gamers in Drug Design (1987); and D. H. Jornada, G. S. dos Santos Fernandes, D. E. Chiba, T. R. F. de Melo, J. L. dos Santos, and M. C. Chung. Molecules, 2016, 21, 42.

[0183] The term “pharmaceutically acceptable salt” refers generally to compounds prepared by reaction of a free acid or base form of a compound described herein with a stoichiometric amount of an appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found, for example, in Remington’s Pharmaceutical Sciences, 20th ed., Lippincot Williams & Wilkins, Baltimore, MD, 2000, p. 704. In some cases, it may be desirable to prepare a salt of a compound described herein due to one or more of the salt’s advantageous physical properties, such as enhanced stability or a desirable solubility or dissolution profile.Attorney Docket No. 10877-004W01

[0184] Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids.

[0185] Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.

[0186] Specific examples of suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2 -hydroxyethanesulfonate, sufanilate, cyclohexylaminosulfonate, algenic acid, -hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, 2- naphthal esulfonate, oxalate, palmoate, pectinate, 3 -phenylpropionate, picrate, pivalate, thiocyanate, tosylate, and undecanoate.

[0187] In some cases, the pharmaceutically acceptable salt may include alkali metal salts, including but not limited to sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. In another embodiment, base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.

[0188] Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. Basic nitrogen -containing groups may be quaternized with agents such as lower alkyl (Ct-Ce) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g.,Attorney Docket No. 10877-004W01

[0189] decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), and others.

[0190] Chemical Definitions

[0191] Terms used herein will have their customary meaning in the art unless specified otherwise. The organic moieties mentioned when defining variable positions within the general formulae described herein (e.g., the term “halogen”) are collective terms for the individual substituents encompassed by the organic moiety. The prefix Cn-Cmpreceding a group or moiety indicates, in each case, the possible number of carbon atoms in the group or moiety that follows.

[0192] As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described below. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, heteroatoms present in a compound or moiety, such as nitrogen, can have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valency of the heteroatom. This disclosure is not intended to be limited in any manner by the permissible substituents of organic compounds. Also, the terms “substitution” or “substituted with” include the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound (e.g., a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.

[0193] “Z1,” “Z2,” “Z3,” and “Z4” are used herein as generic symbols to represent various specific substituents. These symbols can be any substituent, not limited to those disclosed herein, and when they are defined to be certain substituents in one instance, they can, in another instance, be defined as some other substituents.

[0194] As used herein, the term “alkyl” refers to saturated, straight-chained or branched saturated hydrocarbon moieties. Unless otherwise specified, C1-C24 (e.g., C1-C22, C1-C20, Ci-Cis, Ci-Cu,, C1-C14, C1-C12, C1-C10, Ci-Cs, Ci-Ce, or C1-C4) alkyl groups are intended. Examples of alkyl groups include methyl, ethyl, propyl, 1-methyl-ethyl, butyl, 1 -methyl¬ propyl, 2-methyl -propyl, 1,1-diniethyl-ethyl, pentyl, 1-niethyl-butyl, 2-methyl -butyl, 3-Attorney Docket No. 10877-004W01

[0195] methyl-butyl, 2, 2-dimethyl -propyl, 1 -ethyl -propyl, hexyl, 1,1-dimethyl-propyl, 1,2-dimethyl -propyl, 1 -methyl -pentyl, 2-methyl -pentyl, 3-methyl-pentyl, 4-methyl -pentyl, 1,1- dimethyl-butyl, 1,2-dimethyl-butyl, 1,3-dimethyl-butyl, 2,2-dimethyl-butyl, 2,3-dimethyl-butyl, 3,3-dimethyl-butyl, 1 -ethyl -butyl, 2-ethyl-butyl, 1,1,2-trimethyl -propyl, 1,2,2-trimethyl-propyl, 1 -ethyl- 1-methyl-propyl, and l-ethyl-2-methyl -propyl. Alkyl substituents may be unsubstituted or substituted with one or more chemical moieties. The alkyl group can be substituted with one or more groups including, but not limited to, hydroxy, halogen, acyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, acyl, aldehyde, amino, carboxylic acid, ester, ether, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below, provided that the substituents are sterically compatible and the rules of chemical bonding and strain energy are satisfied.

[0196] Throughout the specification “alkyl” is generally used to refer to both unsubstituted alkyl groups and substituted alkyl groups; however, substituted alkyl groups are also specifically referred to herein by identifying the specific substituent(s) on the alkyl group. For example, the term “halogenated alkyl” specifically refers to an alkyl group that is substituted with one or more halides (halogens; e.g., fluorine, chlorine, bromine, or iodine). The term “alkoxyalkyl” specifically refers to an alkyl group that is substituted with one or more alkoxy groups, as described below. The term “alkylamino” specifically refers to an alkyl group that is substituted with one or more amino groups, as described below, and the like. When “alkyl” is used in one instance and a specific term such as “alkylalcohol” is used in another, it is not meant to imply that the term “alkyl” does not also refer to specific terms such as “alkyl alcohol” and the like.

[0197] This practice is also used for other groups described herein. That is, while a term such as “cycloalkyl” refers to both unsubstituted and substituted cycloalkyl moieties, the substituted moieties can, in addition, be specifically identified herein; for example, a particular substituted cycloalkyl can be referred to as, e.g., an “alkylcycloalkyl.” Similarly, a substituted alkoxy can be specifically referred to as, e.g., a “halogenated alkoxy,” a particular substituted alkenyl can be, e.g., an “alkenylalcohol,” and the like. Again, the practice of using a general term, such as “cycloalkyl,” and a specific term, such as “alkylcycloalkyl,” is not meant to imply that the general term does not also include the specific term.

[0198] As used herein, the term “alkenyl” refers to unsaturated, straight-chained, or branched hydrocarbon moieties containing a double bond. Unless otherwise specified, C2-Attorney Docket No. 10877-004W01

[0199]

[0200] alkenyl groups are intended. Alkenyl groups may contain more than one unsaturated bond. Examples include ethenyl, 1 -propenyl, 2-propenyl, 1-niethylethenyl, 1-butenyl, 2-buienyl, 3-butenyl, 1 -methyl- 1 -propenyl, 2-methyl-l-propenyl, l-methyl-2-propenyl, 2-methyl-2- propenyl, 1 -pentenyl, 2 -pentenyl, 3-pentenyl, 4-pentenyl, 1 -methyl- 1-butenyl, 2-methyl-l- butenyl, 3-methyl- 1-butenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2-methyl-3-butenyl, 3 -methyl-3 -butenyl, l,l-dimethyl-2-propenyl, 1,2- dimethyl-1 -propenyl, l,2-dimethyl-2-propenyl, 1 -ethyl- 1 -propenyl, l-ethyl-2-propenyl, 1- hexenyl, 2 -hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1 -methyl- 1 -pentenyl, 2-metliyl-l- pentenyl, 3-methyl- 1 -pentenyl, 4-methyl-l -pentenyl, l-methyl-2-pentenyl, 2-methyl-2- pentenyl, 3-methyl-2 -pentenyl, 4-methyl-2-pentenyl, l-methyl-3-pentenyl, 2-methyl-3- pentenyl, 3-methyl-3-pentenyl, 4-niethyl-3-pentenyl, 1 -methyl -4-pentenyl, 2-methyl-4- pentenyl, 3-methyl -4-pentenyl, 4-niethyl -4-pentenyl, l,l-dimethyl-2-butenyl, 1,1-dimethyl- 3-butenyl, 1,2-dimethyl- 1-butenyl, 1,2-dimethyl -2-butenyl, 1,2-dimethyl-3-butenyl, 1,3- dimethyl- 1 -butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3- butenyl, 2,3-dimethyl- 1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3- dimethyl- 1-butenyl, 3,3-dimethyl-2-butenyl, 1 -ethyl- 1-butenyl, l-ethyl-2-butenyl, l-ethyl-3- butenyl, 2-ethyl- 1 -butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1, 1,2-trimethyl-2-propenyl, 1 -ethyl- 1 -methyl -2-propenyl, 1 -ethyl-2-methyl- 1 -propenyl, and 1 -ethyl-2 -methyl -2- propenyl. The term “vinyl” refers to a group having the structure -CII=CIl2; 1 -propenyl refers to a group with the structure-CH=CH-CH3; and 2- propenyl refers to a group with the structure -CH2-CH=CH2. Asymmetric structures such as (Z1Z2)C=C(Z? Z4) are intended to include both the E and Z isomers. 'This can be presumed in structural formulae herein wherein an asymmetric alkene is present, or it can be explicitly indicated by the bond symbol C=C. Alkenyl substituents may be unsubstituted or substituted with one or more chemical moieties. Examples of suitable substituents include, for example, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, acyl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below, provided that the substituents are sterically compatible and the rules of chemical bonding and strain energy are satisfied.

[0201] As used herein, the term “alkynyl” represents straight-chained or branched hydrocarbon moieties containing a triple bond. Unless otherwise specified, C2-C24 (e.g., C2- alkynyl groups are

[0202]

[0203] Attorney Docket No. 10877-004W01

[0204] intended. Alkynyl groups may contain more than one unsaturated bond. Examples include C'2-C6-alkynyl, such as ethynyl, 1-propynyl, 2-propynyl (or propargyl), 1-butynyl, 2- butynyl, 3-butynyl, l-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 3- methyl- 1-butynyl, 1 -methyl -2-butynyl, l-methyl-3-butynyl, 2-methyl-3-butynyl, 1,1-dimethyl-2-propynyl, l-ethyl-2-propynyl, 1 -hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 3-methyl- 1-pentynyl, 4-methyl- 1-pentynyl, l-methyl-2-pentynyl, 4-methyl-2- pentynyl, l-methyl-3-pentynyl, 2-methyl-3-pentynyl, 1 -methyl -4-pentynyl, 2-methyl-4-pentynyl, 3-methyl -4-pentynyl, l,l-dimethyl-2-butynyl, l,l-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-l-butynyl, l-ethyl-2-butynyl, 1- ethyl-3-butynyl, 2-etliyl-3-butynyl, and 1 -ethyl- l-methyl-2-propynyl. Alkynyl substituents may be unsubstituted or substituted with one or more chemical moieties. Examples of suitable substituents include, for example, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, acyl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below.

[0205] As used herein, the term “aryl,” as well as derivative terms such as aryloxy, refers to groups that include a monovalent aromatic carbocyclic group of from 3 to 20 carbon atoms. Aryl groups can include a single ring or multiple condensed rings. In some embodiments, aryl groups include Ce-Cio aryl groups. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, tetrahydronaphthyl, phenylcyclopropyl, and indanyl. In some embodiments, the aryl group can be a phenyl, indanyl or naphthyl group. The term “heteroaryl” is defined as a group that contains an aromatic group that has at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorus. The term “non-heteroaryl,” which is included in the term “aryl,” defines a group that contains an aromatic group that does not contain a heteroatom. The aryl or heteroaryl substituents may be unsubstituted or substituted with one or more chemical moieties. Examples of suitable substituents include, for example, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, acyl, aldehyde, amino, carboxylic acid, cycloalkyl, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein. The term “biaryl” is a specific type of aryl group and is included in the definition of aryl. Biaryl refers to two aryl groups that are bound together via a fused ring structure, as in naphthalene, or are attached via one or more carbon-carbon bonds, as in biphenyl.Attorney Docket No. 10877-004W01

[0206] The term “cycloalkyl” as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. The term “heterocycloalkyl” is a cycloalkyl group as defined above where at least one of the carbon atoms of the ring is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkyl group and heterocycloalkyl group can be substituted or unsubstituted. The cycloalkyl group and heterocycloalkyl group can be substituted with one or more groups including, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, acyl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein.

[0207] The term “cycloalkenyl” as used herein is a non-aromatic carbon -based ring composed of at least three carbon atoms and containing at least one double bound, i.e., C=C. Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like. The term “heterocycloalkenyl” is a type of cycloalkenyl group as defined above, and is included within the meaning of the term “cycloalkenyl,” where at least one of the carbon atoms of the ring is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. The cycloaikenyl group and heterocycloalkenyl group can be substituted or unsubstituted. The cycloaikenyl group and heterocycioaikenyl group can be substituted with one or more groups including, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, acyl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein.

[0208] The term “cyclic group” is used herein to refer to either aryl groups, non-aryl groups (i.e., cycloalkyl, heterocycloalkyl, cycloaikenyl, and heterocycioaikenyl groups), or both. Cyclic groups have one or more ring systems that can be substituted or unsubstituted. A cyclic group can contain one or more aryl groups, one or more non-aryl groups, or one or more aryl groups and one or more non-aryl groups.

[0209] The term “acyl” as used herein is represented by the formula -Cf() )Z.!where Z1can be a hydrogen, hydroxyl, alkoxy, alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloaikenyl, heterocycloalkyl, or heterocycioaikenyl group described above. As used herein, the term “acyl” can be used interchangeably with “carbonyl.” Throughout this specification “C(O)” or “CO” is a short hand notation for C=O.Attorney Docket No. 10877-004W01

[0210] As used herein, the term “alkoxy” refers to a group of the formula Z^O-, where Z1is unsubstituted or substituted alkyl as defined above. Unless otherwise specified, alkoxy groups wherein Z1is a Ci-C?4 (e.g., C1-C22, C1-C20, Ci-Cis, C1-C16, C1-C14, C1-C12, C1-C10, Ci-Cs, Ci-Ce, C1-C4) alkyl group are intended. Examples include methoxy, ethoxy, propoxy, 1 -methyl-ethoxy, butoxy, 1 -methyl -propoxy, 2-methyl -propoxy, 1,1 -dimethyl- ethoxy, pentoxy, 1-methyl-butyloxy, 2-methyl-butoxy, 3-niethyl-butoxy, 2,2-di-methyl- propoxy, 1 -ethyl -propoxy, hexoxy, 1,1 -dimethyl -propoxy, 1,2-dimethyl -propoxy, 1 -methyl -pentoxy, 2-methyl-pentoxy, 3-methyl-pentoxy, 4-methyl-pentoxy, 1,1 -dimethyl -butoxy, 1,2-dimethyl -butoxy, 1,3 -dimethyl -butoxy, 2, 2-dimethyl -butoxy, 2,3-dimethyl-butoxy, 3,3- dimethyl -butoxy, 1-ethyl-butoxy, 2-ethylbutoxy, 1,1,2-trimethyl -propoxy, 1,2, 2 -trimethyl¬ propoxy, 1 -ethyl -1 -methyl -propoxy, and 1 -ethyl -2-methyl-propoxy.

[0211] The term “aldehyde” as used herein is represented by the formula — C(O)H.

[0212] The terms “amine” or “amino” as used herein are represented by the formula — NZrZ2, where Z1and Z2can each be substitution group as described herein, such as hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above. “Amido” is — C(O)NZ!Z2.

[0213] The term “carboxylic acid” as used herein is represented by the formula — C(O)OH. A “carboxylate” or “carboxyl” group as used herein is represented by the formula — C(O)O"

[0214] The term “ester” as used herein is represented by the formula — ()C(())Zior — C'(O)OZ1, where Z1can be an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.

[0215] The term “ether” as used herein is represented by the formula Z!OZ2, where Z1and Z2can be, independently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloal kenyl group described above.

[0216] The term “ketone” as used herein is represented by the formula Z1C(O)Z2, where Z1and Z2can be, independently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.

[0217] The term “halide” or “halogen” or “halo” as used herein refers to fluorine, chlorine, bromine, and iodine.

[0218] The term “hydroxyl” as used herein is represented by the formula — OH.

[0219] The term “nitro” as used herein is represented by the formula — -NO2.Attorney Docket No. 10877-004W01

[0220] The term “silyl” as used herein is represented by the formula — SiZ1Z2Z3, where Z1, Z2, and Z3can be, independently, hydrogen, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.

[0221] The term “sulfonyl” is used herein to refer to the group represented by the formula --S(O)? Z!, where Z1can be hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.

[0222] The term “sulfonylamino” or “sulfonamide” as used herein is represented by the formula --S(0)2NH--.

[0223] The term “thiol” as used herein is represented by the formula — SH.

[0224] The term “thio” as used herein is represented by the formula — S —.

[0225] As used herein, Me refers to a methyl group; OMe refers to a methoxy group; and i-Pr refers to an isopropyl group.

[0226] “R1,” “R2,” “R3,” “R“,” etc., where n is some integer, as used herein can, independently, possess one or more of the groups listed above. For example, if R1is a straight chain alkyl group, one of the hydrogen atoms of the alkyl group can optionally be substituted with a hydroxyl group, an alkoxy group, an amine group, an alkyl group, a halide, and the like. Depending upon the groups that are selected, a first group can be incorporated within second group or, alternatively, the first group can be pendant (i.e., attached) to the second group. For example, with the phrase “an alkyl group comprising an amino group,” the amino group can be incorporated within the backbone of the alkyl group. Alternatively, the amino group can be attached to the backbone of the alkyl group. The nature of the group(s) that is (are) selected will determine if the first group is embedded or attached to the second group.

[0227] Unless stated to the contrary, a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible stereoisomer or mixture of stereoisomer (e.g., each enantiomer, each diastereomer, each meso compound, a racemic mixture, or scalemic mixture).

[0228] Reference will now be made in detail to specific aspects of the disclosed materials, compounds, compositions, and methods, examples of which are illustrated in the accompanying Examples.Attorney Docket No. 10877-004W01

[0229] Compounds

[0230] Provided herein are compounds that can modulate aryl hydrocarbon receptor (AhR) activity in a subject.

[0231] For example, described herein are compounds defined by Formula I or Formula II:

[0232]

[0233] Formula I Formula II

[0234] or a pharmaceutically acceptable salt or prodrug thereof, wherein

[0235] Q is selected from one of the following:

[0236]

[0237] Z is selected from -CH₂-, -CII2CII2-, and — C(=O)—; A is, individually for each occurrence, selected from N and CH; R1is selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, Ci- C4 alkylsulfonyl, a 5-membered heteroaryl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, - SChNR 'R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, and the 5- membered heteroaryl ring are each optionally substituted with from 1 to 4 RAgroups, or R1and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R2is selected from halogen, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkoxy, - P(=O)R7R8, and -L-RB, wherein the C1-C4 alkoxy group is optionally substituted with from I to 4 RAgroups, or wherein R2and R4, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R3is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R5and R6areAttorney Docket No. 10877-004W01

[0238] independently selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R5and R6, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups, or R5is selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R6and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; Rzand R8are independently C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R7is C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R8and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylaniino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkyl sulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R°, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7RS; L is a bivalent linking group comprising from 2 to 10 atoms; RBis selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylaniino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl sulfinyl, Ci-C4 alkyl sulfonyl, a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, the 5-7 membered aryl ring, the 5-7 membered heteroaryl ring, the 3-7 membered cycloalkyl ring, and the 3-7 membered heterocycloalkyl ring are each optionally substituted with from 1 to 4 RAgroups; n is an integer from 0 to 4; and m is an integer from 0 to 4; with

[0239] the proviso that when R T- is hydroxy, fluoro,

[0240]

[0241] R!is not carboxy; and with the provisio that the compound is not the followingAttorney Docket No. 10877-004W01

[0242]

[0243] In some embodiments, R2is a halogen, such as fluoro.

[0244] In other embodiments, R2is hydroxyl.

[0245] In other embodiments, R2is one of the following

[0246]

[0247] In certain embodiments, R2is one of the followingAttorney Docket No. 10877-004W01

[0248]

[0249] ,

[0250] In other embodiments, R2is -P(=O)R7R8.

[0251] In some embodiments, m is 0.

[0252] In some embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group. In some embodiments, n is 0.

[0253] In some embodiments, R1is a cyano group.

[0254] In other embodiments, R1is -P(=O)R7R8.

[0255] In other embodiments, R1is a sulfonamide group, a methanesulfonamido group, a protected amino group, or a carbamate group.

[0256] In other embodiments, Rlis a carboxy group, an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0257] In other embodiments, R1is a C1-C4 alkoxy group substituted with a carboxy group, a sulfonamido group, a methanesulfonamido group, an amino group, a protected amino group (e.g., an alkyloxycarbonylamino group such as -NH-CO-O-tBu), an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0258] In other embodiments, R1is a tetrazole ring.

[0259] In other embodiments, Rlis -O-CH2-CO2H, -CH2-NH-S()2Me), -NHSChMe), - CH2CO2H), or carboxy.

[0260] Also provided herein are compounds defined by Formula III:

[0261]

[0262] Attorney Docket No. 10877-004W01

[0263] Formula III

[0264] or a pharmaceutically acceptable salt or prodrug thereof, wherein R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; m is an integer from 0 to 4; Y is selected from a thiophenyl ring optionally substituted with one or more substituents individually selected from RA; and RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, Ci- C4 alkoxy, alkyl sulfinyl, alkylsulfonyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl.

[0265] In some embodiments, m is 0.

[0266] In some embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group. In some embodiments, Y is a phenyl ring. In other embodiments, Y is an optionally substituted thiophenyl ring.

[0267] In some embodiments, the compound comprises one of the following:

[0268]

[0269] Attorney Docket No. 10877-004W01

[0270]

[0271] Pharmaceutical Compositions.

[0272] Also provided are compositions that include one or more of the compounds described herein. In some embodiments, AhR-modulating (e.g., increasing or reducing) compositions are provided, comprising a carrier and an effective amount of a compound described herein.

[0273] In some embodiments, the earner can be a pharmaceutically acceptable earner. A “pharmaceutically acceptable earner” as used herein refers to a carrier that, when combinedAttorney Docket No. 10877-004W01

[0274] with a compound described herein, facilitates the application or administration of that compound described herein for its intended purpose (e.g., to modulate AhR activity in a subject).

[0275] The compound described herein may be formulated for administration in a pharmaceutically acceptable carrier in accordance with known techniques. See, e.g., Remington, The Science and Practice of Pharmacy (9th Ed. 1995). The pharmaceutically acceptable carrier can, of course, also be acceptable in the sense of being compatible with any other ingredients in the composition.

[0276] The carrier may be a solid or a liquid, or both, and is preferably formulated with the a compound described herein as a unit-dose composition, for example, a tablet, which may contain from 0.01 or 0.5% to 95% or 99% by weight of the a compound described herein. One or more a compounds described herein can be included in the compositions, which may be prepared by any of the well-known techniques of pharmacy comprising admixing the components, optionally including one or more accessory ingredients.

[0277] In general, compositions may be prepared by uniformly and intimately admixing a compound described herein with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the a compound described herein, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and / or surface active / dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.

[0278] Compositions can be formulated to be suitable for oral, nasal, rectal, topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), topical (i.e., both skin and mucosal surfaces, including airway surfaces) or transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular compound that is being used.

[0279] Compositions suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the compound; as a powder or granules; as a solution or a suspension in an aqueous or non¬ aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such compositions may beAttorney Docket No. 10877-004W01

[0280] prepared by any suitable method of pharmacy, which includes the step of bringing into association the compound and a suitable carrier (which may contain one or more accessory ingredients as noted above).

[0281] Compositions suitable for buccal (sub-lingual) administration include lozenges comprising the compound in a flavored base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

[0282] Compositions suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may contain anti¬ oxidants, buffers, bacteriostats and solutes that render the composition isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents. The compositions may be presented in unit / dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-inj ection immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[0283] For example, the composition can be an injectable, stable, sterile composition comprising a compound described herein in a unit dosage form in a sealed container. The composition can be provided in the form of a lyophilizate that can be reconstituted with a suitable pharmaceutically acceptable earner to form a liquid composition suitable for injection thereof into a subject. The unit dosage form can comprise from about 10 mg to about 10 grams of the compound. When the compound or salt is substantially water¬ insoluble, a sufficient amount of emulsifying agent that is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.

[0284] Compositions suitable for rectal administration can be presented as unit dose suppositories. These may be prepared by mixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

[0285] Compositions suitable for topical application to the skin can take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers that may be used includeAttorney Docket No. 10877-004W01

[0286] petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

[0287] Compositions suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Compositions suitable for transdermal administration may also be delivered by iontophoresis and typically take the form of an optionally buffered aqueous solution of the active compound.

[0288] In some embodiments, the compositions described herein can further include one or more additional active agents. Examples of suitable additional active agents include anticancer agents, antidiabetics, hypotensive agents, perfusion-enhancing agents, lipid metabolism modulators, antithrombotic agents, antioxidants, chemokine receptor antagonists, p38-kinase inhibitors, NPY agonists, orexin agonists, anorectics, PAF-AH inhibitors, antiphlogistics, COX inhibitors, LTEU-receptor antagonists, analgesics, prostacyclin analogs, guanylate cyclase stimulators, endothelin receptor antagonists, PDE5 inhibitors, ACE inhibitors, angiotensin receptor antagonists, diuretics, analgesics (e.g., NSAIDs such as aspirin), antidepressants, and other psychopharmaceuticals.

[0289] Examples of lipid metabolism modulators include HMG-CoA reductase inhibitors, inhibitors of HMG-CoA reductase expression, squalene synthesis inhibitors, AC AT inhibitors, LDL receptor inductors, cholesterol absorption inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, MTP inhibitors, lipase inhibitors, LpL activators, fibrates, niacin, CETP inhibitors, PPAR-a, PPAR-v and / or PPAR-6 agonists, RXR modulators, FXR modulators, LXR modulators, thyroid hormones and / or thyroid mimetics, ATP citrate lyase inhibitors, Lp(a) antagonists, cannabinoid receptor 1 antagonists, leptin receptor agonists, bombesin receptor agonists, histamine receptor agonists, cannabinoid receptor 1 antagonists, and antioxidants / radical scavengers.

[0290] In some embodiments, the lipid metabolism modulator can comprise a statins, such as, by way of example, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, cerivastatin, or pitavastatin.

[0291] In some embodiments, the lipid metabolism modulator can comprise a squalene synthesis inhibitor, such as, by way of example, BMS-188494 or TAK-475.

[0292] In some embodiments, the lipid metabolism modulator can comprise an ACAT inhibitor, such as, by way of example, avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.Attorney Docket No. 10877-004W01

[0293] In some embodiments, the lipid metabolism modulator can comprise a cholesterol absorption inhibitor, such as, by way of example, ezetimibe, tiqueside or pamaqueside.

[0294] In some embodiments, the lipid metabolism modulator can comprise an MTP inhibitor, such as, by way of example, implitapide, BMS-201038, R-103757 or JTT-130.

[0295] In some embodiments, the lipid metabolism modulator can comprise a lipase inhibitor, such as, by way of example, orlistat.

[0296] In some embodiments, the lipid metabolism modulator can comprise a thyroid hormone and / or thyroid mimetic, such as, by way of example, D-thyroxine or 3,5,3'-triiodothyronine (T3).

[0297] In some embodiments, the lipid metabolism modulator can comprise an agonist of the niacin receptor, such as, by way of example, niacin, acipimox, acifran or radecol.

[0298] In some embodiments, the lipid metabolism modulator can comprise a CETP inhibitor, such as, by way of example, dalcetrapib, BAY 60-5521, anacetrapib or CETP vaccine (CETi-1).

[0299] In some embodiments, the lipid metabolism modulator can comprise a PPAR-y agonist, for example from the class of the thiazolidinediones, such as, by way of example, pioglitazone or rosiglitazone.

[0300] In some embodiments, the lipid metabolism modulator can comprise a PPAR-5 agonist, such as, by way of example, GW-501516 or BAY 68-5042.

[0301] In some embodiments, the lipid metabolism modulator can comprise a polymeric bile acid adsorber, such as, by way of example, cholestyramine, colestipol, colesolvam, CholestaGel or colestimide.

[0302] In some embodiments, the lipid metabolism modulator can comprise a bile acid reabsorption inhibitor, such as, by way of example, ASBT (= IB AT) inhibitors, such as, for example, AZD-7806, S-8921, AK-105, BARI-1741, SC-435 or SC-635.

[0303] In some embodiments, the lipid metabolism modulator can comprise an antioxidant / radical scavenger, such as, by way of example, probucol, AGI-1067, BO-653 or AEOL-10150.

[0304] In some embodiments, the lipid metabolism modulator can comprise a cannabinoid receptor 1 antagonist, such as, by way of example, rimonabant or SR-147778.

[0305] Examples of suitable antidiabetics include insulin and insulin derivatives, and also orally effective hypoglycemic active ingredients. Here, insulin and insulin derivatives include both insulins of animal, human or biotechnological origin and also mixtures thereof.Attorney Docket No. 10877-004W01

[0306] The orally effective hypoglycemic active ingredients for example may include sulfonylureas, biguanides, meglitinide derivatives, glucosidase inhibitors and PPAR-gamma agonists.

[0307] In some embodiments, the antidiabetics can comprise insulin and modified insulins. In some embodiments, the antidiabetics can comprise a sulfonylurea, such as, by way of example, tolbutamide, glibenclamide, glimepiride, glipizide or gliclazide.

[0308] In some embodiments, the antidiabetics can comprise a biguanide, such as, by way of example, metformin.

[0309] In some embodiments, the antidiabetics can comprise a meglitinide derivative, such as, by way of example, repaglinide or nateglinide.

[0310] In some embodiments, the antidiabetics can comprise a glucosidase inhibitor, such as, by way of example, miglitol or acarbose.

[0311] In some embodiments, the antidiabetics can comprise a DPP-IV inhibitor, such as, by way of example, sitagliptin and vildagliptin.

[0312] In some embodiments, the antidiabetics can comprise a PPAR-gamma agonist, for example from the class of the thiazolinediones, such as, by way of example, pioglitazone or rosiglitazone.

[0313] Examples of suitable hypotensive agents include calcium antagonists, angiotensin All antagonists, ACE inhibitors, beta-receptor blockers, alpha-receptor blockers and diuretics.

[0314] In some embodiments, the hypotensive agent can comprise a calcium antagonist, such as, by way of example, nifedipine, amlodipine, verapamil or diltiazem.

[0315] In some embodiments, the hypotensive agent can comprise an angiotensin All antagonist, such as, by way of example, losartan, valsartan, candesartan, embusartan, olmesartan or telmisartan.

[0316] In some embodiments, the hypotensive agent can comprise an ACE inhibitor, such as, by way of example, enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.

[0317] In some embodiments, the hypotensive agent can comprise a beta-receptor blocker, such as, by way of example, propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipranolol, nadolol, mepindolol, carazalol, sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucindolol.Attorney Docket No. 10877-004W01

[0318] In some embodiments, the hypotensive agent can comprise an alpha-receptor blocker, such as, by way of example, prazosin.

[0319] In some embodiments, the hypotensive agent can comprise a diuretic, such as, by way of example, furosemide, bumetanide, torsemide, bendroflumethiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichloromethiazide, chlorothalidone, indapamide, metolazone, quinethazone, acetazolamide, dichlorophenamide, methazolamide, glycerol, isosorbide, mannitol, amiloride or triamteren.

[0320] In some embodiments, the one or more additional active agents can comprise an aldosterone or mineralocorticoid receptor antagonist, such as, by way of example, spironolactone or eplerenone.

[0321] In some embodiments, the one or more additional active agents can comprise a vasopressin receptor antagonist, such as, by way of example, conivaptan, tolvaptan, lixivaptan or SR-121463.

[0322] In some embodiments, the one or more additional active agents can comprise an organic nitrate or NO donor, such as, by way of example, sodium nitroprusside, nitroglycerol, isosorbide mononitrate, isosorbide dinitrate, molsidomin or SIN-1, or in combination with inhalative NO.

[0323] In some embodiments, the one or more additional active agents can comprise a positive- inotropic compound, such as, by way of example, cardiac glycosides (digoxin), beta-adrenergic and dopaminergic agonists, such as isoproterenol, adrenaline, noradrenaline, dopamine or dobutamine.

[0324] In some embodiments, the one or more additional active agents can comprise an antisympathotonic, such as reserpine, clonidine or alpha-methyldopa, or a potassium channel agonist, such as minoxidil, diazoxide, dihydralazine or hydralazine, or a substance which releases nitrogen oxide, such as glycerol nitrate or sodium nitroprusside.

[0325] Examples of antithrombotics include platelet aggregation inhibitors and anticoagulants.

[0326] In some embodiments, the antithrombotic can comprise a platelet aggregation inhibitor, such as, by way of example, aspirin, clopidogrel, ticlopidine or dipyridamol.

[0327] In some embodiments, the antithrombotic can comprise a thrombin inhibitor, such as, by way of example, ximelagatran, melagatran, dabigatran, bivalirudin or clexane.Attorney Docket No. 10877-004W01

[0328] In some embodiments, the one or more additional active agents can comprise a GPIIb / IIIa antagonist, such as, by way of example, tirofiban or abciximab.

[0329] In some embodiments, the one or more additional active agents can comprise a factor Xa inhibitor, such as, by way of example, rivaroxaban (BAY 59-7939), DU-176b, apixaban, otamixaban, fidexaban, razaxaban, fondaparinux, idraparinux, PMD-3112, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428,

[0330] In some embodiments, the one or more additional active agents can comprise heparin or a low molecular weight (LMW) heparin derivative.

[0331] In some embodiments, the one or more additional active agents can comprise a vitamin K antagonist, such as, by way of example, coumarin.

[0332] In some embodiments, the one or more additional active agents can comprise an endothelin receptor antagonist, such as, by way of example, bosentan or ambrisentan.

[0333] In some embodiments, the one or more additional active agents can comprise a phosphodiesterase type 5 inhibitor, such as, by way of example, sildenafil or tadalafil.

[0334] In some embodiments, the one or more additional active agents can comprise a prostacyclin analogue, such as, by way of example, epoprostenol, treprostinil or iloprost.

[0335] In some embodiments, the one or more additional active agents can comprise sotatercept, sold under the brand name Winrevair.

[0336] In some embodiments, the one or more additional active agents can comprise an anticancer agent, such as an anticancer agent described below. In certain embodiments, the one or more additional active agents can comprise an immunotherapy for the treatment of cancer.

[0337] Coating compositions are also provided. A “coating” as used herein is generally known. Any of a variety of organic and aqueous coating compositions, with or without pigments, may be modified to contain one or more compounds described herein. Examples of suitable coating compositions include, for example, the coating compositions described in U. S. Pat. Nos. 7,109,262, 6,964,989, 6,835,459, 6,677,035, 6,528,580, and 6,235,812, each incorporated by reference herein in their entirety.

[0338] In some examples, coating compositions can comprise (in addition to one or more compounds described herein) a film-forming resin, an aqueous or organic solvent that disperses the resin; and, optionally, at least one pigment. Other ingredients such as colorants, secondary pigments, stabilizers and the like can be included if desired. The oneAttorney Docket No. 10877-004W01

[0339] or more compounds described herein may be dissolved or dispersed in the solvent and / or resin, so that the compound(s) are dispersed or distributed on an article or substrate coated by the coating composition. The resin may comprise, for example, a polymeric material. A polymeric material is a material that is comprised of large molecules made from associated smaller repeating structural units, often covalently linked. Common examples of polymeric materials are unsaturated polyester resins, and epoxy resins.

[0340] Any suitable article can be coated, in whole or in part, with the coating compositions described herein. Suitable articles include, but are not limited to, the surface of implantable medical devices such as stents. Coating of the article with the composition can be carried out by any suitable means, such as by brushing, spraying, electrostatic deposition, dip coating, doctor blading, etc.

[0341] The compositions described herein can include an effective amount of a compound described herein to achieve the intended purpose, e.g. to modulating DDAH and ADMA levels in a subject. The determination of an effective dose is well within the capability of those skilled in the art in view of the present disclosure.

[0342] For any compound, the therapeutically effective dose can be estimated initially either in in vitro assays, e.g. those described in the Examples herein, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0343] A therapeutically effective dose refers to that amount of a compound described herein that ameliorates the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in vitro or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, ED50 / ED50. Exemplary pharmaceutical compositions exhibit large therapeutic indices. The data obtained from in vitro assays and animal studies are used in formulating a range of dosage for human use. The dosage of such compounds lies for example within a range of circulating concentrations what include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.Attorney Docket No. 10877-004W01

[0344] Normal dosage amounts may vary from 0.1 to 1000 milligrams total dose, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature. See U. S, Pat. No, 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art will employ different formulations for polynucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0345] Methods of Use

[0346] The compounds described herein can modulate AhR activity in a subject. In some embodiments, the compounds described herein can effectively reduce AhR pathway gene expression, fibrosis, oxidative stress, cancer, and the progression pulmonary arterial hypertension, and kidney disease in a preclinical model of CKD.

[0347] Also provided are methods of treating or preventing a disease or condition associated with elevated levels of AhR activity in a subject. These methods can comprise administering a therapeutically effective amount of a compound described herein.

[0348] Administration of the compounds described herein may reduce AhR activity in the subject.

[0349] Also provided are methods of inhibiting SIN3A expression, thereby reducing immune suppression by T regulatory and Thl7 cells and increasing expression of MHC-1 (HLA-1, HLA-2). These methods can comprise administering a therapeutically effective amount of a compound described herein. Administration of the compounds described herein may reduce SIN3A expression in the subject, thereby reducing immune suppression by T regulatory and Thl7 cells and increasing expression of MHC-1 (HLA-1, HLA-2).

[0350] In some embodiments, provided herein are methods for modulating aryl hydrocarbon receptor (AhR) activity in a subject. These methods can comprise administering to the subject a composition comprising a therapeutically effective amount of a compound defined by Formula I or Formula II:

[0351]

[0352] Attorney Docket No. 10877-004W01

[0353] or a pharmaceutically acceptable salt or prodrug thereof, wherein

[0354] Q is selected from one of the following:

[0355]

[0356] Z is selected from -CH₂-, CH CH'. and -C(=O)-; A is, individually for each occurrence, selected from N and CH; R1is selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, Ci- C4 alkylsulfonyl, a 5-membered heteroaryl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, - SChNR 'R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, and the 5-membered heteroaryl ring are each optionally substituted with from 1 to 4 RAgroups, or R1and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R2is selected from halogen, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkoxy, - P(=O)R7R8, and -L-RB, wherein the C1-C4 alkoxy group is optionally substituted with from 1 to 4 RAgroups, or wherein R2and R4, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R3is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; R5and R6are independently selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R5and R6, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups, or R5is selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R6and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups; R7and R8are independently C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R7is C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R8and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1Attorney Docket No. 10877-004W01

[0357] to 4 RAgroups; RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkyl carbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 di alkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8; L is a bivalent linking group comprising from 2 to 10 atoms; RBis selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, Ci-C4 alkylsulfonyl, a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, - S(=())(=NR5)R7, -NH-S(=O)(=NR:’)R7, and -P(=())R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, the 5-7 membered aryl ring, the 5-7 membered heteroaryl ring, the 3-7 membered cycloalkyl ring, and the 3-7 membered heterocycloalkyl ring are each optionally substituted with from 1 to 4 RAgroups; n is an integer from 0 to 4; and m is an integer from 0 to 4.

[0358] In some embodiments,

[0359]

[0360] In some embodiments, A is CH.

[0361] In some embodiments,

[0362]

[0363] is a halogen, such as fluoro.

[0364] In some embodiments, R2is hydroxyl.

[0365] In some embodiments, R2is one of the followingAttorney Docket No. 10877-004W01

[0366]

[0367] In certain embodiments, R2is one of the following

[0368]

[0369] In some embodiments, R2is -P(=O)R7R8.

[0370] In some embodiments, m is 0. In other embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

[0371] In some embodiments, n is 0.Attorney Docket No. 10877-004W01

[0372] In some embodiments, R1is a cyano group.

[0373] In other embodiments, R1is -P(=O)R7R8.

[0374] In other embodiments, R1is a sulfonamide group, a methanesulfonamido group, a protected amino group, or a carbamate group.

[0375] In other embodiments, R1is a carboxy group, an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0376] In other embodiments, Rlis a C1-C4 alkoxy group substituted with a carboxy group, a sulfonamide group, a methanesulfonamido group, an amino group, a protected amino group (e.g., an alkyloxycarbonylamino group such as -NH-CO-O-tBu), an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

[0377] In other embodiments, R1is a tetrazole ring.

[0378] In other embodiments, R1is -O-CH2-CO2H, -CH2-NH-SO2Me), -NHSO2Me), -CH2CO2H), or carboxy.

[0379] Also provided herein are methods for modulating aryl hydrocarbon receptor (AhR) activity in a subject. These methods can comprise administering to the subject a composition comprising a therapeutically effective amount of a compound defined by¬ Formula III:

[0380]

[0381] Formula III

[0382] or a pharmaceutically acceptable salt or prodrug thereof, wherein

[0383] R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; m is an integer from 0 to 4;

[0384] Y is selected from a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, each optionally substituted with one or more substituents individually selected from RA; and

[0385] RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8.Attorney Docket No. 10877-004W01

[0386] In some embodiments, m is 0. In other embodiments, m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

[0387] In some embodiments, Y is a phenyl ring. In certain embodiments, Y is an optionally substituted thiophenyl ring.

[0388] In some embodiments, the methods described herein can comprise a method of treating a fibrotic condition in a subject in need thereof, a method of treating obesity in a subject in need thereof, a method of treating kidney disease in a subject in need thereof, a method of treating pulmonary arterial hypertension (PAH) in a subject in need thereof, a method of treating chronic kidney disease (CKD) in a subject in in need thereof, a method of treating COPD in a subject in need thereof, a method of treating pulmonary fibrosis in a subject in in need thereof, a method of treating liver fibrosis in a subject in in need thereof, a method of treating obstructive sleep apnea in a subject in in need thereof, a method of treating heart failure in a subject in in need thereof, a method of treating skin disease, such as atopic dermatitis and / or psoriasis in a subject in in need thereof, a method of treating colitis in a subject in in need thereof, a method of treating sarcopenia and / or fatty liver disease in a subject in in need thereof, a method of treating acute stroke in a subject in in need thereof, a method of treating Alzheimer’s disease in a subject in in need thereof, a method of treating Parkinson’s disease in a subject in in need thereof, a method of treating traumatic brain injury (TBI) in a subject in in need thereof, a method of treating cancer in a subject, a method of reducing tumor progression in a subject, a method of treating an autoimmune disease in a subject, such as allergic rhinitis and Hashimoto’s thyroiditis or a combination thereof.

[0389] In some embodiments, the methods described herein can comprise a method of reducing fibrosis in a cell or tissue. In some embodiments, the methods described herein can comprise a method of treating a fibrotic condition in a subject in need thereof, a method of treating obesity in a subject in need thereof, or a method of treating kidney disease in a subject in need thereof.

[0390] In therapeutic applications, the compounds described herein are administered to a patient already suffering from a disease, condition or disorder, in an amount sufficient to cure or at least partially arrest the symptoms of the disease, disorder or condition. Such an amount is defined to be a “therapeutically effective amount,” and will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician. It isAttorney Docket No. 10877-004W01

[0391] considered well within the skill of the art for one to determine such therapeutically effective amounts by routine experimentation (e.g., a dose escalation clinical trial).

[0392] In prophylactic applications, the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition. Such an amount is defined to be a "prophylactically effective amount." In this use, the precise amounts also depend on the patient's state of health, weight, and the like. It is considered well within the skill of the art for one to determine such prophylactically effective amounts by routine experimentation (e.g., a dose escalation clinical trial).

[0393] The compounds described herein can be used to modulate the activity of AhR in a patient. In one embodiment, a subject in need thereof receives a therapeutic amount of a compound described herein that would decrease the subject’s AhR activity by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%’, 100%, more than 100%’, 150%’, more than 150%, 200%’, more than 200%.

[0394] The compounds described herein can also be used to treat or prevent cancer. In some embodiments, the compounds described herein can be administered as a monotherapy. In other embodiments, the compounds described herein can be administered in combination with and additional anticancer agent.

[0395] The additional anticancer agent may be any compound or composition known to inhibit tumor growth or induce tumor cell death. In one aspect, the agent is a conventional small-molecule chemotherapeutic. Such agents include platinum-based drugs that form DNA cross-links (cisplatin, carboplatin, oxaliplatin), taxanes that stabilize microtubules (paclitaxel, docetaxel, cabazitaxel), antimetabolites that interfere with nucleic-acid synthesis (5-fluorouracil, capecitabine, gemcitabine, pemetrexed), and anthracyclines that intercalate DNA and generate free radicals (doxorubicin, epirubicin, idarubicin). These compounds are well-established in the treatment of solid tumors and hematologic malignancies and provide a solid foundation for the claimed composition.

[0396] In another aspect, the additional anticancer agent is a targeted-therapy molecule that selectively modulates a signaling pathway critical for tumor survival. Examples include tyrosine-kinase inhibitors that block epidermal growth factor receptor (EGFR), BCR-ABL, or VEGFR signaling (e.g., erlotinib, gefitinib, imatinib, sunitinib), PARP inhibitors that exploit synthetic lethality in BRCA-deficient cancers (olaparib, niraparib, rucaparib, talazoparib), mTOR inhibitors that dampen the PI3K / AKT / mTOR axis (everolimus, temsirolimus), a STAT inhibitor, a KRAS inhibitor,, and PI3K inhibitors that upstreamAttorney Docket No. 10877-004W01

[0397] suppress proliferative signaling (idelalisib, duvelisib). Targeted agents often confer improved therapeutic indices compared with cytotoxic chemotherapy.

[0398] In another aspect, the additional anticancer agent is an immunotherapy agent that harness the host immune system to recognize and eliminate cancer cells.

[0399] Immune-checkpoint inhibitors such as anti-PD-1 antibodies (pembrolizumab, nivolumab, cemiplimab), anti-PD-Ll antibodies (atezolizumab, durvalumab, avelumab), and anti-CTLA-4 antibodies (ipilimumab) release inhibitory brakes on T-cells.

[0400] Chimeric-antigen -receptor (CAR) T-cell therapies engineer autologous T-cells to express tumor-specific receptors (e.g., CD19-CAR, BCMA-CAR). Bispecific T-cell engagers (e.g., blinatumomab) simultaneously bind CD3 on T-cells and a tumor antigen (CD 19, BCMA). Oncolytic viruses (e.g., talimogene laherparepvec) are engineered to replicate selectively within tumor cells, causing lysis and releasing tumor antigens. Therapeutic cancer vaccines (peptide-based, nucleic-acid, or dendritic-cell vaccines) present tumor-associated or neo-antigens to stimulate adaptive immunity. Cytokine therapies (IL-2, IL-15, IFN-a) augment lymphocyte activation and proliferation. These modalities represent the cutting edge of immuno-oncology and provide robust support for the immunotherapy-dependent claim. In some embodiments, the compounds described herein may improve the efficacy of the immunotherapy by, for example, inhibiting SIN3A expression, thereby reducing immune suppression by T regulatory and Thl7 cells and increasing expression of MHC-1 (HLA-1, HLA-2). In some embodiments, this effect can by synergistic in nature.

[0401] Additionally, the additional anticancer agent may be a hormone -therapy agent that interferes with endocrine signaling pathways that drive certain tumors. Selective estrogen-receptor modulators (e.g., tamoxifen, raloxifene) and selective estrogen-receptor degraders (fulvestrant) block estrogen signaling in breast cancer. Aromatase inhibitors (anastrozole, letrozole, exemestane) reduce estrogen synthesis in post-menopausal patients. Androgen-receptor antagonists (bicalutamide, enzalutamide, apalutamide) inhibit androgen signaling in prostate cancer, while gonadotropin-releasing-hormone agonists or antagonists (leuprolide, goserelin, degarelix ) suppress testicular androgen production. Hormone therapies are indispensable in managing hormone-responsive malignancies.

[0402] Finally, the additional anticancer agent can be a biologic such as a naked monoclonal antibody that binds a tumor-associated antigen (trastuzumab for HER2, bevacizumab for VEGF, cetuximab for EGFR, rituximab for CD20). Antibody-drug conjugates link such antibodies to cytotoxic payloads (e.g., trastuzumab emtansine,Attorney Docket No. 10877-004W01

[0403] trastuzumab deruxtecan, brentuximab vedotin) to deliver drugs directly to antigen-positive cells. Fusion proteins (e.g., etanercept) and cell-based therapies (CAR-T, TCR-engineered T-cells, tumor-infiltrating lymphocytes) further expand the biologic armamentarium.

[0404] Including these biologies in the disclosure ensures that the specification adequately supports each of the dependent claim categories.

[0405] In some embodiments, the methods described herein comprise administering a compound described herein in an effective amount to inhibit SIN3A expression, thereby reducing immune suppression by T regulatory and Thl7 cells and increasing expression of MHC-1 (HLA-1, HLA-2).

[0406] In some embodiments, the cancer is selected from brain cancer, breast cancer, colorectal cancer, esophageal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, melanoma, pancreatic, prostate and GI cancer.

[0407] The compounds described herein can also be used to treat or prevent fibrotic conditions. Example fibrotic conditions that can be treated or prevented using the compounds described herein include, but are not limited to, a fibrotic condition of the lung, liver, heart, vasculature, kidney, skin, gastrointestinal tract, bone marrow, or a combination thereof. Each of these conditions is described in more detail herein.

[0408] Fibrosis of the lung (also referred to herein as “pulmonary fibrosis”) is characterized by the formation of scar tissue within the lungs, which results in a decreased function. Pulmonary fibrosis is associated with shortness of breath, which progresses to discomfort in the chest weakness and fatigue, and ultimately to loss of appetite and rapid weight-loss. Approximately 500,000 people in the U. S. and 5 million worldwide suffer from pulmonary fibrosis, and 40,000 people in the U. S. die annually from the disease. Pulmonary fibrosis has a number of causes, including radiation therapy, but can also be due to smoking or hereditary factors (Meltzer, E B et al. (2008) Orphanet J. Rare Dis. 3:8).

[0409] Pulmonary fibrosis can occur as a secondary effect in disease processes such as asbestosis and silicosis, and is known to be more prevalent in certain occupations such as coal miner, ship workers and sand blasters where exposure to environmental pollutants is an occupational hazard (Green, F H et al. (2007) Toxicol Pathol. 35:136-47). Other factors that contribute to pulmonary fibrosis include cigarette smoking, and autoimmune connective tissue disorders, like rheumatoid arthritis, scleroderma and systemic lupus erythematosus (SLE) (Leslie, K O et al. (2007) Semin Respir Crit. Care Med. 28:369-78; Swigris, J J et al. (2008) Chest. 133:271-80; and Antoniou, K M et al. (2008) Curr Opin Rheumatol. 20:686-Attorney Docket No. 10877-004W01

[0410] 91). Other connective tissue disorders such as sarcoidosis can include pulmonary fibrosis as part of the disease (Paramothayan, S et al. (2008) RespirMed. 102:1-9), and

[0411] infectious diseases of the lung can cause fibrosis as a long term consequence of infection, particularly chronic infections. Pulmonary fibrosis can also be a side effect of certain medical treatments, particularly radiation therapy to the chest and certain medicines like bleomycin, methotrexate, amiodarone, busulfan, and nitrofurantoin (Catane, R et al.

[0412] (1979) Int J Radiat Oncol Biol Phys. 5:1513-8; Zisman, D A et al. (2001) Sarcoidosis Vase Diffuse Lung Dis. 18:243-52; Rakita, L et al. (1983) Am Heart J. 106:906-16; Twohig, K J et al. (1990) Clin Chest Med. 11:31-54; and Witten C M. (1989) Arch Phys Med.

[0413] Rehabil. 70:55-7). In other embodiments, idiopathic pulmonary fibrosis can occur where no clear causal agent or disease can be identified. Increasingly, it appears that genetic factors can play a significant role in these cases of pulmonary fibrosis (Steele, M P et al. (2007) Respiration 74:601-8; Brass, D M et al. (2007) Proc Am Thorac Soc. 4:92-100 and du Bois R M. (2006) Semin Respir Crit. Care Med. 27:581-8).

[0414] In some examples, the fibrotic condition of the lung can be chosen from one or more of: pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonitis (UIP), interstitial lung disease, cryptogenic fibrosing alveolitis (CPA), or bronchiectasis.

[0415] In other examples, the pulmonary fibrosis can include, but is not limited to, pulmonary fibrosis associated with chronic obstructive pulmonary disease (COPD), scleroderma, pleural fibrosis, chronic asthma, acute lung syndrome, amyloidosis, bronchopulmonary dysplasia, Caplan's disease, Dressier's syndrome, histiocytosis X, idiopathic pulmonary haemosiderosis, lymphangiomyomatosis, mitral valve stenosis, polymyositis, pulmonary edema, pulmonary arterial hypertension (e.g., idiopathic pulmonary hypertension (IPH)), pneumoconiosis, radiotherapy (e.g., radiation induced fibrosis), rheumatoid disease, Shaver's disease, systemic lupus erythematosus, systemic sclerosis, tropical pulmonary eosinophilia, tuberous sclerosis, Weber-Christian disease, Wegener's granulomatosis, Whipple's disease, or exposure to toxins or irritants (e.g., pharmaceutical drugs such as amiodarone, bleomycin, busulphan, carmustine, chloramphenicol, hexamethonium, methotrexate, methysergide, mitomycin C, nitrofurantoin, penicillamine, peplomycin, and practolol; inhalation of talc or dust, e.g., coal dust, silica). In certain embodiments, the pulmonary fibrosis is associated with an inflammatory disorder of the lung, e.g., asthma, COPD.Attorney Docket No. 10877-004W01

[0416] In some embodiments, the fibrotic condition can be a fibrotic condition of the liver (also referred to herein as “hepatic fibrosis”), such as fatty liver disease e.g., steatosis such as nonalcoholic steatohepatitis (NASH), biliary fibrosis, cholestatic liver disease (e.g., primary biliary cirrhosis (PBC), and cholangiopathies (e.g., chronic cholangiopathies)).

[0417] In certain embodiments, the fibrotic of the liver or hepatic fibrosis can be chosen from one or more of: fatty liver disease, steatosis (e.g., nonalcoholic steatohepatitis (NASH), cholestatic liver disease, primary biliary cirrhosis (PBC), biliary fibrosis, cirrhosis, alcohol induced liver fibrosis, biliary duct injury, infection or viral induced liver fibrosis, congenita] hepatic fibrosis, autoimmune hepatitis, or cholangiopathies (e.g., chronic cholangiopathies).

[0418] In certain embodiments, hepatic or liver fibrosis includes, but is not limited to, hepatic fibrosis associated with alcoholism, viral infection, e.g., hepatitis (e.g., hepatitis C, B or D), autoimmune hepatitis, non-alcoholic fatty liver disease (NAFLD), progressive massive fibrosis, exposure to toxins or irritants (e.g., alcohol, pharmaceutical drugs and environmental toxins such as arsenic), alpha- 1 antitrypsin deficiency, hemochromatosis, Wilson’s disease, galactosemia, or glycogen storage disease. In certain embodiments, the hepatic fibrosis is associated with an inflammatory disorder of the liver.

[0419] In some embodiments, the fibrotic condition can be a fibrotic condition of the heart or vasculature, such as myocardial fibrosis. Fibrotic conditions of the heart or vasculature can include, but are not limited to, myocardial fibrosis (e.g., myocardial fibrosis associated with radiation myocarditis, a surgical procedure complication (e.g., myocardial postoperative fibrosis), vascular restenosis, atherosclerosis, cerebral disease, peripheral vascular disease, infectious diseases (e.g., Chagas disease, bacterial, trichinosis or fungal myocarditis)); granulomatous, metabolic storage disorders (e.g., cardiomyopathy, hemochromatosis); developmental disorders (e.g., endocardial fibroelastosis); arteriosclerotic, or exposure to toxins or irritants (e.g., drug induced cardiomyopathy, drug induced cardiotoxicity, alcoholic cardiomyopathy, cobalt poisoning or exposure). In certain embodiments, the myocardial fibrosis is associated with an inflammatory disorder of cardiac tissue (e.g., myocardial sarcoidosis).

[0420] In some embodiments, the fibrotic condition can be a fibrotic condition of the kidney, such as renal fibrosis (e.g., chronic kidney fibrosis). Renal fibrosis can include, but is not limited to, nephropathies associated with injury / fibrosis (e.g., chronic nephropathies associated with diabetes (e.g., diabetic nephropathy)), lupus, scleroderma of the kidney,Attorney Docket No. 10877-004W01

[0421] glomerular nephritis, focal segmental glomerular sclerosis, IgA nephropathyrenal fibrosis associated with human chronic kidney disease (CKD), chronic kidney fibrosis, nephrogenic systemic fibrosis, chronic progressive nephropathy (CPN), tubulointerstitial fibrosis, ureteral obstruction (e.g., fetal partial urethral obstruction), chronic uremia, chronic interstitial nephritis, radiation nephropathy, glomerulosclerosis (e.g., focal segmental glomerulosclerosis (FSGS)), progressive glomerulonephrosis (PGN), endothelial / thrombotic microangiopathy injury, scleroderma of the kidney, HIV-associated nephropathy (HIVVAN), or exposure to toxins, irritants, chemotherapeutic agents. In one embodiment, the kidney fibrosis is mediated by a bone morphogeneic protein (BMP). In certain embodiments, the renal fibrosis is a result of an inflammatory disorder of the kidney.

[0422] In some embodiments, the fibrotic condition can be a fibrotic condition of the bone marrow. In certain embodiments, the fibrotic condition of the bone marrow is myelofibrosis (e.g., primary myelofibrosis (PMF)), myeloid metaplasia, chronic idiopathic myelofibrosis, or primary myelofibrosis. In other embodiments, bone marrow fibrosis is associated with a hematologic disorder chosen from one or more of hairy cell leukemia, lymphoma, or multiple myeloma.

[0423] In other embodiments, the bone marrow fibrosis can be associated with one or more myeloproliferative neoplasms (MPN) chosen from: essential thrombocythemia (FT), polycythemia vera (PV), mastocytosis, chronic eosinophilic leukemia, chronic neutrophilic leukemia, or other MPN.

[0424] In some examples, the fibrotic condition can be primary myelofibrosis. Primary myelofibrosis (PMF) (also referred to in the literature as idiopathic myeloid metaplasia, and Agnogenic myeloid metaplasia) is a clonal disorder of multipotent hematopoietic progenitor cells (reviewed in Abdel-Wahab, O. et al. (2009) Annu. Rev. Med. 60:233-45; Varicchio, L. el al. (2009) Expert Rev. Hematol. 2(3):315-334; Agrawal, M. et al. (2010) Cancer 1-15). The disease is characterized by anemia, splenomegaly and extramedullary hematopoiesis, and is marked by progressive marrow fibrosis and atypical megakaryocytic hyperplasia. CD 34+ stem / progenitor cells abnormally traffic in the peripheral blood and multi organ extramedullary erythropoiesis is a hallmark of the disease, especially in the spleen and liver. The bone marrow structure is altered due to progressive fibrosis, neoangiogenesis, and increased bone deposits. A significant percentage of patients with PMF have gain-of-function mutations in genes that regulate hematopoiesis, including Janus kinase 2 (JAK2) ("50%) (e.g., JAK2V617F) or the thrombopoietin receptor (MPL) (5-10%), resulting inAttorney Docket No. 10877-004W01

[0425] abnormal megakaryocyte growth and differentiation. Studies have suggested that the clonal hematopoietic disorder leads to secondary proliferation of fibroblasts and excessive collagen deposition. Decreased bone marrow fibrosis can improve clinical signs and symptoms, including anemia, abnormal leukocyte counts, and splenomegaly.

[0426] Bone marrow fibrosis can be observed in several other hematologic disorders including, but not limited to hairy cell leukemia, lymphoma, and multiple myeloma.

[0427] However, each of these conditions is characterized by a constellation of clinical, pathologic, and molecular findings not characteristic of PMF (see Abdel- Wahab, O. et al. (2009) supra at page 235).

[0428] In other embodiments, the bone marrow fibrosis can be secondary to non-hematologic disorders, including but not limited to, solid tumor metastases to bone marrow, autoimmune disorders (systemic lupus erythematosus, scleroderma, mixed connective tissue disorder, polymyositis), and secondary hyperparathyroidism associated with vitamin I) deficiency (see Abdel -Wahab, O. et al. (2009) supra at page 235). In most cases, it is possible to distinguish between these disorders and PMF, although in rare cases the presence of the J AK2V617F or MPLW 15L / K mutation can be used to demonstrate the presence of a clonal MPN and to exclude the possibility of reactive fibrosis.

[0429] Optionally, monitoring a clinical improvement in a subject with bone marrow fibrosis can be evaluated by one or more of: monitoring peripheral blood counts (e.g., red blood cells, white blood cells, platelets), wherein an increase in peripheral blood counts is indicative of an improved outcome. In other embodiments, clinical improvement in a subject with bone marrow fibrosis can be evaluated by monitoring one or more of: spleen size, liver size, and size of extramedullary hematopoiesis, wherein a decrease in one or more of these parameters is indicative of an improved outcome.

[0430] In other embodiments, the fibrotic condition can be a fibrotic condition of the skin. In certain embodiments, the fibrotic condition is chosen from one or more of: skin fibrosis and / or scarring, post-surgical adhesions, scleroderma (e.g., systemic scleroderma), or skin lesions such as keloids.

[0431] In certain embodiments, the fibrotic condition can be a fibrotic condition of the gastrointestinal tract. Such fibrotic conditions can be associated with an inflammatory disorder of the gastrointestinal tract, e.g., fibrosis associated with scleroderma; radiation induced gut fibrosis; fibrosis associated with a foregut inflammatory’ disorder such as Barrett's esophagus and chronic gastritis, and / or fibrosis associated with a hindgutAttorney Docket No. 10877-004W01

[0432] inflammatory disorder, such as inflammatory bowel disease (IBD), ulcerative colitis and Crohn's disease. In certain embodiments, the fibrotic condition can be diffuse scleroderma.

[0433] Fibrotic conditions can further include diseases that have as a manifestation fibrotic disease of the penis, including Peyronie's disease (fibrosis of the cavernous sheaths leading to contracture of the investing fascia of the corpora, resulting in a deviated and painful erection).

[0434] In certain embodiments, the fibrotic condition can be selected from pulmonary fibrosis, bronchiectasis, interstitial lung disease; fatty liver disease; cholestatic liver disease, biliary fibrosis, hepatic fibrosis; myocardial fibrosis; and renal fibrosis.

[0435] In certain embodiments, the fibrotic condition can be selected from biliary fibrosis, hepatic fibrosis, pulmonary fibrosis, myocardial fibrosis and renal fibrosis

[0436] In certain embodiments, the fibrotic condition can be selected from nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

[0437] Other fibrotic conditions that can be treated with the methods and compositions of the invention include cystic fibrosis, endomyocardial fibrosis, mediastinal fibrosis, sarcoidosis, scleroderma, spinal cord injury / fibrosis.

[0438] A number of models in which fibrosis is induced are available in the art.

[0439] Administration of ERP agonists can be readily used to evaluate whether fibrosis is ameliorated in such models. Examples of such models, include but are not limited to, the unilateral ureteral obstruction model of renal fibrosis (see Chevalier et al., “Ureteral Obstruction as a Model of Renal Interstitial Fibrosis and Obstructive Nephropathy” Kidney International (2009) 75:1145-1152), the bleomycin induced model of pulmonary fibrosis (see Moore and Hogaboam “Murine Models of Pulmonary Fibrosis” Am. J. Physiol. Lung. Cell. Mol. Physiol. (2008) 294: L152-L160), a variety of liver / biliary fibrosis models (see Chuang et al., “Animal Models of Primary Biliary Cirrhosis” Clin Liver Dis (2008) 12:333-347; Omenetti, A. et al. (2007) Laboratory Investigation 87:499-514 (biliary duct-ligated model); or a number of myelofibrosis mouse models as described in Varicchio, L. (2009) supra. Regardless of the model, ER agonists can be evaluated in essentially three paradigms: 1) test whether ER agonists can inhibit the fibrotic state; 2) test whether ER agonists can stop fibrotic progression once initiated; and / or 3) test whether ERp agonists can reverse the fibrotic state once initiated.

[0440] In certain embodiments, the fibrotic condition is provided in a tissue (e.g., biliary tissue, liver tissue, lung tissue, heart tissue, kidney tissue, skin tissue, gut tissue, or neuralAttorney Docket No. 10877-004W01

[0441] tissue). In certain embodiments, the tissue is biliary tissue. In certain embodiments, the tissue is liver tissue. In certain embodiments the tissue is lung tissue. In certain embodiments, the tissue is heart tissue. In certain embodiments, the tissue is kidney tissue. In certain embodiments, the tissue is skin tissue. In certain embodiments, the tissue is gut tissue. In certain embodiments, the tissue is bone marrow tissue. In certain embodiments, the tissue is epithelial tissue. In certain embodiments, the tissue is neural tissue.

[0442] Also provided are composition for use, and use of, a compound described herein, alone or in combination with another agent, for preparation of one or more medicaments for use in reducing fibrosis, or treatment of a fibrotic condition.

[0443] By way of non-limiting illustration, examples of certain embodiments of the present disclosure are given below.

[0444] EXAMPLES

[0445] Example 1. Selective Aryl Hydrocarbon Receptor Modulators (SAhRMs) Significantly Reduced Cellular Mechanisms of PAH, Vascular Remodeling, Lung inflammation and Improved Lung Function in a Disease Progression Model of PAH, and Reduced Fibrosis and Improved Kidney Function in a Preclinical Model of Kidney Disease Progression.

[0446] Materials and Methods

[0447] Cell Culture. Human embryonic kidney (HEK293) in 10% FBS DMEM, human pulmonary artery smooth muscle cells (HPASMC) in SmGM-2 BulletKit media (Lonza), and human umbilical vein endothelial cells (HUVEC) in Endothelial Cell Growth Medium V2 (cell applications) were cultured at 37 °C under 5% CO2, and 95% relative humidity atmosphere. Primary cells at the 4thto 8thpassages were used for all experiments.

[0448] XRE-NanoLuciferase Reporter Assay. Human embryonic kidney cells (HEK-293) were transfected with XRE-Nluc plasmid using TurboFect™ transfection reagent (Thermo Fisher Scientific) for 48h. Transfected cells were washed with lx PBS 2 times before seeding into 96-well plate and incubated overnight at 37 °C. Compounds were added for 24h at 37 °C and used medium was removed before adding luciferase reagents. The plate was shaken for 5 min at room temperature and measured luminescence (0.5s integration, full light emission, top optics, and 1mm read height) using Biotek synergy Hl microplate reader.Attorney Docket No. 10877-004W01

[0449] Measurement of plasma AhR agonist. Briefly. HEK-293 were transfected with XRE-Nluc plasmid for 48h. Then transfected cells were seeded into 96-well plate and incubated with plasma samples for 24h at 37 °C. Afterward, luciferase reagents were added onto each well, shaken and measured luminescence.

[0450] Human Pulmonary Artery Smooth Muscle Cell ( HPASMC) proliferation. HPASMCs were seeded in 24-well plates in growth medium and allowed to adhere overnight at 37 °C. Cells were washed with phosphate buffered saline (PBS) and incubated with growth medium containing various concentrations of compounds for 24h. Cells were trypsinized and counted in a Beckman-Coulter cell counter.

[0451] Cellular reactive oxygen species (ROS) measurement. Intracellular ROS level was assessed with DCFDA / H2DCFDA-Cellular ROS Assay Kit (Abeam). Cells were seeded in a dark, clear bottom 96-well plate and allowed to adhere overnight. Cells were then washed with lx buffer and treated in lx supplemented buffer overnight and 2x DCFDA staining solutions were added 2h prior to completion of treatment. The plate was read on a fluorescence plate reader at Ex / Em=485 / 535 nm.

[0452] Reverse transcription-polymerase chain reaction. The total RNA was extracted using the Direct-zol RNA MiniPrep (Zymo Research) and reverse transcribed to cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative real-time polymerase chain reaction was performed using Taqman gene expression master mix (Applied biosystems) and was run in the QuantStudio 3 (Thermo Fisher Scientific). Expression level of each tested gene was analyzed in triplicate for each sample and normalized to the 18s as a housekeeping gene. The data were processed by the delta-delta method.

[0453] Pharmacokinetic studies. Compound 101 solution was administered to male Sprague Dawley rats at a single intravenous at 2 mg / kg and oral at 10 mg / kg dose. Blood samples (120 pL) were collected were collected under light isoflurane anesthesia at various times after administration. Plasma was harvested and analyzed with fit-for-purpose LC-MS / MS method. The plasma pharmacokinetic parameters were estimated using noncompartmental analysis tool of Phoenix® WinNonlin software (Ver 8.0) and parameters were determined.

[0454] Co-Transcription Factor Recruitment Assays. PathHunter NHR Protein Interaction (Pro) and Nuclear Translocation (NT) assays were performed by Eurofins. Briefly, cells were seeded into white walled, 384-well microplates and incubated at 37°.Attorney Docket No. 10877-004W01

[0455] For antagonist determination, cells were pre-incubated with antagonist followed by agonist. Sample was added to cells and incubated at 37°C or room temperature for 60 minutes. aAgonist in assay buffer was added to the cells and incubated at 37°C or room temperature for 3-16 hours. Assay signal was generated through a single addition (50% v / v) of PathHunter Detection reagent followed by a one hour incubation at room temperature. Microplates were read following signal generation with a PerkinElmer EnvisionTM instrument for chemiluminescent signal detection. Compound activity was analyzed using CBIS data analysis suite (Chemlnnovation). For antagonist mode assays, percentage inhibition was calculated using the following formula: % Inhibition =100% x (1 - (mean RLE of test sample - mean RLU of vehicle control) / (mean RLU of EC80 control - mean RLU of vehicle control)).

[0456] Western Blotting. Cell lysates were prepared with 2X Laemmli sample buffer (65.8 mM Tris-HCl, pH 6.8 26.3% (w / v) glycerol, 2.1% SDS, 0.01% bromophenol blue) and boiled for 10 min at 95 °C. Protein extracts were collected after centrifugation, resolved on a SDS-PAGE 12% gel, and transferred to PVDF membranes using wet transfer apparatus. Membranes were blocked using Odyssey® blocking buffer (TBS) for 1 h. Primary antibody (1:1000 dilutions) and a-tublin (1:2000) antibody were incubated overnight at 4 °C.

[0457] Membranes were washed in TBS / T five times and then incubated in diluted IRDye® 800CW secondary antibody for 1 h at room temperature in rolling conditions. Membranes were washed in TBS / T five times and imaged for fluorescence using Odyssey® Fc system.

[0458] ADMA Measurement. The ADMA analysis was performed after solid-phase extraction (SPE) with a Waters Oasis MCX 1 cc Vac Cartridge. The column was conditioned with 1 mL of elution buffer (10 / 0.5 / 40 / 50; 28-30% ammonium hydroxide / 1 M NaOH / water / methanol; v / v / v / v), followed by 1 mL of ultrapure water. Then 40 uL of plasma was mixed with 60 uL of PBS and loaded on the column. The column was lightly centrifuged and rinsed with 1 mL of 0.1M HC1 and 1 mL of MeOH two times. Then analytes were eluted with 450 uL elution buffer and dried under a gentle stream of nitrogen gas. Dried eluates were then redissolved in 50 uL of ultrapure water and derivatized with ortho-phthaldialdehyde (OP A) reagent (4:1; v / v). After mixing, the analytes were heated at 30 °C for 1 min and 10 uL was injected into the HPLC system, with a fluorescent detector RF-10AXL (ex: 340, em: 455) and Chromolith® performance RP-18e column (100 x 4.6 mm). Mobile phase A consisted of 25 mM potassium phosphate buffer (pH 6.5) and mobile phase B was methanol / THF (97 / 3; v / v). Chromatographic separation was performed at roomAttorney Docket No. 10877-004W01

[0459] temperature and a flow rate of 2 mL / min using 27 min gradient (10-22% solvent A). After elution, mobile phase was switched to 100% B for cleaning followed by 10% A for equilibration at a flow rate of 3 mL / min for 2 min each.

[0460] PAH model. A rat model of sugen-hypoxia-induced PAH was used. Male Sprague Dawley rats about 250g received a single sc injection of 20mg / kg sugen Day 0. The cages was controlled with air adjusted to receive a FiO2equivalent to 0.10 (10%) using a mixture of nitrogen and ambient air controlled by tire ventilated cage system. They were exposed to ambient oxygen levels from Day 22 to 56. Treatment with the compound or vehicle was administered by gavage bid at the dose of 30mg / kg twice a day beginning on Day 22.

[0461] Venous blood (0.5mL) was sampled from all groups on day 56. An echocardiogram monitoring was carried out using an echocardiograph (Model Q9) connected to a Chison 12.0 MHz probe on Day 22 and 56. The pulmonary artery maximum velocity (Vmax) and the cardiac output was the parameters used for the selection and randomization. After weeks, the disease development was determined by pulmonary artery (PA) pressure measurements, echocardiography, and histology. PA pressure was determined by right heart catheterization using a 1,4-F micromanometer-tipped Millar catheter with fluoroscopy guidance. Transthoracic echocardiography was performed using a GE vivid i with 5.0-13.0 MHz H2L-RS linear array transducer. Tissue and blood samples were collected at termination.

[0462] CKD model. Male Sprague Dawley rats (230 - 250 g) were purchased from Envigo (Indianapolis, IN). A total of 21 rats were maintained either on a 0.25% adenine diet (TD.08672, 1 Harlan, Teklad) or a control diet (TD.08670, Inotive) for total of 9 weeks. The diet contained 1%’ calcium, 1% phosphate, 0.2 mg / kg vitamin K, 6% protein and 0.25% adenine or 0% adenine. After 3 weeks on the adenine-fed diet, blood samples were collected from rat’s tail vein, and plasma creatinine was measured. The adenine-fed rats were randomized into two groups to ensure similar plasma creatinine levels at baseline, before starting the treatment. One group received Compound 101 (dose 20 mg / kg; administered twice by gavage with a total volume approx. 1.2 ml / day) and another group received vehicle (PEG300: Saline= 30:70 solvent, total gavage volume approx. 1.2 ml / day). Compound 101 was administered by gavage every day between 8 am to 9 am and 4:00 pm to 5:00 pm over a 6-week treatment period. The sham group, maintained on a control diet, received treatment similar to vehicle group throughout the study period. For each rat, plasma creatinine and body weight were measured after -1, -2,-4, -5 and -6 weeks of treatment.Attorney Docket No. 10877-004W01

[0463] After 6 weeks of treatment, animals were euthanized and blood and tissues collected for further analysis (see below). Blood (300 uL) was collected in heparinized-Eppendorf tube and centrifuged at 3000 xg for 10 minutes. Plasma was stored in -20 °C for later analysis. Kidney tissues were harvested either in -80 °C followed by snap frozen in liquid nitrogen or formalin for studying gene expression and tissue histopathology respectively.

[0464] Measurement of plasma creatinine and creatinine clearance. Plasma creatinine was quantified using a Point Scientific QT 180 Analyzer (Point Scientific Inc, USA) according to the manufacturer’s instructions. Creatinine clearance was estimated by plasma creatinine and body weight using Neural Network-Based Calculator developed by Pellicer-Valero et al 2022

[0045] , The link to the calculator is https: / / idal.uv.es / aclara / .

[0465] Histology for CKD model. To evaluate the renal and cardiac fibrosis, formalin-fixed paraffin-embedded sections were stained with Masson’s Trichrome stain and imaged with a Leica DMI 4000B microscope using a 20x objective, equipped with a Leica DEC 300 EX camera using Lieca LAS Software. At least 3 random images through the renal cortex and medulla were obtained from each

[0466] animal. Fibrosis segmentation was performed using the pixel classifier tool with QuPath software. Briefly, several annotations were made for each region of

[0467] interstitial fibrosis. A classifier was trained from the annotations and then applied to the set of images. 'The ratio of fibrosis was defined as the ratio between the area classified as interstitial fibrosis and the total surface of the image.

[0468] Histology for PAH model. The left lobes of the lungs were perfused and fixed in 10% formalin. A transversal section of the middle left lobe was cut and embedded in paraffin, sliced at 5 pm thicknesses. The slides were stained with H& E and F4 / 80 and imaged using a Nikon E600 light microscope with digital interface.

[0469] Statistical analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical analysis was performed with GraphPad prism 9.2 (GraphPad Software, USA). Dichotomous comparisons were made using Student’s t-test. Variables measured at multiple time-points were analyzed using repeated measures analysis of variance (AN OVA) or using two-way repeated measures analysis of variance (RM-ANOVA) as appropriate. To protect against increased risk of type 1 error from the use of multiple comparisons either Tukey’s test (when all possible comparison were made) or Dunnell’s test (when multipleAttorney Docket No. 10877-004W01

[0470] time-points were compared to a control condition) were applied. Student’s unpaired t-test was used for dichotomous comparisons. Two-sided P < 0.05 was considered statistically significant.

[0471] Preparation of Example SAhRMs

[0472] Synthesis of Compound 101

[0473] Compound 101 was prepared as shown below. First, 4-[2-(4-vinylphenoxy)ethyl]morpholine was prepared (Step 1). Then 3 -bromobenzonitrile was added to yield (E)-3-(4-(2-morpholinoethoxy) styryl) benzonitrile (Step 2). The final target was then isolated as the crystalline HC1 salt (Step 3).

[0474]

[0475] Synthesis of (E)-2-(4-(4-Fluorostyryl)phenyl)acetic acid (Compound 103)

[0476]

[0477] Step-1: Synthesis of methyl (E)-2-(4-(4-fluorostyryl)phenyl)acetate: To a stirring solution of l-fluoro-4-vinylbenzene (10 g, 81.87mmol, 1 eq) in triethylamine (100 mL) was added methyl 2-(4-bromophenyl)acetate (18.75 g, 81.87mmol, 1 eq) in a sealed tube and purged with argon for 5 min. To the reaction mixture was added tri-o-tolylPhosphine (4.98 g, 16.37mmol, 0.2 eq), Pd(OAc)2 (1.84 g, 8.19 mmol, 0.1 eq) at RT and again purged under argon for 5 min. The reaction mixture was heated to 100 °C and stirred for 16 h. The reaction mixture was cooled to RT, diluted with EtOAc (100 mL), and filtered through celite bed and concentrated in vacuo. The obtained crude compound was purified by silica gel column chromatography to afford methyl (E)-2-(4-(4-iluorostyryl)phenyl)acetate (14 g, 51.79 mmol, 63.26 % ).Attorney Docket No. 10877-004W01

[0478] Step-2: Synthesis of (E)-2-(4-(4-Fluorostyryl)phenyl)acetic acid. To a stirring solution of methyl (E)-2-(4-(4-fluorostyryl)phenyl)acetate ( 14 g, 51.79μmol,l eq ) in THF (70 mL) and Water (70 mL) was added LiOH (3.72g, 155.38mmol, 3 eq ) and stirred at RT for 3 h. The obtained aqueous layer was washed with EtOAc (30 mL) and then acidified with IN HC1. 'The precipitated solids were collected by filtration, dried under vacuum to afford (E)-2-(4-(4-fluorostyryl)phenyl)acetic acid (12.5g, 46.82mmol, 90.41%) (Compound 103).

[0479] Synthesis of tert-butyl (E)-(3-(4-fluorostyryl)phenyl)carbamate (Compound 102)

[0480]

[0481] Step-1: Synthesis of tert-butyl (3-bromophenyl)carbamate: To a stirring solution of 3-bromoaniline ( 2 g, 11.63 mmol, 1 eq ) in DCM ( 20 mL) was added triethylamine (2.95 mL, 29.07 mmol, 2.5 eq), BOC2O (3.04 mL, 13.95mmol, 1.2 eq) at RT and stirred at RT for 16 h. After completion of the reaction the reaction mixture was diluted with DCM (20 mL) and washed with water (20 mL), brine solution (20 mL), dried (over Na2SO4) and concentrated in vacuo. The obtained crude compound was purified by Combi-flash to afford tert-butyl (3-bromophenyl)carbaraate (1.4 g, 5.14mmol. 44.25 %).

[0482] Step-2: Synthesis of tert-butyl (E)-(3-(4-fluorostyryl)phenyl)carbamate: To a stirring solution of tert-butyl (3-bromophenyl)carbamate (1 g, 3.67mmol 1 eq ) in triethylamine (10 mL) was added l-fluoro-4-vinylbenzene (0.448g, 3.67mmol, leq) in a sealed tube and purged with argon for 5 min. To the reaction mixture was added tri o- tolylPhosphine (0.25g, 0.734mmol 0.2 eq), PdtOAc (0.8 g, 0.367mmol, 0.1 eq) atRT and again purged under argon for 5 min. The reaction mixture was heated to 100 °C and stirred for 8 h. After completion of the reaction, the reaction mixture was cooled to RT, diluted with EtOAc (100 mL), and filtered through celite bed and concentrated in vacuo. The obtained crude compound was purified by silica gel column chromatography to afford methyl tert-butyl (E)-(3-(4-fluorostyryl)phenyl)carbamate (0.4 g, 1.28 mmol, 34.74 % ) (Compound 102).

[0483] Synthesis of (E)-5-(4-fluorostyryl)thiophene-2-carboxylic acid (Compound 117)Attorney Docket No. 10877-004W01

[0484]

[0485] Step-1: Synthesis of (E)-5-(4-fluorostyryl)thiophene-2-carboxylic acid: To a stirring solution of l-fluoro-4-vinylbenzene (0.5 g, 4.09mmol, 1 eq) in triethylamine (5 mL) was added 5-bromothiophene-2-carboxylic acid (0.847g, 4.09mmol, leq) in a sealed tube and purged with argon for 5 min. To the reaction mixture was added tri-o-tolylphosphine (0.288g, 0.818 mmol 0.2 eq), Pd(OAc)2 (0.091g, 0.409mmol 0.1 eq) atRT and again purged under argon for 5 min. The reaction mixture was heated to 100 °C and stirred for 16h. After completion of the reaction the reaction mixture was cooled to RT, diluted with EtOAc (50 ml.,), and filtered through celite bed and concentrated in vacuo. The obtained crude compound was purified by silica gel column chromatography to afford (E)-5-(4-fluorostyryl)thiophene-2-carboxylic acid (0.2g, 0.80 mmol, 19.68 % ) (Compound 117).

[0486] Synthesis of (E)-3-(4-fluorostyryl)thiophene-2-carboxylic acid (Compound 118)

[0487]

[0488] Step-1: Synthesis of (E)-3-(4-fluorostyryl)thiophene-2-carboxylic acid: To a stirring solution of l-fluoro-4-vinylbenzene (0.25g, 2.05mmol, 1 eq) in triethylamine (5 mL) in a sealed tube stirred was added 3-Iodothiophene-2-carboxylic acid (0. 19 g, 2.05mmol, leq) and purged with argon for 5 min. To the reaction mixture was added tri o- tolylPhosphine (0.144g, 0.409mol, 0.2 eq), Pd(OAc)2 (0.045 g, 0.204mmol, 0.1 eq) at RT and again purged under argon for 5 min. The reaction mixture was heated to 100 °C and stirred for 16 h. After completion of the reaction the reaction mixture was cooled to RT, diluted with EtOAc (25 mL), andfiltered through celite bed and concentrated in vacuo. The obtained crude compound was purified by silica gel column chromatography to afford (£’)-Attorney Docket No. 10877-004W01

[0489] 3-(4-fluorostyryl)thiophene-2-carboxylic acid (0.2g, 0.80mmol, 19.68 % )(Compound 118).

[0490] Synthesis of (E)-N-(3-(4-fluorostyryl)benzyl)methanesulfonamide (Compound

[0491]

[0492] Step-1: Synthesis of tert-butyl (3-iodobenzyl)carbamate: To a stirring solution of (3-iodophenyl)methanamine (2 g, 8.58mmol, 1 eq ) in DCM ( 20 mL) was added

[0493] triethylamine (2.17 mL, 21.45mmol, 2.5 eq), Boc2O (2.25mL, 10.30mmol, 1.2 eq) at RT and stirred at RT for 16 h. After completion of the reaction the reaction mixture was diluted with DCM (20 mL) and washed with water (20 mL), brine solution (20 mL), dried (over Na2SO4) and concentrated concentrated in vacuo. The obtained crude compound was

[0494] purified by Combi-flash to afford tert-butyl (3-bromophenyl)carbamate. (1.5 g, 4.50mmol.

[0495] 52%).

[0496] Step-2: Synthesis of tert-butyl (E)-(3-(4-fluorostyryl)benzyl)carbamate: To

[0497] stirred solution of tert-butyl (3-iodobenzyl)carbamate (0.5g, 1.50mmol, leq) in DMF (3mL) was added l-fluoro-4-vinylbenzene (0.2g, 1.65mmol, 1.1 eq), triethylamine (0.379mL, 3.75mmol, 2.5 eq), tri-o-tolylphosphine (0.144g, 0.40mmol, 0.2 eq) in a sealed tube and purged with argon for 5 min. To the reaction mixture was added Pd(OAc)2 (0.033g, 0.150mmol, O.leq) and heated to 100 °C for 10 h. After completion of the reaction, the reaction mixture was cooled to RT and diluted with EtOAc (50 mL). The reaction mixture was filtered through celite bed and concentrated in vacuo. The obtained crude compound was purified by silica gel column chromatography to afford tert-butyl (E)-(3-(4-fluorostyryl)benzyl)carbamate (0.2g, 0.61mmol, 40%).

[0498] Step-3 Synthesis of (E)-(3-(4-fluorostyryl)phenyl)methanamine: To stirred

[0499] solution of tert-butyl (E)-(3-(4-fluorostyryl)benzyl)carbamate (0.19g, 0. 80mmol, 1 eq) inAttorney Docket No. 10877-004W01

[0500] 1,4-Dioxane (1 ml.,) was added 4M HC1 in Dioxane (1 ml.,) at 0°C and stirred for 30 min at RT. The reaction was monitored by TLC,. After completion of the reaction, the reaction was evaporated to dryness to afford (E)-(3-(4-fluorostyryl)phenyl)methanamine (0.12g 0.52 mmol 90%) as a HC1 salt.

[0501] Step-4: Synthesis of (E)-(3-(4-fluorostyryl)phenyl)methanamine: To stirred solution of (E)-(3-(4-fluorostyryl)phenyl)methanamine (0.1g, 0.43mmol, 1 eq ) in DCM (2 mL) was added triethylamine (0.170 mL, 1.32mol 3eq) and cooled the reaction to -20 °C. To the reaction mixture MsCl (0.060g, 0.52mmol, 1.2 eq) was added slowly at -20 °C and stirred at RT for 3h. After completion of the reaction, the reaction mixture was evaporated to dryness. The obtained crude compound was taken in EtOAc (20 mL) and was washed with sat. NaHCO3 solution (5 mL) dried (over Na2SO4) and concentrated in vacuo. The obtained crude compound was purified by Combi-flash to afford (E)-N-(3-(4-fluorostyryl)benzyl)methanesulfonamide ( 0.050g, 0.163 mmol, 0.04%) (Compound 110).

[0502] Synthesis of (E)-3-(4-fluorostyryl)aniline (Compound 111)

[0503]

[0504] Step-1: Synthesis of (E)-3-(4-fluorostyryl)aniline: To stirred solution of tert-butyl (E)-(3-(4-fluorostyryl)phenyl)carbamate (0.020g, 0.063mmol, leq) in 1,4-Dioxane (0.5 mL) was added 4M HC1 in Dioxane (0.5 mL) at 0°C and stirred at RT for 1 h. The reaction mixture was stirred for 30 min at RT. The reaction was monitored by TLC, after completion of the reaction the reaction solvent was removed under reduced pressure and dried. The obtained crude compound was taken DCM (5 mL) and basify using 10%’ NaHCO3 solution. The organic layer was separated, dried (over Na2SO4) and evaporated to dryness to afford (E)-(3-(4-fluorostyryl)phenyl)methanamine (0.015g 0.07 mmol 98%) (Compound 111).

[0505] Synthesis of (E)-N-(3-(4-fluorostyryl)phenyl)methanesulfonamide (Compound 112)

[0506]

[0507] Step-1: Synthesis of (E)-N-(3-(4-fluorostyryI)phenyl)methanesulfonamide: To stirred solution of (E)-3-(4-fluorostyryl)aniline (0.1g, 0.468mmol, leq) in DCM (2 mL)Attorney Docket No. 10877-004W01

[0508] was added triethylamine (0.182mL, 1.41mmol, 3eq) and cooled the reaction mixture to -20°C. To the reaction mixture MsCl (0.64g, 0.56mmol, 1.2 eq) was added slowly at -20°C. The reaction mixture was stirred at RT for 3h. The reaction solvent was removed under reduced pressure, add sat. NaHCO3 (5 mL) and extracted by EtOAc (2x5 mL), dried (over Na2SO4) and concentrated in vacuo. The obtained crude compound was purified by Combi-flash to afford (E)-N-(3-(4-fluorostyryl)phenyl)methanesulfonamide ( 0.025g, 0.085 mmol, 18%) (Compound 112).

[0509] Synthesis of (E)-l-(3-(4-fluorostyryl)phenyl)urea (Compound 104)

[0510]

[0511] Step-1: Synthesis of (E)-l-(3-(4-fhiorostyryl)phenyl)urea: To stirred solution of (E)-3-(4-fluorostyryl)aniline (0.15g, 0.70mmol, leq) in AcOH (2 mL) and Water (0.5 mL) was added sodium cyanate (0.91g, 1.41 mmol 2eq) at RT and heated at 50 °C for 3h. After completion of the reaction, the reaction was diluted with water (10 mL) and extracted with EtOAC (2xl0mL) dried (over Na2SO4) and concentrated in vacuo. The obtained crude compound was purified by Combi-flash to afford (E)- l-(3-(4-fluorostyryl)phenyl)urea (0.04g, 0.15mmol, 22%) (Compound 104).

[0512] Synthesis of (E)-2-(4-(4-fluorostyryl)phenyl)-N-phenylacetamide (Compound 105)

[0513]

[0514] Step-1: Synthesis of (E)-2-(4-(4-fluorostyryl)phenyl)-N-phenylacetamide: To a stirred solution of (E)-2-(4-(4-fluorostyryl)phenyl)acetic acid ( 0.1g, 0.39mniol, leq) in DCM (5 mL), were added DIPEA (0.20ml., 0.78 mmol, 2 eq), HATU (0.183g, 0.78mmol, 1.5eq) followed by Aniline (0.054g, 0. 8mmol, 1.5 eq) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. After completion of the reaction, the reaction mixture was quenched with water (5 mL) and extracted with DCM (15 mL). The combined organic layers were washed with brine (10 mL). dried over anhydrous Na2SO4 and concentrated under reduced pressure. The obtained crude was compound was purified by Combi-flash toAttorney Docket No. 10877-004W01

[0515] get 150 mg of desired product with 30% purity. The enriched material has been purified by prep-HPLC purification to afford (E)-2-(4-(4-fluorostyryl)phenyl)-N-phenylacetamide (30 mg, 23%) (Compound 105).

[0516] Synthesis of (E)-2-(4-(4-fluorostyryl)phenyl)propanoic acid (Compound 106):

[0517]

[0518] Step-1: Synthesis of methyl 2-(4-bromophenyl)propanoate: To a stirred solution of methyl 2-(4-bromophenyl)acetate (0.5g, 2.18mmol, leq) in Anhydrous THF (5 mL), were added LDA (0.86 mL, 2.62mmol, 1.2 eq) dropwise at -78°C, stirred 30 min at -78°C, and Mel (0.16mL, 2.62mmol, 1.2eq) was added by at -78°C. The reaction mixture was stirred at -78°C. After completion of the reaction, the reaction mixture was quenched with sat. NH4C1 (5 mL) and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The obtained crude compound was purified by Combi-flash to afford methyl 2-(4-bromophenyl)propanoate (0.3g, 1.23mmol, 56%)

[0519] Step-2: Synthesis of methyl (E)-2-(4-(4-fluorostyryl)phenyl)propanoate: To a stirring solution of methyl 2-(4-bromophenyl)propanoate (0.3g, 1.23mmol, 1 eq) in triethylamine (5 mL) in a sealed tube stirred was added 1 -fluoro-4-vinylbenzene (0.15 g, 1.23mmol, leq) and purged with argon for 5 min. To the reaction mixture was added tri-o-tolylphosphine (0.030g, 246.81μmol, 0.2 eq), Pd(OAc)2 (0.027 g, 123.41μmol, 0.1 eq) at RT and again purged under argon for 5 min. The reaction mixture was heated to 100 °C and stirred for 16 h. After completion of the reaction the reaction mixture was cooled to RT and diluted with EtOAc (1 mL). The reaction mixture was filtered through celite bed and concentrated in vacuo. The obtained crude compound was purified by silica gel column chromatography to afford methyl (E)-2-(4-(4-fluorostyryl)phenyl)propanoate (0.2g, 805.57μmol, 19.68% ).Attorney Docket No. 10877-004W01

[0520] Step-3: Synthesis of (E)-2-(4-(4-fluorostyryl)phenyl)propanoic acid: To a stirring solution of methyl (E)-2-(4-(4-fluorostyryl)phenyl)propanoate (0.1 g, 51.79μmol, l eq ) in THE (5mL) and Water (2mL) was added LiOH (38 mg, 1.58mmol, 3 eq ) and stirred at RT for 3 h. After completion of the reaction the reaction mixture was evaporated to remove THE. The obtained aqueous layer was washed with EtOAc (10 mL) and then acidified with IN HC1. The precipitated solids were collected by filtration, dried under vacuum to afford (E)-2-(4-(4-fluorostyryl)phenyl)propanoic acid (80 mg, 0.29 mmol, 56%) (Compound 106).

[0521] Synthesis of (E)-5-(3-(4-fluorostyryl)phenyl)-lH-tetrazole (Compound 108)

[0522]

[0523] Step-1: Synthesis of (E)-3-(4-fluorostyryl)benzonitrile (3): To a stirring solution of 3-iodobenzonitrile 1 (2.5 g, 0.01 mmol, 1 eq) and l-fluoro-4-vinylbenzene (3.16 g, 0.014 mmol) in 1,4-dioxane (30 niL) under inert atmosphere were added Triethyl amine (4.41 g, 0.043 mmol, 4 eq) at RT and purged under argon atmosphere for 15 min. To this was added Pd(PPh3)4 (367 mg, 0.05 eq) and purged under argon atmosphere for 10 min; heated to 100 °C and stirred for 16 h. After completion of the reaction, filtered through celite bed and concentrated in vacuo to obtain the crude. The crude was purified by silica gel column chromatography using 20% EtOAc / heptanes to afford (E)-3-(4-fluorostyryl) benzonitrile 3 (750 mg, 25.8 %) as a pale yellow solid.

[0524] Step-2: Synthesis of (E)-5-(3-(4-fluorostyryl)phenyl)-lH-tetrazole (Compound 108): To a stirring solution of (E)-3-(4-fluorostyryl)benzonitrile 3 (250 mg, 1.11 mmol, 1 eq) in DMF (5 ml.., 20 vol) under inert atmosphere were added NaN3 (218 mg, 3.35 mmol, 3 eq) and AlCh (21 mg, 0.1 mmol, 0.14 eq) at RT and the reaction mixture was stirred heated at 120 °C and stirred for 16 h. After completion of the reaction, the reaction mixture was poured in ice cold water (10 mL), the precipitated solid was filtered and dried. The solid was triturated with Di ethyl ether (5 mL) to afford the (E)-5-(3-(4-fluorostyryl)phenyl)-lH-tetrazole (Compound 108) (90 mg, 30.1%) as an off-white solid.

[0525] Synthesis of (E)-2-(3-(4-fluorostyryl)phenoxy)acetic acid (Compound 109)Attorney Docket No. 10877-004W01

[0526]

[0527] Step-1: (E)-3-(4-Fluorostyryl)phenol: To a stirred solution of l-fluoro-4- vinylbenzene (0.5g, 4.09mmol, leq) and 3-bromophenol (0.708 g, 4.09, leq) in 1,4 Dioxane was added Cs2CO3 (2.67g, 8.19mmol, 2eq) and the reaction mixture was purged with argon gas for 20 min. To this stirred reaction mixture Pd (PPh3)4 (0. 378g 327.49μmol, 0.08eq) was added and the resulting reaction mixture was heated to 90°C for 16 h. After completion of the reaction, the reaction mixture was quenched with water (20 mL) and extracted with Ethyl acetate (2x15 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by Combi flash to afford (E)-3-(4-fluorostyryl)phenol (0.400 g, 1.87mmol, 45.61%).

[0528] Step-2: Ethyl (E)-2-(3-(4-fluorostyryl)phenoxy)acetate: To a stirred solution of (E)-3-(4-fluorostyryl)phenol (0.2g, 933.54μmol, leq) in ACN (3niL) was added K2CO3 (0.387g, 2.80mmol, 3 eq) and ethyl 2-bromoacetate (1.55g, 933.54μmol, leq) at RT. The resulting reaction mixture was heated to 70°C for 6 h. After completion of the reaction, the reaction mixture was diluted with water (15 mL) and extracted with Ethyl acetate (2x10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by Combi flash to afford ethyl (E)-2-(3-(4-fluorostyryl)phenoxy)acetate (0.160g, 532.75μmol, 57.07).

[0529] Step-3: (E)-2-(3-(4-fluorostyryl)phenoxy)acetic acid: To a stirring solution of ethyl (E)-2-(3-(4-fluorostyryl)phenoxy)acetate (0.16 g, 532.75μmol,1 eq ) in THE (3mL) and water (3 mL) was added LiOH (0.038g, 1.60mmol, 3 eq ) and stirred at RT for 3 h. After completion of the reaction the reaction mixture was evaporated to remove THE. The obtained aqueous layer was diluted with water (10ml) and washed with EtOAc (5 mL) and then acidified with IN HC1. The precipitated solids were collected by filtration, dried under vacuum to afford (E)-2-(3-(4-fluorostyryl)phenoxy)acetic acid ( 0.1g, 367.28μmol 68.94%) (Compound 109).

[0530] Results and Discussion

[0531] Compound 101 inhibited AhR activation. Figures 1A-1B show that in the presence of AhR agonist 6-formylindolo (3,2-b) carbazole (FICZ), Compound 101Attorney Docket No. 10877-004W01

[0532] produced a concentration -dependent inhibition of AhR promoter activity. The effect was unexpectedly dependent on the nature of the ligand. For example, the 50% inhibitory concentration of FICZ was 644nM (Figure 1A). AhR inhibition was also demonstrated by the inhibition of Compound 101 on AhR agonist induced C YP1 Al gene expression in endothelial cells (Figure IB).

[0533] Compound 101 is a selective modulator of AhR. Our investigation showed that Compound 101 selectively modulated AhR activity. Using an assay involving AhR-dependent recruitment of its co-activator Steroid Receptor Co-activator (SRC) in cells expressing SRC peptide-P-Galactosidase (P-gal) fusion protein we found that AhR agonist FICZ induced chemiluminescence signal as a result of SRC-P-gal-AhR interaction (Figure 2A). A lack of chemiluminescence signal in the Compound 101 treated cells indicated that it did not act as an AhR agonist in the SRC recruitment assay. Figure 2B shows that treatment with a known AhR antagonist CH-223192 inhibited the activity of FICZ, whereas Compound 101 did not inhibit FICZ induced SRC-P-gal recruitment. These data showed that unlike the AhR antagonist CH-223192, Compound 101 did not involve recruitment of co-activator SRC, indicating its selectivity toward AhR co-activators.

[0534] Studies with different cell types also showed that Compound 101 acted in a cell selective manner. As shown in Figure 3A, Compound 101 inhibited CYP1A1 expression in response to AhR agonist Sugen in endothelial cells. On the other hand, Compound 101 enhanced response to AhR agonist Sugen in HepG2 cells (Figure 3B). These data show that Compound 101 exhibited Selective Aryl hydrocarbon Receptor Modulation (SAhRM) activity which was cell-type dependent.

[0535] That Compound 101 exhibited unique activity as compared to AhR antagonist was also demonstrated by DDAH-1 gene expression in HPASMC as shown in Figure 4.

[0536] Cell selectivity of compounds is further illustrated by inhibition of AhR in human pulmonary artery smooth muscle cells where as stimulation in hepatocyte HepG2 cells (Figure 5).

[0537] Compound 101 inhibited pulmonary artery smooth muscle cell responses associated with PAH. Lung arterial smooth muscle cells play a critical role in the aterial wall thickening and PAH disease progression. We examined the effect of Compound 101 on the proliferation of human pulmonary artery smooth muscle cells (HPASMC) and theAttorney Docket No. 10877-004W01

[0538] generation of reactive oxygen species (ROS). Figures 6A-6B show that Compound 101 inhibited the proliferation of HPASMC and ROS generation.

[0539] We also examined the effect of Compound 101 on fibrosis pathway genes in HPASMC. Figures 7A-7B show that AhR agonist increased the expression of fibrosis genes Collagenl Al (Figure 7A) and TGF-P (Figure 7B) in HPASMC. Treatment with Compound 101 significantly reduced the expression of Collagenl Al and TGF-p. These data show that Compound 101 inhibited major cellular response involved in the pathology of PAH.

[0540] Disease modifying efficacy of Compound 101 in rat PAH model. The activation of the AHR pathway plays a critical role in humans with PAH and preclinical models. Therefore, inhibition of AhR may provide a new mechanistic approach for the treatment of the progressive vascular pathology of PAH. Based on the cellular activities of Compound 101 on HPASMC and the desirable pharmacokinetic properties, we tested Compound 101 in the Sugen-Hypoxia (Su-Hx) model of PAH. It is considered a most relevant preclinical model of PAH. Compound 101 was tested in a treatment protocol by administering after the initiation of disease by exposure to Sugen and Hypoxia. The data in Figures 8A-8B show the increased in pulmonary pressure in the Sugen-Hypoxia treated group. Administration of Compound 101 starting 3 weeks after disease initiation significantly reduced systolic pulmonary pressure (sPAP) and right ventricular systolic pressure (RVSP).

[0541] Histological assessment and quantification of small and medium size artery occlusion in the lung showed a significant reduction in arterial wall thickening and the number of muscularized vessels (Figures 9A-9B) indicating that Compound 101 reduced vascular remodeling and disease progression in the lung. Inflammation in the lung plays a major role PAH development in humans and preclinical models. Figure 10 shows that in the Su-Hx model there was a high level of macrophage infiltration in the lungs of the vehicle control group whereas In the Compound 101, treated group macrophage infiltration was greatly reduced. The efficacy studies have demonstrated that Compound 101 significantly reduced arterial wall thickening, lung inflammation and improved sPAP.

[0542] These findings support the modification of vascular remodeling by Compound 101, a predominant feature of PAH pathology. In addition, inflammation is another important driver in the progressive pathophysiology of PAH. In these studies, macrophage infiltration in the lungs was reduced by greater than 90% in the Compound 101 treated animals.

[0543] Compound 101 inhibited AhR activation by uremic toxin Indoxyl sulfate.

[0544] Indoxyl sulphate (IS) is a major uremic toxin that acts as an activator of AhR. High indoxylAttorney Docket No. 10877-004W01

[0545] sulphate occur in CKD and kidney failure patients which contributes to CKD progression and complications of CKD such as cardiovascular disease. Figures 11 shows that Compound 101 inhibited activity of indoxyl sulfate in the AhR promoter assay and also inhibited AhR pathway gene cyp1A1 expression in human kidney

[0546] HK-2 cells.

[0547] Compound 101 reduced indoxyl sulfate mediated oxidative stress and fibrosis gene expression in renal tubular HK-2 cells. In order to determine if the antagonism of AhR by Compound 101 reduced the pathological responses to IS, we determined the effect of Compound 101 on oxidative stress and fibrosis gene expression in human kidney tubular HK-2 cells. Figure 12A shows that treatment of kidney tubular HK-2 cells with IS induced production of reactive oxygen species (ROS) which was significantly reduced by treatment with Compound 101. IS increased the expression of fibrosis genes TGF-P and collagenlAl in HK-2 cells. Treatment with Compound 101 significantly reduced the IS induced fibrosis genes TGF-P (Figure 12B) and collagenlAl (Figure 12C). These data showed that in kidney tubular’ cells, Compound 101 antagonized indoxyl sulphate and reduced the pathological responses associated with AhR activation.

[0548] Compound 101 reduced kidney disease progression in a rat model. Based on the inhibition of AhR activation and the pathological responses induced by IS, we tested the effect of Compound 101 on CKD progression in a rat model. For these studies, we have used the adenine diet fed model of CKD. Animals were fed 0.25% adenine containing diet for three weeks to initiate kidney disease. The animals were then randomized into vehicle or Compound 101 treatment groups and continued on the adenine diet for an additional 6 weeks. Figure 13B shows that creatinine levels in the vehicle group continued to rise over the experimental period indicating further development of progressive kidney dysfunction. In animals treated with Compound 101, the creatinine levels were significantly reduced as compared to the vehicle group at 4 weeks onward. These data suggest that Compound 101 reduced progression of CKD.

[0549] Compound 101 reduced fibrosis in CKD model. Fibrosis is a major pathology of progressive kidney disease and particularly important in diabetic kidney disease. Previous studies have shown that fibrosis is a prominent feature of the adenine induced CKD in rats. We performed histological staining of kidneys from sham, vehicle and Compound 101 treated animals for fibrosis using trichrome staining and then quantification using image analysis. The trichrome staining in Figure 14 shows that adenine diet induced severe tubularAttorney Docket No. 10877-004W01

[0550] interstitial fibrosis in the vehicle treated animals. Extensive fibrosis was observed in the cortex as well as in the medulla. Quantitative image analysis showed that in the kidneys of Compound 101 treated animals, fibrosis was significantly reduced in the cortex and medulla. These data provided strong evidence of reduced disease progression in the Compound 101 treated animals.

[0551] Compound 101 reduced cardiac fibrosis. Cardiac fibrosis is an important consequence of CKD in humans and in animal models. To determine if the fibrosis in the heart of CKD animal was affected by Compound 101, we analyzed fibrosis in trichrome stained hearts harvested from the animals participated in this study. Figure 14 shows that animals on adenine diet developed significant fibrosis in the heart which was reduced in the animals treated with Compound 10. Thus, Compound 101 exhibited strong antifibrotic activity in the kidney and the heart.

[0552] Compound 101 reduced AhR pathway genes in the kidney: The effect of Compound 101 on AhR pathway gene expression in the kidney of adenine induced CKD rats was examined. A hallmark of AhR activation is the induction of CYP1 Al gene in the target tissues. We analyzed the kidney extracts from the sham, vehicle and Compound 101 treated animals for CYP1A1 expression by western blotting. Figure 15A shows that vehicle group with severe kidney disease exhibited significantly higher levels of CYP1A1 as compared to the kidneys from the sham animals. In Compound 101 treated animals the kidney level of CYP1A1 was significantly reduced. These data show that Compound 101 treatment effectively reduced AhR activation in the kidney. Since, we observed a major effect of Compound 101 treatment on fibrosis in the kidney, we examined the AhR induced fibrosis pathway genes in the three experimental groups. Figure 15B and C, shows that in Compound 101 treated animals, the expression of fibrosis pathway gene including collagenlAl and TGF-0 were significantly attenuated. The histological analysis of fibrosis and the reduced expression of fibrosis molecular markers in the kidney show that Compound 101 produced a major effect on fibrosis in the kidney.

[0553] Compound 101 reduced obesity in a rat model: As shown in Figures 16A-16B, Compound 101 reduced body weight in both male and female rats as compared to a control.

[0554] Compound 107 reduced fibrosis in a mouse liver injury model: As shown in Figure 17, Compound 107 also reduced fibrosis in mouse liver injury model.Attorney Docket No. 10877-004W01

[0555] Figure 17 shows the percent collagen in liver slices of sham, vehicle and Compound 107 treated groups. For CCL4 liver model, animals received intraperitoneal injection of 5 pl per gram (0.5mL / kg) of 10% CC14 solution twice weekly for 4 weeks. Treatment with Compound 107 was initiated on Day 0 by oral administration twice a day. After 4 weeks liver was perfused with ice-cold PBS, harvested and dissected for homogenization to quantify hydroxyproline and collagen content. A third part of the liver was fixed with 10% neutral buffered formalin, embedded in paraffin, sliced at 5 pm thickness, mounted, stained with Hematoxylin and Eosin (H& E). Another two slices per liver sample will be stained with Sirius Red for collagen quantification and Ishak Scale

[0556] The AhR ligands progressively accumulate in serum during CKD progression, reaching 30-100 fold higher in ESRD patients than the normal population. The persistent high levels of IS may contribute to cardiac complications in dialysis patients. For example, high IS plasma levels corelate with higher incidence of first heart failure event in dialysis patients. IS is considered a risk factor for cardiovascular complications of CKD and a strong predictor of overall and cardiovascular mortality risk in CKD patients. Furthermore, serum IS levels corelate with the magnitude of aortic calcification, vascular stiffness and cardiovascular mortality. A variety of studies in cellular systems have shown that AhR activation by IS induces oxidative stress, progressive glomerular damage, podocytes injury, pro-inflammatory phenotype and TGF-p l production. Accumulation of IS induces glomerular sclerosis, interstitial fibrosis, nephron loss, and damage to renal tubulointerstitial cells and vasculature.

[0557] Our studies showed that Compound 101 inhibited AhR activation by IS and prevented the expression of AhR modulated downstream gene expression. In vitro, Compound 101 inhibited reactive oxygen species (ROS) induced by IS in kidney tubular HK-2 cells. Such reduction in ROS may reduce the progressive damage to the kidney and mitigate CKD pathogenesis. Further, Compound 101 produced significant reduction in fibrosis genes induced by IS. These studies show that Compound 101 directly attenuated the mechanisms involved in AhR activation and CKD.

[0558] Our in vivo studies have shown that oral administration of Compound 101 significantly reduced the progressive increase in serum creatinine levels over time in the adenine induced CKD model. More importantly, the animals treated with Compound 101 exhibited significant reduction in fibrosis in the kidney as well as in the heart. Our studies have further established that in vivo efficacy of Compound 101 is mediated by reducingAttorney Docket No. 10877-004W01

[0559] AhR pathway signaling. In particular, Compound 101 produced a major reduction in fibrosis in the kidney and the fibrosis pathway genes collagen 1 Al and TGF- p. The reduction in kidney fibrosis and the fibrosis pathway marker are particularly important pharmacological properties of Compound 101.

[0560] The role of AhR in fibrosis is complex and may be dependent on the target organ and the presence of certain ligand. For example, studies in liver disease models have shown that AhR activation reduces fibrosis. Similarly, AhR activation with agonist FICZ was found cardioprotective in mice, preventing cardiac hypertrophy and reducing the expression of pro-fibrotic genes. Whereas other studies have shown that AhR plays a profibrotic and proinflammatory role and therefore inhibition of AhR is beneficial. Thus, the selectivity for modulating the signaling pathway and the resulting physiological outcome are critical considerations for targeting AhR for the development of therapeutic strategy. In the case of kidney disease, AhR plays a disease promoting mechanism which was effectively reduced by Compound 101. Thus far, no AhR antagonist has been tested for treatment of human CKD. Compound 101 is a new mechanism-based therapy for CKD and provides a new paradigm for drug targeting for CKD and fibrosis.

[0561] Table 1. Pharmacokinetic (PK) properties of Compound 101 in rats. Rats were doses intravenously (IV) or orally (PO ). Blood samples were collected at 0.083, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, and 24 h. and analyzed by LC / MS.

[0562]

[0563] Example 2. Activity of Example Aryl Hydrocarbon Receptor Modulators

[0564] Table 2 below summarizes the aryl hydrocarbon receptor modulating activity of other example compounds described herein.

[0565] Table 2. Aryl Hydrocarbon Receptor Modulating Activity of Example Compounds

[0566]

[0567] Attorney Docket No. 10877-004W01

[0568]

[0569] Attorney Docket No. 10877-004W01

[0570]

[0571] Attorney Docket No. 10877-004W01

[0572]

[0573] Attorney Docket No. 10877-004W01

[0574]

[0575] Attorney Docket No. 10877-004W01

[0576]

[0577] Attorney Docket No. 10877-004W01

[0578]

[0579] Attorney Docket No. 10877-004W01

[0580]

[0581] Attorney Docket No. 10877-004W01

[0582]

[0583] The promoter assay was performed in the presence of 1.3 pM compound and 10 nM AhR agonist Sugen.

[0584] The CYP1 Al assay was performed in the presence of 20 pM compound and 1 pM Sugen, 10 nM FICZ*. or 200 pM Kynurenine#.

[0585] Table 3. Additional Example Aryl Hydrocarbon Receptor ModulatorsAttorney Docket No. 10877-004W01

[0586]

[0587]

[0588] Attorney Docket No. 10877-004W01

[0589]

[0590] Other example aryl hydrocarbon receptor modulators include the compounds shown below.

[0591]

[0592] Attorney Docket No. 10877-004W01

[0593]

[0594] Attorney Docket No. 10877-004W01

[0595]

[0596] Preparation of Example Aryl Hydrocarbon Receptor Modulators

[0597]

[0598] Synthesis of (£')-3-(4-fluoro-2-methylstyryl)benzenesulfonamide (Compound

[0599]

[0600] Step-1: Synthesis of 4-fluoro-2-methyl-l-vinylbenzene (LIL- 104-087): A 250 mL round-botom flask was charged with methyl triphenyl phosphine bromide (10g, 0.028 mol, 2 equiv) and tetrahydrofuran (THF, 100 mL). The reaction mixture was cooled to -10 °C, and sodium bis(trimethylsilyl)amide solution (5.13 g, 29 mL, 0.028 mol, 2 equiv) was added dropwise. The reaction mixture was then stirred at 0 °C for 1 h. Subsequently, the mixture was cooled again to -10 °C, and 4-fIuoro-2 -methylbenzaldehyde (2 g, 0.014 mol, 1 equiv) was added slowly. The reaction mixture was stirred at room temperature for 16 h.Attorney Docket No. 10877-004W01

[0601] The reaction mixture was quenched with a saturated ammonium chloride (NEkCl) solution and extracted with ethyl acetate. The organic layer was separated, and the aqueous phase was extracted with ethyl acetate. The combined organic layers were dried over anhy.

[0602] NaiSCh and concentrated under reduced pressure. The crude product was purified by column chromatography using 5% ethyl acetate in hexane as the eluent. 'The desired product, 1 -ethenyl -4-fluoro-2-methylbenzene, was obtained as a pure compound 4-fluoro-2-methyl-l-vinylbenzene 1.2 g (0.0088 mol, 61 % yield) as colorless liquid.

[0603]

[0604] Step-2: Synthesis of (E)-3-(4-fluoro-2-methylstyryl)benzenesulfonamide (L1L-104-088): A 50 mL sealed tube round-bottom flask was charged with 1 -ethenyl -4-fluoro-2-methylbenzene (400 mg, 2.938 mmol, 1 equiv) dissolved in N, N-dimethylfonnamide (DMF, 5 mL). To this solution, 4-bromobenzenesulfonamide (693.6 mg, 2.938 mmol, 1 equiv), tetrabutylammonium iodide (97.5 mg, 0.264 mmol, 0.09 equiv), and potassium carbonate (1218.1 mg, 8.814 mmol, 3 equiv) were added. The reaction mixture was degassed for 30 minutes. Palladium (II) acetate (59.3 mg, 0.264 mmol, 0.09 equiv) was then added, and the reaction mixture was heated to 100 °C and maintained at this temperature for 16 hours. After completion of the reaction, the mixture was cooled, and water was added. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhy. NasSO4 and concentrated under reduced pressure. The crude product was purified by column chromatography using a gradient of 20% ethyl acetate in hexane, followed by 30% ethyl acetate in hexane, to afford the desired product (E)-3-(4-fluoro-2- methylstyryl)benzenesulfonamide, 80 mg (10%) as off-white solid.

[0605] Synthesis of (E)-3-(4-fluoro-2-methylstyryl)benzamide (Compound 148)

[0606]

[0607] A 50 mL sealed tube round-bottom flask was charged with 1 -ethenyl -4-fluoro-2-methylbenzene (400 mg, 2.938 mmol, 1 equiv) and dissolved in N, N-dimethylformamideAttorney Docket No. 10877-004W01

[0608] (DMF, 5 mL). To this solution, 4-bromobenzenesulfonamide (693.6 mg, 2.938 mmol, 1 equiv), tetrabutylammonium iodide (97.5 mg, 0.264 mmol, 0.09 equiv), and potassium carbonate (1218.1 mg, 8.814 mmol, 3 equiv) were added. The reaction mixture was degassed for 30 minutes. Palladium(II) acetate (59.3 mg, 0.264 mmol, 0.09 equiv) was then added, and the reaction mixture was heated to 100 °C and maintained at this temperature for 16 hours. After completion of the reaction, the mixture was cooled, and water was added. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhy. Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography using a gradient of 20% ethyl acetate in hexane, followed by 30% ethyl acetate in hexane, to afford the desired product.

[0609] Synthesis of (E)-3-(4-methoxy-2-(trifluoromethyl)styryl)benzenesulfonamide (Compound 127)

[0610]

[0611] Step-1: Synthesis of 3-vinylbenzenesulfonamide (LIL-102-176): A sealable round-botom flask was charged with 3 -bromobenzene- 1 -sulfonamide (500 mg, 2.118 mmol, 1 equiv) and dissolved in a mixture of dioxane (5 mL) and water (0.5 mL). The reaction mixture was degassed for 5 minutes, after which potassium carbonate ( 85.4 mg, 4.236 mmol, 2 equiv) was added. The reaction mixture was degassed again for 10-12 minutes. Vinyltrifluoroborate (301.3 mg, 3.177 mmol, 1.5 equiv) was then added, followed by [l, T-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (62 mg, 0.085 mmol, 0.04 equiv), and the flask was immediately sealed. The reaction mixture was stirred at 100 °C for 4 hours. After completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the crude product was purified by flash column chromatography using 15-20% ethyl acetate in hexane as the eluent to afford 3-vinylbenzenesulfonamide (300 mg, 77%) as white solid.Attorney Docket No. 10877-004W01

[0612]

[0613] Step-2: Synthesis of (E)-3-(4-methoxy-2-(trifluoromethyl)styryl)benzenesulfonamide (LIL-104-103 ): A 50 niL round-bottom flask was charged with l-bromo-4-methoxy-2-(trifluoromethyl)benzene (417 mg, 2.193 mmol, 1 equiv) and dissolved in N, N-dimethylformamide (DMF, 3 mL). To this solution were added 3-ethenylbenzene-l -sulfonamide (401.8 mg, 2.193 mmol, 1 equiv), tetrabutylammoniuni iodide (72.8 mg, 0.197 mmol, 0.09 equiv), and sodium carbonate (232.4 mg, 2.193 mmol, 1 equiv). The reaction mixture was degassed for 30 minutes.

[0614] Palladium(II) acetate (44.2 mg, 0.197 mmol, 0.09 equiv) was then added, and the reaction mixture was heated to 100 °C and maintained at this temperature for 16 hours. After completion, the reaction mixture was cooled, and water was added. The mixture was extracted with ethyl acetate. The combined organic layers were dried over anhy. NaaSCh and concentrated under reduced pressure. The crude product was purified by column chromatography using a gradient of 20% ethyl acetate in hexane to 30% ethyl acetate in hexane to elute the second spot for the desired product (E)-3-(4-methoxy-2-(trifluoromethy])styryl)benzenesulfonamide (80 mg, 10%) as off-white solid.

[0615] Synthesis of (E)-3-(4-(methoxymethoxy)-2-methylstyryl)benzenesulfonamide (Compound 132)

[0616]

[0617] Step-1: Synthesis of 4-(methoxymethoxy)-2-methyIbenzaldehyde: A 100 mL round-bottom flask was charged with4-hydroxy-2-methylbenzaldehyde (1 g, 0.0073 mol, 1 equiv) and dissolved in dichloromethane (DCM, 9 mL). The solution was cooled to 0 °C. N, N-diisopropylethylamine (1.81 g, 2.439 mL, 0.014 mol, 2 equiv) was added, followed by chloromethyl methyl ether (MOM-CI, 0.56 g, 0.553 mL, 0.007 mol, 1 equiv). The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was extracted with water and dichloromethane. The organic layer was separated andAttorney Docket No. 10877-004W01

[0618] concentrated on a rotary evaporator. The crude product was purified by combi flash chromatography using 10% ethyl acetate in hexane as the eluent to afford 4-(methoxymethoxy)-2-methylbenzaldehyde (1.3 g, 0.0078 mol, 100%’ yield).

[0619]

[0620] Step-2: Synthesis of 4-(methoxymethoxy)-2-methyl-l-vinylbenzene (L1L-101- 311): A 250 mL round-bottom flask was charged with methyl triphenyl phosphine bromide (5.72 g, 0.016 mol, 2 equiv) and tetrahydrofuran (THF, 13 mL). The reaction mixture was cooled to -10 °C, and sodium bis(triniethylsilyl)amide solution (2.64 g, 0.0144 mol, 1.8 equiv) was added dropwise. The mixture was stirred for 1 hour at 0 °C and then cooled again to -10 °C. To this, a solution of 4-methoxy-2-methylbenzaldehyde (2 g, 0.0133 mol, 1 equiv) in THF (10 mL) was added. The reaction mixture was stirred for 16 hours at room temperature. The reaction mixture was quenched with a saturated NILCl solution and extracted with ethyl acetate and water. The organic layer was separated and concentrated on a rotary evaporator. The crude product was purified by silica-gel column chromatography using a gradient of 5%-10% ethyl acetate in hexane as the eluent. The desired product, 4- (methoxymethoxy)-2-methyl-l-vinylbenzene, was obtained as a solid (1.1 g, 0.0062 mol, 79% yield).

[0621]

[0622] Step-3: Synthesis of (E)-3-(4-(methoxymethoxy)-2-methylstyryllbenzenesulfonamide: A 50 mL round-bottom flask was charged with 4-(methoxymethoxy)-2-methyl-1-vinylbenzene (200 mg, 1.122 mmol, 1 equiv) and dissolved in N, N-dimethylformamide (DMF, 4 mL). To this solution were added 3-bromobenzene-l-sulfonamide (264.9 mg, 1.122 mmol, 1 equiv), tetrabutylammonium iodide (41.4 mg, 0.112 mmol, 0.1 equiv), and potassium carbonate (465.2 mg, 3.366 mmol, 3 equiv). The reaction mixture was degassed by bubling N2 for 20 minutes. Palladium(II) acetate (12.6 mg, 0.056 mmol, 0.05 equiv) was then added. The reaction mixture was heated to 100 °C and maintained at this temperature for 16 hours. After confirming the completion of the reaction, the mixture was extracted with water and ethyl acetate. The organic layer was separated and concentrated on a rotary evaporator. The crude product was purified by flashAttorney Docket No. 10877-004W01

[0623] column chromatography using 20% ethyl acetate in hexane as the eluent. The desired product, (E)-3-(4-(methoxymethoxy)-2-methylstyryl)benzenesulfonamide, as off-white solid with a yield of 50 mg (0.15 mmol, 13% yield).

[0624] Synthesis of 3-[(E)-2-(4-hydroxy-2-methylphenyl)ethenyl]benzenesulfonamide (Compound 100)

[0625]

[0626] A 50 mL round-bottom flask was charged with 3-[(E)-2-(4-hydroxy-2- methylphenyl)ethenyl]benzenesulfonamide (2.00 mg, 0.6 mmol, 1 equiv). The reaction mixture was cooled to 0 °C and then allowed to warm to room temperature. To tills, 1,4-dioxane hydrochloride (78.5 mg, 2 L, 0.63 mmol, 1 equiv) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was quenched with a saturated sodium bicarbonate solution and extracted with ethyl acetate and water. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash column chromatography using 45% ethyl acetate in hexane as the eluent. The desired product, 3-[(E)-2-(4-hydroxy-2-methylphenyl)etheny]]benzenesulfonamide, was obtained as a solid with a yield of 50 mg (0.173 mmol, 29% yield).

[0627] Synthesis of (E)-3-(4-methoxy-2-methylstyryl)benzenesulfonamide (Compound 125)

[0628]

[0629] Step-1: Synthesis of 4-methoxy-2-methyl-l-vinylbenzene: A 250 mL round¬ bottom flask was charged with methyl triphenyl phosphine bromide (9.5 g, 0.02.66 mol, 2 equiv) and tetrahydrofuran (THF, 90 mL). The solution was cooled to -10 °C, and sodiumAttorney Docket No. 10877-004W01

[0630] bis(trimethylsilyl)amide solution (4.38 g, 23.9 mL, 0.0239 mol, 1.8 equiv) was added dropwise. The reaction mixture was stirred for 1 hour at 0 °C, then cooled again to -10 °C 4-Methoxy-2-methylbenzaldehyde (2 g, 0.0133 mol, 1 equiv) dissolved in THE (10 mL) was added to the reaction mixture. The mixture was stirred for 16 hours at room temperature. The reaction mixture was quenched with a saturated NH4Q solution and extracted with ethyl acetate and water. The organic layer was separated and concentrated on a rotary evaporator. The crude product was purified by silica-gel column chromatography using a gradient of 2%-5% ethyl acetate in hexane as the eluent. The desired product, 4- methoxy-2-methyl-l-vinylbenzene, was obtained as a solid with a yield of 1.9 g (96%

[0631]

[0632] Step-2: Synthesis of (E)-3-(4-methoxy-2-methylstyryl)benzenesulfonamide (L1L-1O1-293): A 50 mL round-bottom flask was charged with l-ethenyl-4-methoxy-2- methylbenzene (500 mg, 3.374 mmol, 1 equiv) and dissolved in N. N-dimethylformamide (DMF, 3 mL). To this solution, 3 -bromobenzenesulfonamide (876.2 mg, 3.711 mmol, 1.1 equiv), tetrabutylammonium iodide (112.3 mg, 0.304 mmol, 0.09 equiv), and potassium carbonate (1398.9 mg, 10,122 mmol, 3 equiv) were added. The reaction mixture was degassed for 20 minutes. Palladium(II) acetate (68.3 mg, 0.304 mmol, 0.09 equiv) was then added. The reaction mixture was heated to 100 °C and maintained at this temperature for 16 hours. After confirming the completion of the reaction, the mixture was extracted with water and ethyl acetate. The organic layer was separated and concentrated under reduced pressure using a rotary evaporator. The crude product was purified by flash column chromatography using 20% ethyl acetate in hexane as the eluent. The desired product, (E)- 3-(4-methoxy-2-methylstyryl)benzenesulfonamide, was obtained as a solid with a yield of 100 mg (0.33 mmol, 10% yield).

[0633] Synthesis of (E)-3-(2-methyl-4-(2-morpholinoethoxy)styryl)benzenesulfonamide (Compound 128)

[0634]

[0635] Attorney Docket No. 10877-004W01

[0636]

[0637] Step-1: Synthesis of 2-methyl-4-(2-morpholinoethoxy)benzaldehyde: A 50 mL round-bottom flask was charged with 4-hydroxy-2-methylbenzaldehyde (500 mg, 3.672 mmol, 1 equiv) and acetonitrile (ACN, 5 ml,). Potassium carbonate (913.4 mg, 6.609 mmol, 3 equiv) was added to the solution, and the mixture was cooled to 0 °C. To this cooled mixture, 4-(2-bromoethyl)morpholine (427.5 mg, 2.203 mmol, 1 equiv) w'as added. The reaction mixture was allowed to warm to room temperature and stirred for 16 hours. The reaction mixture was concentrated under reduced pressure to remove acetonitrile. The residue was extracted with water and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate (anliy. NazSCL), and concentrated under reduced pressure. The crude product was purified to afford 2-methyl-4-(2-morpholin-4- ylethoxylbenzaldehyde (400 mg, 1.604 mmol, 43 % yield).

[0638]

[0639] Step-2: Synthesis of 4-(2-(3-methyl-4-vinylphenoxy)ethyl)morpholine: A 250 mL round-bottom flask was charged with methyl triphenyl phosphine bromide (1146 mg, 3.208 mmol, 2 equiv) and tetrahydrofuran (THF, 5 mL). The mixture was cooled to -10 °C, and sodium bis(trimethylsilyl)amide solution (529.4 mg, 2.887 mL, 2.887 mmol, 1.8 equiv) was added dropwise. The reaction mixture was stirred for 1 hour at 0 °C, then cooled again to -10 °C. 2-methyl-4-(2-morpholin-4-ylethoxy)benzaldehyde (400 mg, 1.604 mmol, 1 equiv) was dissolved in THF (10 mL) and added to the reaction mixture. The mixture was stirred for 16 hours at room temperature. The reaction mixture was quenched with a saturated NILCl solution and extracted with ethyl acetate and water. The organic layer was concentrated using a rotary evaporator. The crude product was purified by silica-gel column chromatography using a gradient of 3% -35% ethyl acetate in hexane to afford the product and triphenylphosphine oxide (600 mg). The mixture was treated with 1.5 N HC1 solution and extracted with methyl tert-butyl ether (MTBE, 2x). The aqueous layer was neutralized with sodium bicarbonate solution and then extracted with ethyl acetate (2x50 mL). TheAttorney Docket No. 10877-004W01

[0640] ethyl acetate layer was concentrated to give the desired product, 4-(2-(3-methyl-4- vinylphenoxy)ethyl)morpholine, as a solid (300 mg, 1.213 mmol, 75% yield).

[0641]

[0642] Step-3: Synthesis of (E)-3-(2-methyl-4-(2- morpholinoethoxy)styryl)benzenesulfonamide: A 50 mL round-bottom flask was charged with l-ethenyl-4-methoxy-2-methylbenzene (500 mg, 3.374 mmol, 1 equiv) and dissolved in N, N-dimethylformamide (DMF, 3 mL). To this solution were added 3-bromobenzenesulfonamide (876.1 mg, 3.711 mmol, 1.1 equiv), tetrabutylammonium iodide (74.6 mg, 0.202. mmol, 0.1 equiv), and potassium carbonate (838.3 mg, 6.066 mmol, 3 equiv). The reaction mixture was degassed for 20 minutes. Palladium(ll) acetate (22.7 mg, 0.101 mmol, 0.05 equiv) was then added. The reaction mixture was heated to 100 °C and maintained at this temperature for 16 hours. After confirming the completion of the reaction, the mixture was extracted with water and ethyl acetate. The organic layer was separated and concentrated on a rotary evaporator. The crude product was purified by flash column chromatography using 80% ethyl acetate in hexane as the eluent. The desired product, (E)-3-(2-methyl-4-(2-morpholinoethoxy)styryl)benzenesulfonamide, was obtained as a solid with a yield of 40 mg (0.099 mmol, 5% yield).;

[0643] Synthesis of (E)-3-(4-hydroxy-2-(trifliioromethyl)styryl)benzenesiilfonamide (Compound 147)

[0644]

[0645] Attomev Docket No. 10877-004W01

[0646] Step-1: Synthesis of 4-bromo-3-(tnfluoromethyl)phenol: A 50 mL round-bottom flask was charged with l-bromo-4-methoxy-2-(trifluoromethyl)benzene (1.0 g, 0.005 mol, 1 equiv) and dissolved in dichloromethane (DCM, 10 mL). The reaction mixture was cooled to 0 °C, and borane tribromide (6.23 g, 2.4.866 mL, 0.0249 mol, 5 equiv) was added slowly. The reaction mixture was stirred at this temperature for 6 h. The reaction mixture was concentrated under reduced pressure. Methanol was added slowly to the residue, and the mixture was concentrated again. The residue was then treated with a sodium hydroxide solution, followed by extraction with methyl tert-butyl ether (MTBE). The aqueous layer was carefully acidified by adding concentrated hydrochloric acid dropwise and extracted again with MTBE. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography using 20% ethyl acetate in hexane as the eluent to afford the desired product 4-bromo-3-(trifluoromethyl)phenoi (1.0g, 83%) as colorless liquid).

[0647]

[0648] Step-2: Synthesis of l-bromo-4-(methoxymethoxy)-2-(trifluoromethyl)benzene: A 100 mL round-bottom flask was charged with 4-hydroxy-2-(trifluoromethyl)benzaldehyde (1.0 g, 0.0053 mol, 1 equiv) and dissolved in dichloromethane (DCM, 10 mL). The reaction mixture was cooled to 0 °C, and N, N- diisopropylethylamine (1.59 g, 0.0123 mol, 3 equiv) was added, followed by the slow addition of chloromethyl methyl ether (MOM-CI) (0.33 g, 0.0041 moi, 1 equiv). The reaction mixture was stirred at 35 °C for 16 hours. The reaction mixture was concentrated under reduced pressure. The crude product was worked up with dichloromethane and purified by column chromatography using 5% ethyl acetate in hexane to afford the pure product l-bromo-4-(methoxymethoxy)-2.-(trifluoromethyl)benzene (1.1g, 93%).

[0649]

[0650] Step-3: Synthesis of (E)-3-(4-(methoxymethoxy)-2-(trifluoromethyl)styryl)benzenesulfonamide: A 50 mL round-bottom flask was charged with l-bromo-4-(methoxymethoxy)-2-(trifluoromethyl)benzene (315 mg, 1.363 mmol, 1 equiv) and dissolved in N, N-dimethyiformamide (DMF, 2.5 ml,). To this solution wereAttorney Docket No. 10877-004W01

[0651] added 3-ethenyl benzene- 1 -sulfonamide (249.7 mg, 1.363 mmol, 1 equiv), tetrabutylammonium iodide (45.4 mg, 0.123 mmol, 0.09 equiv), and sodium carbonate (143 mg, 1.349 mmol, 0.99 equiv). The reaction mixture was degassed for 30 minutes.

[0652] Palladium(II) acetate (27.6 mg, 0.123 mmol, 0.09 equiv) was then added, and the reaction mixture was heated to 100 °C and maintained at this temperature for 16 hours. After completion, the reaction mixture was cooled, and water was added. The mixture was extracted with ethyl acetate. The combined organic layers were dried over anhy. NasSCfi and concentrated under reduced pressure. The crude product was purified by column chromatography using a gradient of 20% ethyl acetate in hexane, followed by 30% ethyl acetate in hexane, to afford the desired products., to afford the desired product (E)-3-(4-(methoxymethoxy)-2-(trifluoromethyl)styryl)benzenesulfonamide (150 mg, 28%).

[0653]

[0654] Step-4: Synthesis of (E)-3-(4-hydroxy-2-(trifluoromethyl)styryl)benzenesulfonamide: A 50 mL round-bottom flask was charged with (E)-3-(4-(methoxymethoxy)-2-(trifluoromethyl)styryl)benzenesulfonamide (150 mg, 0.387 mmol, 1 equiv) and dissolved in dioxane (1 mL). The reaction mixture was cooled to 0 °C, and 1,4-dioxane hydrochloride (48.2 mg, 0.387 mmol, 1 equiv) was added slowly. The reaction mixture was stirred at room temperature for 1.5 hours. After confirming the completion of the reaction, lire mixture was concentrated under reduced pressure. The crude product was purified by column chromatography. Impurities were eluted with 15% ethyl acetate in hexane, and the pure product (E)-3-(4-hydroxy-2- (trifluoromethyl)styryl)benzenesulfonamide (40 mg, 30%) was obtained using 30% ethyl acetate in hexane.

[0655] Synthesis of Compounds 142-144Attorney Docket No. 10877-004W01

[0656]

[0657] The synthetic scheme for ((E)-(3-(4-met.hoxy-2-methylstyryl) phenyl) dimethyl phosphine oxide, (E)-(3-(4-hydroxy-2-methylstyryl)phenyl)dimethyl phosphine oxide, and (E)-dimethyl (3-(2-methyl-4-(2-morpholinoethoxy)styryl) phenyl) phosphine oxide is

[0658]

[0659] Step-1: Synthesis of 4-methoxy-2~methyi~l" VinyIbenzene (InL-2)

[0660]

[0661] Attorney Docket No. 10877-004W01

[0662] A stirred solution of 4-nie(Iioxy-2-methylbenzaldehyde (1A) (2.0 g, 13.32 mmol, 1.0 eq.) and Ph3MeBr (5.6 g, 17.31 mmol, 1.3 eq.) in THF (30 ml,) with KO‘Bu (IM Soln, in THF) (mL, 17. 1 mmol, 1.3 eq) at 0 °C and reaction mixture was allowed to stir for 1 h at room temperature. After completion of reaction on TLC, reaction mass quenched with water (25 mL) and extracted in ethyl acetate (3 x 25mL). Combined organic layer was dried over Na2SO4, Filtered and concentrated under reduced pressure to afford crude material. Crude material was purified by flash chromatography, product eluted at 10% EtOAc in n-hexane gives 4-methoxy-2-methyl-l-vinylbenzene (Int.-2A) (1.8 g, yield: 92%) as colorless oil.

[0663] Step-2: Synthesis of (3-bromophenyl) dimethyl phosphine oxide (2)

[0664]

[0665] A stirred solution of l-bromo-3-iodobenzene (1) (500 mg, 1.76 mmol, 1.0 eq.) and Me2PH() (170 mg, 2.2 mmol, 1.3 eq.) in 1,4-Dioxane (15 mL) was purged with N2(g) for 15min. In a separate vial mixture of Pd(OAc)2 (59 mg, 0.26 mmol, 0.15 eq.), Xantphos (510 mg, 0.88 mmol, 0.5 eq.) and EtsN (0.75 mL, 5.3 mmol, 3.0 eq.) in 1,4-Dioxane (5 mL), was purged with N2(g) for 15 min. and was added to the above vial at room temperature and stirred for 6h. After completion of reaction on TLC, reaction mass quenched with water (25 mL) and extracted in ethyl acetate (3 x 25mL). Combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford crude residue. Crude compound was purified by flash chromatography, using 10% EtOAc in n-hexane as eluent to afford (3-bromophenyl) dimethyl phosphine oxide (400 nig yield: 58%) as brown solid.

[0666] Step-3: Synthesis of (E)-(3-(4-methoxy-2-methylstyryl) phenyl) dimethyl phosphine oxide (Compound 144)

[0667]

[0668] To a stirred solution of 4-methoxy-2-methyl-l-vinylbenzene (Int-2) (400 mg, 2.70 mmol, 1.0 eq.), (3-bromophenyl)dimethyl phosphine (2) (620 mg, 2.70 mmol, 1.0 eq.) and K2CO3 (480 mg, 5.40 mmol, 2.0 eq.) in DMF (3 mL), was purged with N(g) for 15 min.Attorney Docket No. 10877-004W01

[0669] Pd(OAc)?. (90 mg, 0.41 mmol, 0.15 eq.) and THAI (480 mg, 1.35 mmol, 0.5 eq.) was added to reaction mixture at room temperature and the resulting reaction mixture was heated to 130°C and stirred for 16h. After completion of reaction on TLC, reaction mixture was diluted with ethyl acetate (25 mL) and washed with ice- water (3 x 10 mL). Organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford crude residue. The crude residue was purified by flash chromatography to give (E)-(3-(4- methoxy-2-methylstyryl) phenyl) dimethyl phosphine oxide (310 nig, yield: 38%) as an off white solid.

[0670] Step-4: Synthesis of (E)-(3-(4-hydroxy-2-methylstyryl) phenyl) dimethyl phosphine oxide (Compound 142)

[0671]

[0672] To a stirred solution of (E)-(3-(4-methoxy-2-methylstyryl)phenyl)dimeihyl phosphine oxide (280 mg, 0.94 mmol, 1.0 eq.) in DCM (1.5 mL), was added BBiy (1.0M in DCM) (1.40 mL, 1.40 mmol, 1.5 eq.) at 0°C temperature and stirred for 30 minutes at same temperature. Then the reaction temperature gradually increases up to room temperature and stirred for 3h. After completion of reaction on TLC, RM was quenched with ice-water (20 mL), neutralized with sat. aq. NaHCOy solution and extracted with EtOAc (3 x 20 mL). Combined Organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford crude residue. The obtained crude material was purified by flash chromatography and followed by purification by Prep. HPLC purification using ACN and Water as a mobile phase to get (E)-(3-(4-hydroxy-2-methylstyryl) phenyl) dimethyl phosphine oxide (150 mg, yield: 56%).

[0673] Step-5: Synthesis of (E)-dimethyl(3-(2-methyl-4-(2-morpholinoethoxy) styryl) phenyl) phosphine oxide (Compound 143)

[0674]

[0675] To a stirred solution of (E)-(3-(4-hydroxy-2-methylstyryl)phenyl)dimethyl phosphine oxide (80 mg, 0.27 mmol, 1.0 eq.) in DMF (1 mL), was added K2CO3 (110 mg,Attorney Docket No. 10877-004W01

[0676] 0.8 mmol, 3.0 eq.) at room temperature and stirred for 15 min. 4-(2-chloroethyl)morpholine (50 mg, 0.27 mmol, 1.0 eq.) was added at room temperature and resulting reaction mixture was heated to 85°C and stirred for 6h. After completion of reaction on TLC, reaction mass diluted with ethyl acetate (30 mL) and washed with ice-water (3 x 30 mL). Organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford crude residue. Crude material was purified by flash chromatography using 4% MeOH in DCM as eluent to afford titled compound (E)-dimethyl(3-(2-methyl-4-(2-morpholinoethoxy) styryl) phenyl) phosphine oxide (45 mg, yield: 40%) as a light brown sticky liquid.

[0677] Synthetic scheme for (E)-(3-(4-hydroxy-2-methylstyryl) phenyl) (imino) (methyl)-16-sulfanone (Compound 131)

[0678]

[0679] Step-1: Synthesis of 4-(methoxy methoxy)-2-methylbenzaldehyde (2A)

[0680]

[0681] Step -1

[0682] To a stirred solution of 4-hydroxy-2-methylbenzaldehyde (1A) (250 mg, 1.83 mmol, 1.0 eq.) in DMF (2.5 mL) was added DIPEA (0.71 g, 5.5 mmol, 3.0 eq.) at room temperature. After 10 min of stirring MOM-CI (170 mg, 2.2 mmol, 1.2 eq. ) was added to the reaction mixture and stirred for 6h at 85 °C. After completion of reaction on TLC, reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (3 15 ml.,). Combined organic layer was dried over Na? SO4, filtered and concentrated under reduced pressure to afford crude residue. The obtained crude material was purified by flash column chromatography, using 3% Ethyl acetate in n-Hexane as eluent to give title compound 4-(methoxy methoxy)-2-methylbenzaldehyde (250 mg, yield: 75.6%) as white solid.

[0683] Step-2: Synthesis of 4-(methoxy methoxy)-2-methyl-l-vinylbenzene (3)Attorney Docket No. 10877-004W01

[0684]

[0685] To a stirred solution of PPhsMeBr (0.64g, 1.8 mmol, 1.3 eq.) in THF (2.5 mL) was cooled to 0°C and was added KO'Bu (1.85 mL, 1.8 mmol, 1.3 eq.) drop wise at same temperature and stirred for 1 min. 4-(methoxy methoxy)-2-methylbenzaldehyde (2A) (250 mg, 1.3 mmol, 1.0 eq.) (solution in THF) was added drop wise to the reaction mixture at 0°C temp, and resulting reaction mixture was warmed to room temperature and stirred for Ih. After completion of reaction on TLC, reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (2 x 20 mL). Combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford crude residue. The obtained crude material was purified by flash column chromatography, using 2% Ethyl acetate in n-Hexane as eluent to give title compound 4-(methoxy methoxy)-2-methyl-l- vinylbenzene (3) (230 mg, yield: 93%) as colorless oil.

[0686] Step-3: Synthesis of tert-butyl ((3-bromophenyl) (methyl) (oxo)-16- sulfaneylidene) carbamate (2)

[0687]

[0688] To a stirred solution of (3-bromophenyl)(iniino)(raethyl)-16-sulfanone (1) (100 mg, 0.4 mmol, 1.0 eq.) in THF (1 mL) was cooled to 0°C and was added NaH (15 mg, 0.64 mmol, 1.5 eq.) at same temperature and stirred for 30 min. then (Boc O (57 mg, 0.51 mmol, 1.2. eq.) was added to the reaction and resulting reaction mixture was warmed to room temperature and stirred for 16h. After completion of reaction on TLC, reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (3 x 15 mL). Combined organic layer was dried over Na2. SO4, filtered and concentrated under reduced pressure to afford crude title compound tert-butyl ((3-bromophenyl) (methyl) (oxo)-16- sulfaneylidene) carbamate (2) (140 mg, yield: 98%) as white solid. The obtained etude compound was carried to next step without further purification.

[0689] Step-4: Synthesis of tert-butyl (E)-((3-(4-(methoxy methoxy)-2-methylstyryl) phenyl) (methyl)(oxo)-16-sulfaneylidene) carbamate (4)Attorney Docket No. 10877-004W01

[0690]

[0691] To a solution of 4-(methoxy methoxy)-2-methyl-l-vinylbenzene (3) (100 mg, 0.29 mmol, 1.0 eq.), tert-butyl ((3-broniophenyl)(methyl)(oxo)-16-sulfaneylidene)carbamate (2) (53 mg, 0.2.9 mmol, 1.0 eq.) and K2CO3 (82. mg, 0.59 mmol, 2.0 eq.) in DMF (1 mL), was purged with

[0692]

[0693] for 15 min. then Pd(OAc)2 (10 mg, 0.044 mmol, 0.15 eq.) and TBAI (55 mg, 0.14 mmol, 0.5 eq.) was added to the reaction mixture at room temperature under inert atmosphere. The resulting reaction mixture was heated at 130°C and stirred for 16h. After completion of reaction on TLC, reaction mixture was diluted with ethyl acetate (25 mL) and washed with ice-water (3 x 10 mL). Organic layer was dried over Na? SO4, filtered and concentrated under reduced pressure to afford crude residue. The obtained crud material was purified by flash chromatography using 35% EtOAc in hexane as eluent to give tert¬ butyl (E)-((3-(4-(methoxy methoxy)-2-methylstyryl) phenyl) (methyl)(oxo)-16- sulfaneylidene) carbamate (4) (70 mg, Yield: 54%) as white solid.

[0694] Step-5: Synthesis of (E)-(3-(4-hydroxy-2-methylstyryl) phenyl) (imino) (methyl)-16-sulfanone

[0695]

[0696]

[0697] To a stirred solution of tert-butyl (E)-((3-(4-(methoxy methoxy)-2 -methylstyryl ) phenyl) (methyl)(oxo)-16-sulfaneylidene) carbamate (4) (60 mg, 0.13mmol, 1.0 eq.) in DCM (1 mL), was added 4M HC1 in 1,4-Dioxane (1 mL) at 0°C. The resulting reaction mixture was warmed to room temperature and stirred for 4h. After completion of reaction on TLC, reaction mixture was concentrated under reduced pressure, resulting residue was dissolved in water and pH ~7 adjusted by using saturated NaHCCh solution, then concentrated under reduced pressure to afford crude residue. The obtained crude material was purified by flash column chromatography using 2.3%' MeOH in DCM as eluent to giveAttomev Docket No. 10877-004W01

[0698] (E)-(3-(4-hydroxy-2-methylstyryl) phenyl) (imino) (methyl)-16-sulfanone (25 mg, yield: 63%) as white solid.

[0699] Synthesis of (E)-6-(4-methoxy-2-methylstyryl)-2,3-dihydrobenzo[d] isothiazole 1,1-dioxide (Compound 130)

[0700]

[0701] To a stirred solution of 4-methoxy-2-methyl-l-vinylbenzene (Int.-2) (250 mg, 1.68 mmol, 1.0 eq.) and 6-bromo-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (410 mg, 1.68 mmol, 1.0 eq.) in DMF (2.5 mL), was added K2CO3 (460 mg, 3.36 mmol, 2 eq.) at room temperature and purged with N2(g) for 15 min. Pd(OAc)2 (56 mg, 0.25 mmol, 0.15 eq.) and TBAI (310 mg, 0.84 mmol, 0.5 eq.) was added to the reaction and the resulting reaction mixture was heated to H0°C and stirred for 2h in microwave synthesizer. Note: Reaction performed in 2 batches of 250 mg each). After completion of both reactions on TLC, both reaction masses were mixed & diluted with EtOAc (30 mL) then washed with ice-water (3 x 10 mL). Organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford crude residue. The obtained crude material was purified by flash column chromatography using 3% MeOII in DCM as eluent & followed by Prep. HPLC purification using (A) TEA in Water and (B) ACN as mobile phase to give title compound (E)-6-(4-methoxy-2-methylstyryl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (3.5 mg, yield: 3.3%).

[0702] Synthesis of (E)-(3-(2-(indolin-5-yl)vinyl)phenyl)dimethylphosphineoxide (Compound 151)

[0703]

[0704] Step 1: (E)-(3-(4-hydroxy-2-methylstyryl)-5-methylphenyl) dimethyl phosphine oxide (Iiit-2)

[0705] Step-1: To a stirred solution of tert-butyl 5 -bromoindoline- 1 -carboxylate (298 mg, 1.0 mmol) and dimethyl(3-vinylphenyl) phosphine oxide (150 mg, 0.83 mmol) in Et? N (1.5 m ) was added Tris(o-tolyl) phosphine (25mg, 0.083 mmol), and Argon was bubbledAttorney Docket No. 10877-004W01

[0706] through the mixture for 10 minutes. Then Pd (OAc)? (19 mg, 0.083 mmol) was added to the mixture, and again Argon was bubbled through the mixture for 5 minutes. The mixture was then stirred at 100 °C for 2 h. After completion of the reaction, the reaction mass was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under vacuo to get crude, which was purified by combi-flash purification by using 5% MeOH / DCM as eluent to get the title compound as an off-white solid (250 mg, 65 %).

[0707] Step-2: To a stirred solution of tert-butyl (E)-5-(3-(dimethyl phosphoryl) styryl) indoline- 1 -carboxylate (150 mg, 0.37 mmol) in DCM (1.5 mL) was added 4M HCi in 1,4- Dioxane (5 eq) (0.1ml, 1.88 mmol) at 0 °C. The mixture was then stirred at RT for 3h. After completion of the reaction, the reaction mass was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under vacuo to obtain the crude product, which was purified by prep. IIPLC to get the title compound (20 mg, 16.8 %).

[0708] en-2-yl)vinyl)phenyl)phosphine oxide

[0709]

[0710]

[0711] Step-1

[0712] Step 1: (E)-dimethyl(3-(2-(naphthalen-2-yl)vinyl)phenyl)phosphine oxide: To a stirred solution of 2-vinylnaphthalene (79 mg, 0.504 mmol) and l-bromo-3- dimethylphosphorylbenzene (100 mg, 0.42. mmol) in DMF (0.5 mL) was added tetrabutylammonium iodide (50 mg, 0.13 mmol) and K2CO3 (70 mg, 0.18 mmol), and Argon was bubbled through the mixture for 10 minutes. Then Pd(OAc)2 (16 mg, 0.07 mmol) was added to the mixture, and again Argon was bubbled through the mixture for 5 minutes. The mixture was then stirred at 80 °C for 2 h. After completion of the reaction, the reaction mass was diluted with water (10 mL.) and extracted with EtOAc (2 x 20 mL.). The combined organic layer was dried over Na2SO4, filtered, and concentrated under vacuo to obtain the crude product, which was purified by prep. HPLC to get the title compound (26 mg, 20 %)Attorney Docket No. 10877-004W01

[0713] Synthesis of (E)-(3-(2-(6-hydroxy-4-methylpyridin-3-yl)vinyl)phenyl)dimethylphosphine oxide (Compound 158)

[0714]

[0715] Step-1

[0716] Step 1: (E)-(3-(2-(6-methoxy-4-methylpyridin-3-yl) vinyl) phenyl) dimethylphosphine oxide (Compound 152): To a stirred solution of 5-bromo-2-methoxy-4-niethylpyridine (404 mg, 1.996 mmol) and dimethyl(3-vinylphenyl) phosphine oxide (300 mg, 1.66 mmol) in DMF (1 ml.) was added tetrabutylammonium iodide (306 mg, 0.82 mmol) and K2CO3 (460 mg, 3.33 mmol), and Argon was bubbled through the mixture for 10 minutes. Then Pd (OAc)2 (37 mg, 0.37 mmol) was added to the mixture, and again Argon was bubbled through the mixture for 5 minutes. The mixture was then stirred at 80 °C for 2 h. After completion of the reaction, the reaction mass was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was dried over Na2SOr, filtered, and concentrated under vacuo to obtain the crude product, The combined organic layer was dried over Na2. SO4, filtered, and concentrated under vacuo to get crude, which was purified by combi-flash purification by using 5% MeOH / DCM as eluent to get the title compound as an off-white solid (250mg, 35 %). Out of 250 mg, 50mg submitted for prep, which was purified by prep. HPLC to get the title compound (4 mg, 4.79 %).

[0717] Step 2: (( )-(3-(2-(6-hydroxy-4-methylpyridin-3-yl) vinyl) phenyl) dimethylphosphine oxide (Compound 158)

[0718] To a stirred solution of (E)-(3-(2-(6-methoxy-4-methylpyridin-3-yl) vinyDphenyl) dimethylphosphine oxide (150 mg, 0.49 mmol) in DMF (1 mL) was added p-Toluenesulfonic acid (428 mg, 2.5 mmol) and Li Cl (104 mg, 2.5 mmol). The mixture was then stirred at 120 °C for 12 h. After completion of the reaction, the reaction mass was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under vacuo to obtain the crude product, which was purified by prep. HPLC to get the title compound (10 mg, 6.92 %).

[0719] Synthesis of E)-(3-(2-(2-hydroxy-4-methyIpyrimidin-5-yl) vinyl) phenyl) dimethyl phosphine oxide (Compound 154)Attorney Docket No. 10877-004W01

[0720]

[0721]

[0722] Step-1

[0723] Step 1: (E)-(3-(2-(2-hydroxy-4-methylpyrimidin-5-yl) vinyl) phenyl) dimethylphosphine oxide (Compound 153):

[0724] To a stirred solution of 5-bromo-2-methoxy-4-methylpyrimidine (406 mg, 2.0 mmol) and dimethyl(3-vinylphenyl) phosphine oxide (300 mg, 1.66 mmol) in DMF (1 mL) was added tetrabutylammonium iodide (306 mg, 0.82 mmol) and K2CO3 (460 mg, 3.33 mmol), and Argon was bubbled through the mixture for 10 minutes. Then Pd(OAc)2 (37 mg, 0.37 mmol) was added to the mixture, and again Argon was bubbled through the mixture for 5 minutes. The mixture was then stirred at 80 °C for 2 h. After completion of the reaction, the reaction mass was diluted with water (100 mL) and extracted with EtOAc (2 x 40 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under vacuo to obtain the crude product, The combined organic layer was dried over Na2. SO4, filtered, and concentrated under vacuo to get crude, which was purified by combi -flash purification by using 5% MeOH / DCM as eluent to get the title compound as an off-white solid (180mg, 96% purity, 35.50 %). Out of 180 mg, 50mg submitted for prep, which was purified by prep. HPLC to get the title compound (15mg, 2.98 %).

[0725] Step 3: (E)-(3-(2-(2-hydroxy-4-methylpyrimidin-5-yr) vinyl) phenyl) dimethylphosphine oxide (Compound 154)

[0726] To a stirred solution of (E)-(3-(2-(2-methoxy-4-methylpyrimidin-5-yl) vinyl) phenyl)dimethyl phosphine oxide (130 mg) in MeOH (2 mL) was added IM HC1 (1.3 mLl. The mixture was then refluxed at 60 °C for 4 h. After completion of the reaction, the reaction mass was concentrated under vacuo to obtain the crude product, which was purified by prep. HPLC to get the title compound (18 mg, 14 %).

[0727] Synthesis of (E)-(3-fluoro-5-(4-hydroxy-2-methylstyryl) phenyl) dimethyl phosphine oxide (Compound 157)Attorney Docket No. 10877-004W01

[0728]

[0729] Step-1: (3-fluoro-5-vinylphenyl)dimethylphosphine oxide (Int-3):

[0730] To a stirred solution of (3-bromo-5-fluorophenyl)dimethylphosphine oxide (400 nig, 1.46 mmol) in 1,4-Dioxane (5 mL) and water (2 l,) were added potassium trifluoro ( vinyl) borate(221 nig, 1.60 mmol) and CS2CO3 (1.19 g, 3.65 mmol) at room temperature. The reaction mixture was degassed under nitrogen for 5 minutes followed by the addition of Pd(PPli3)4 (171 mg, 0.146 mmol). The reaction mixture was stirred at 100 °C for 1 h. The progress of the reaction monitored by LCMS. After completion of the reaction, the reaction mixture was quenched with a water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous NaiSOi, filtered and concentrated under reduced pressure. The crude was purified by 5% Methanol / DCM to afford (3-fluoro- 5-vinylphenyl) dimethylphosphine oxide (300 mg, 95 %).

[0731] Step 2: (E)-(3-fluoro-5-(4-methoxy-2-methylstyryl) phenyl) dimethylphosphine oxide (Compound 156)

[0732] To a stirred solution of (3-bromo-5-fluorophenyl) dimethylphosphine oxide (300 mg, 1.19 mmol) and l-bromo-4-methoxy-2-methylbenzene (288 mg, 1.43 mmol) in EtsN (3 mL) was added Tris(o-tolyl) phosphine (36mg, 1.19 mmol) and Argon was bubbled through the mixture for 10 minutes. Then Pd (OAc)2 (26mg, 0.12 mmol) was added to the mixture, and again Argon was bubbled through the mixture for 5 minutes. The mixture was then stirred at 100 °C for 2 h. After completion of the reaction, the reaction mass was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under vacuo to get crude, (500 mg, lOOmg submitted for prep HPLC) which was purified by combi -flash purification by usingAttorney Docket No. 10877-004W01

[0733] 5% MeOH / DCM as eluent to get the title compound as a semi-solid (270mg, 84% purity, 63 %). Out of 500 mg crude, lOOmg submitted for prep, which was purified by prep. HPLC to get the title compound (10 mg, 4.79 %).

[0734] Step 3: (£’)-(3-fluoro-5-(4-hydroxy-2- methylstyryl) phenyl) dimethyl phosphine oxide (Compound 157)

[0735] To a stirred solution of (E)-(3-fluoro-5-(4-methoxy-2-methylstyryl) phenyl) dimethyl phosphine oxide (200 nig, 0.63 mmol) in DCM (3 mL) was added IM BB in DCM (0.55 mL, 3.1 mmol) in 0 °C. The mixture was then stirred at RT for 2 h. After completion of the reaction, the reaction mass was diluted with ice cold water (10 ml.,) and extracted with DCM (2 x 20 mL). The combined organic layer was dried over NazSO^ filtered, and concentrated under vacuo to obtain the crude product, which was purified by prep. HPLC to get the title compound (8 mg, 4.2 %).

[0736] Synthesis of (E')-(3-(4-hydroxy-2-methylstyryl)-5-methylphenyl) dimethyl phosphine oxide (Compound 155)

[0737]

[0738] Step-1: (3-bromo-5-methylphenyl)dimethylphosphine oxide (lnt-3)

[0739] To a stirred solution of l-bromo-3-iodo-5 -methylbenzene (500 mg, 1.68 mmol) in 1,4-dioxane (5 mL) was added with EtaN (0.590 ml., 4.20 mmol), dimethylphosphine oxide (144 mg, 1.85 mmol) and after that the reaction mixture was purged with argon gas for 10 min, then 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (502 mg, 0.841 mmol) and Pd2(dba)3 (162 mg, 0.168 mmol) was added, the reaction mixture stirred at RT for 16 h. After completion, the reaction mixture was poured into H -( ) (50 mL), filtered, extracted with EtOAc (2 x 50 mL) washed with water (50 mL) and brine sequentially. The combined organic layer was dried over NajSCL, filtered, and concentrated under vacuo to get the crude, which was purified by combi-flash chromatography (5% MeOH / DCM) to afford title compound (270 mg, 54%) as brown syrup.

[0740] Step 2: (£)-(3-(4-hydroxy-2-methylstyryl)-5-methylphenyl) dimethyl phosphine oxide (Compound 155)Attorney Docket No. 10877-004W01

[0741] To a stirred solu on of (3-bromo-5-methylphenyl) dimethyl phosphine oxide (200 mg, 0.81 mmol) and 3-methyl-4-vinylphenol (130 mg, 0.97 mmol) in DMF (6 mL) was added tetrabutylammonium iodide (149 nig, 0.4 mmol) and K2CO3 (223 mg, 1.61 mmol). The Argon was bubbled through the mixture for 10 minutes and Pd (OAc)2 (19 mg, 0.081 mmol) was added and again argon was bubbled through the mixture for 5 minutes. Then the mixture was stirred at 80°C for 6h. The reaction was monitored by TLC, after completion of the reaction, the reaction mass was diluted with water (100 ml) and extracted by EtOAc (2 x 50 mL), the combined organic layer was dried over NaiSOi, filtered, and concentrated under vacuo to get crude and which was purified by RP prep. HPLC to get a mixture of E & Z. The mixture was separated by SEC purification to get 10 mg (8.26%) of (E-(3-(4- hydroxy-2-methylstyryl)-5 -methylphenyl) dimethyl phosphine oxide as title compound.

[0742] Synthesis of 3-methyl-4-vinylphenol (4):

[0743]

[0744] To a stirred solution of 1 M in sodium bis(trimethylsilyl)amide in THF (7 ml, 7 mmol) was added the solution of methyl triphenyl phosphonium bromide (3 g, 7 mmol) in THE (10 ml) at 0 °C and allowed to stir at the same temperature for 1.5 h. Then solid 4- hydroxy-3-methyl-benzaldehyde (500 mg, 4 mmol) was added to the reaction mixture and stirred at 0 °C for 4 h. The reaction mixture was quenched with 0.5M H2SO4 (10 mL) and extracted by DCM (2 x 50 mL). The combined organic layer was dried over Na2. SO4, filtered, and concentrated under vacuo to get crude, which was purified by combi-flash purification by using 70% EtOAc / Heptane as eluent to get the title compound as an off- white solid (400 mg, 81 %).

[0745] Synthesis of (E)-(3-(4-hydroxy-2-methylstyryl)phenyl)(imino)(methyl)-k6- sulfanone

[0746]

[0747] Attorney Docket No. 10877-004W01

[0748] Step-1: imino(methyl)(3-vinylphenyl)-k6-sulfanone: To a stirred solution of (3-bromophenyl) (imino)(methyl)-X6-sulfanone(1.5 g, 6.44 mmol) in 1,4-Dioxane (1.5 mL) and water (0.15 mL) were added potassium trifluoro (vinyl) borate(l.l g, 7.7 mmol) and CS2CO3 (4.2. g, 13 mmol) at room temperature. The reaction mixture was degassed under nitrogen for 5 minutes followed by the addition of Pd(PPh?)4 (760mg, 0.64 mmol). The reaction mixture was stirred at 80 °C for 16 h. After completion of the reaction, the reaction mixture was quenched with a water (75 mL) and extracted with EtOAc (3 x 75 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by 5% Methanol / DCM to afford the title compound (1.1 g, 72 %).

[0749] Step-2: Synthesis of (E)-(3-(4-hydroxy-2-methyIstyryI)phenyl)(imino)(methyl)-l6-sulfanone:

[0750] To a stirred solution of iraino(methyl)(3-vinylphenyl)-k<’-sulfanone(100 mg, 0.551 mmol) and 4-bromo-3-methylphenol (103 mg, 0.5 1 mmol) in EtsN (2 mL) was added Tris(o-tolyl) phosphine (17.3 mg, 0.0551 mmol) and Argon was bubbled through the mixture for 10 minutes. Then Pd (OAch (13 mg, 0.05 1 mmol) was added to the mixture, and again Argon was bubbled through the mixture for 5 minutes. The mixture was then stirred at 100 °C for 2 h. After completion of the reaction, the reaction mass was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under vacuo to get crude, which was purified by Prep. HPLC purification to effort the title compound ((10 mg, 6.31 %).

[0751] Synthesis of (E)-imino(3-(4-methoxy-2-methylstyryl)phenyl)(niethyl)-k6-sulfanone (Compound 159)

[0752]

[0753] Step-1

[0754] To a stirred solution of imino(methyl)(3-vinylphenyl)-16-sulfanone(i00 mg, 0.5 1 mmol) and l-bronio-4-methoxy-2-methylbenzene (110 mg, 0.5 1 mmol) in EtsN (2 mL) was added Tris(o-tolyl) phosphine (17.3 mg, 0.0551 mmol) and Argon was bubbled through the mixture for 10 minutes. Then Pd (OAc)2 (13 mg, 0.0551 mmol) was added to the mixture, and again Argon was bubbled through the mixture for 5 minutes. The mixture wasAttorney Docket No. 10877-004W01

[0755] then stirred at 100 °C for 2 h. After completion of the reaction, the reaction mass was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was dried over NaiSOi, filtered, and concentrated under vacuo to get crude, which was purified by Prep. HPLC purification to effort the title compound (18.5 mg, 11.3 %).

[0756] Synthesis of (E)-imino(3-(2-(6-methoxy-4-methylpyridin-3-yl)vinyl)phenyl)(methyl)-16-sulfanone

[0757]

[0758]

[0759] phosphine, Et3N,

[0760] int-4 100 °C, 2 h

[0761] Step-1

[0762] To a st irred solution of imino(methyl)(3-vinylphenyl)-16-sulfanone(120 mg, 0.667 mmol) and 5-bromo-2-methoxy-4-methylpyridine (133 mg, 0.667 mmol) in Et? N (2 niL) was added Tris(o-tolyl) phosphine (20.1 mg, 0.0667 mmol) and Argon was bubbled through the mixture for 10 minutes. Then Pd (OAc)2 (14.8 mg, 0.0667 mmol) was added to the mixture, and again Argon was bubbled through the mixture for 5 minutes. The mixture was then stirred at 100 °C for 2 h. After completion of the reaction, the reaction mass was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was dried over NaiSOi, filtered, and concentrated under vacuo to get crude, which was purified by Prep. HPLC purification to effort the title compound (18 mg, 9 %).

[0763] Synthesis of (E)-imino(methyl)(3-(2-methyl-4-(2-morpholinoethoxy)styryI)phenyl)-A°-sulfanone

[0764]

[0765] 2 3,

[0766] 80 °C, 16 h

[0767] Step-1

[0768] To a stirred solution of (E)-(3-(4-hydroxy-2-methylstyryl)phenyl)(imino)(methyl)-A°-sulfanone (70 mg, 0.243 mmol) in CHyCN (1.4 mL) were added K2CO3 (100 mg, 0.729 mmol) 4-(2-chloroetliyl)morpholine (36.3 nig, 0.243 mmol). The mixture was then stirred atAttorney Docket No. 10877-004W01

[0769] 80 °C for 16 h. After completion of the reaction, the reaction mass was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under vacuo to get crude, which was purified by Prep. HPLC purification to effort the title compound (10 mg, 10.25 %).

[0770] Example 3. Evaluation of the Anti-Cancer Activity of Example Aryl Hydrocarbon Receptor Modulators

[0771] The SIN3A co-activator suppresses the expression of MHC-I and increases immune suppressive T regulatory and Thl7 cells. SIN3A induces IL-17 and IL-22 which are a major cause of cancer immune evasion. As a consequence, SIN3A modulators can alleviate the immune system suppression and therefore achieve cancer immunotherapeutic action alone and in combination with other immune-therapeutics such as checkpoint inhibitors or chemotherapy, KRAS inhibitors, STAT inhibitors and gemcitabine. SIN3A also plays a significant role in the pathogenesis of allergies such as allergic rhinitis by regulating the Thl7 / Treg immune cells and therefore modulating SIN3A can reduce allergic rhinitis.

[0772] SIN3A inhibition study. Human pulmonary artery smooth muscle cells were treated with AhR agonists kynurenine, FICZ. or TCDD in the absence or presence of 20uM Compound 101. After 20 hours RNA was extracted and SIN3A mRNA expression was determined using SIN3A specific primer and RT-PCR. As shown in Table 4 below, the aryl hydrocarbon receptor modulators described herein, such as Compound 101 can inhibit SIN3A

[0773] Table 4. Inhibition of SIN3 expression by Compound 101

[0774]

[0775] Pancreatic cancer study. Pancreatic cancer was induced by orthotropically implanted pancreatic cancer cells to C57BL / 6 mice. Caprofen was administered before surgery and Isoflurane was used to produce anesthesia. A small incision was made on the abdominal wall and a single cell suspensions of cancer cells with matrigel (up to 50 pl) was injected into the parenchyma of the distal pancreas. The incision was closed usingAttorney Docket No. 10877-004W01

[0776] absorbable suture, separately from the skin (non-absorbable suture or wound clips). One week after tumor inoculation, TCDD 1-10 ug / kg was administered via intraperitoneal route on a weekly base for two weeks. At the same time, Compound 101 treatment group mice received 30 mg / kg of twice a day by oral gavage for two weeks. The results are shown in Table 5 below.

[0777] Table 5. Compound 101 reduces cancer progression in a model of pancreatic cancer.

[0778]

[0779] The compounds, compositions, and methods of the appended claims are not limited in scope by the specific compounds, compositions, and methods described herein, which are intended as illustrations of a few aspects of the claims. Any compounds, compositions, and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the compounds, compositions, and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims. Further, while only certain representative compounds, compositions, and method steps disclosed herein are specifically described, other combinations of the compounds, compositions, and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein or less, however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.

[0780] The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of’ and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments of the invention

[0781] 1'22Attorney Docket No. 10877-004W01

[0782] and are also disclosed. Other than where noted, all numbers expressing geometries, dimensions, and so forth used in the specification and claims are to be understood at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, to be construed in light of the number of significant digits and ordinary rounding approaches.

[0783] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.

[0784] 1'23

Claims

1. Attorney Docket No. 10877-004W01WHAT IS CLAIMED IS:

1. A method for modulating aryl hydrocarbon receptor (AhR) activity in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound defined by Formula I or Formula II:or a pharmaceutically acceptable salt or prodrug thereof, whereinQ is selected from one of the following:Z is selected from -CH2-, -CH2CH2-, and -C(=O)-;A is, individually for each occurrence, selected from N and CH;R1is selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl sulfinyl, C1-C4 alkylsulfonyl, a 5-membered heteroaryl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxy carbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R?R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, and the 5-membered heteroaryl ring are each optionally substituted with from 1 to 4 RAgroups, or R1and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R2is selected from halogen, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkoxy, -P(=O)R'R8, and -L-RB, wherein the C1-C4 alkoxy group is optionally substituted with from 1 to 4 RAgroups, or wherein R2and R4, together with theAttorney Docket No. 10877-004W01atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R3is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy;R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy;R5and R6are independently selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R5and R6, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups, or R' is selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 R '• groups and R6and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R7and R8are independently C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or Rzis C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R8and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C i-C 4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8;L is a bivalent linldng group comprising from 2 to 10 atoms;RBis selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl sulfinyl, C1-C4 alkylsulfonyl, a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2. NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R / R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, the 5-7 membered aryl ring, the 5-7 membered heteroaryl ring, the 3-7 membered cycloalkyl ring, and the 3-7 membered heterocycloalkyl ring are each optionally substituted with from 1 to 4 RAgroups;n is an integer from 0 to 4; andm is an integer from 0 to 4.Attorney Docket No. 10877-004W01The method of claim 1, wherein A is CH.

3. The method of any one of claims 1-2, wherein R is a halogen, such as fluoro.

4. The method of any one of claims 1-2, wherein R2is hydroxyl.

5. The method of any one of claims 1-2, wherein R2is one of the following6. The method of claim 5, wherein R2is one of the followingAttorney Docket No. 10877-004W017. The method of claim 6, wherein R2is8. The method of any one of claims 1-2, wherein R2is -P(=O)R7R8.

9. The method of any one of claims 1 -8, wherein m is 0.

10. The method of any one of claims 1-8, wherein m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

11. The method of any one of claims 1-10, wherein n is 0.

12. The method of any one of claims 1-11, wherein R1is a cyano group13. The method of any one of claims 1-11, wherein R1is -P(=O)R7R8.

14. The method of any one of claims 1-11, wherein R1is a sulfonamide group, a methanesulfonamido group, a protected amino group, or a carbamate group.

15. The method of any one of claims 1-11, wherein R1is a carboxy group, an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

16. The method of any one of claims 1-11, wherein R1is a C1-C4 alkoxy group substituted with a carboxy group, a sulfonamide group, a methanesulfonamido group, an amino group, a protected amino group (e.g., an alkyloxycarbonylamino group such as -NH- CO-O-tBu), an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

17. The method of any one of claims 1-11, wherein R1is a tetrazole ring.Attorney Docket No. 10877-004W0118. The method of any one of claims 1-11, wherein R1is -O-CH2-CO2H, -CH2-NH-SO2Me), -NHSChMe), -CH2CO2H), or carboxy.

19. A method for modulating aryl hydrocarbon receptor (AhR) activity in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound defined by Formula III:Formula IIIor a pharmaceutically acceptable salt or prodrug thereof, whereinR4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; m is an integer from 0 to 4;Y is selected from a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, each optionally substituted with one or more substituents individually selected from RA; andRAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alk l carbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8.

20. The method of claim 19, wherein m is 0.

21. The method of claim 19, wherein m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

22. The method of any one of claims 19-21, wherein Y is a phenyl ring.

23. The method of any one of claims 19-21, wherein Y is an optionally substituted thiophenyl ring.Attorney Docket No. 10877-004W0124. The method of any one of claims 1 -23, wherein the method comprises a method of reducing fibrosis in a cell or tissue.

25. The method of any one of claims 1-23, wherein the method comprises a method of treating a fibrotic condition in a subject in need thereof, a method of treating obesity in a subject in need thereof, a method of treating kidney disease in a subject in need thereof, a method of treating pulmonary arterial hypertension (PAH) in a subject in need thereof, a method of treating chronic kidney disease (CKD) in a subject in in need thereof, a method of treating COPD in a subject in need thereof, a method of treating pulmonary fibrosis in a subject in in need thereof, a method of treating liver fibrosis in a subject in in need thereof, a method of treating obstructive sleep apnea in a subject in in need thereof, a method of treating heart failure in a subject in in need thereof, a method of treating skin disease, such as atopic dermatitis and / or psoriasis in a subject in in need thereof, a method of treating colitis in a subject in in need thereof, a method of treating sarcopenia and / or fatty liver disease in a subject in in need thereof, a method of treating acute stroke in a subject in in need thereof, a method of treating Alzheimer’s disease in a subject in in need thereof, a method of treating Parkinson’s disease in a subject in in need thereof, a method of treating traumatic brain injury (TBI) in a subject in in need thereof, a method of treating cancer in a subject, a method of reducing tumor progression in a subject, a method of treating an autoimmune disease in a subject, such as allergic rhinitis and Hashimoto’s thyroiditis, or a combination thereof.

26. A compound defined by Formula I or Formula II:or a pharmaceutically acceptable salt or prodrug thereof, whereinQ is selected from one of the following:Attorney Docket No. 10877-004W01Z is selected from -CH₂-, -CH2CH2-, and -C(=O)-;A is, individually for each occurrence, selected from N and CH;R1is selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkyl sulfonyl, a 5-membered heteroaryl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, and the 5-membered heteroaryl ring are each optionally substituted with from 1 to 4 R ' groups, or R1and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R2is selected from halogen, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkoxy, -P(=O)R7R8, and -L-RB, wherein the C1-C4 alkoxy group is optionally substituted with from 1 to 4 RAgroups, or wherein R2and R4, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R3is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy;R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy;R5and R6are independently selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R5and R6, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups, or R' is selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R6and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R7and R8are independently C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R7is C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R8and R3, together with the atomsAttorney Docket No. 10877-004W01to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkyl sulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SChNR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7RS;L is a bivalent linking group comprising from 2 to 10 atoms;RBis selected from halogen, cyano, hydroxyl, amino, C1-C4 alkyiamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=())R'R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, the 5-7 membered aryl ring, the 5-7 membered heteroaryl ring, the 3-7 membered cycloalkyl ring, and the 3-7 membered heterocycloal kyi ring are each optionally substituted with from 1 to 4 RAgroups;n is an integer from 0 to 4; andm is an integer from 0 to 4;with the proviso that when R2is hydroxy, fluoro, oris not carboxy; andwith the provisio that the compound is not the following27. The compound of claim 26, wherein A is CH.

28. The compound of any one of claims 26-27, wherein R2is a halogen, such as fluoro.

29. The compound of any one of claims 26-27, wherein R2is hydroxyl.Attorney Docket No. 10877-004W0130. The compound of any one of claims 26-27, wherein R2is one of the following31. The compound of claim 30, wherein R2is one of the following32. The compound of claim 31, wherein R2is33. The compound of any one of claims 26-27, wherein R2is -P(=O)R?R8.Attorney Docket No. 10877-004W0134. The compound of any one of claims 26-33, wherein m is 0.

35. The compound of any one of claims 26-33, wherein m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

36. The compound of any one of claims 26-35, wherein n is 0.

37. The compound of any one of claims 26-36, wherein R1is a cyano group38. The compound of any one of claims 26-36, wherein R1is -P(=O)R7R8.

39. The compound of any one of claims 26-36, wherein Rlis a sulfonamido group, a metlianesulfonamido group, a protected amino group, or a carbamate group.

40. The compound of any one of claims 26-36, wherein R1is a carboxy group, an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

41. The compound of any one of claims 26-36, wherein Rlis a C1-C4 alkoxy group substituted with a carboxy group, a sulfonamido group, a methanesulfonamido group, an amino group, a protected amino group (e.g., an alkyloxycarbonylamino group such as -NH-CO-O-tBu), an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

42. The compound of any one of claims 26-36, wherein R1is a tetrazole ring.

43. The compound of any one of claims 26-36, wherein Rlis -O-CH2-CO2H, -CH2-NH- SO2Me), -NHSChMe), -CII2CO2II), or carboxy.

44. A compound defined by Formula III:Attorney Docket No. 10877-004W01Formula IIIor a pharmaceutically acceptable salt or prodrug thereof, whereinR4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; m is an integer from 0 to 4;Y is selected from a thiophenyl ring optionally substituted with one or more substituents individually selected from R andRAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, alkylsulfinyl, alkylsulfonyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkyl aminocarbon yl.

45. The compound of claim 44, wherein ni is 0.

46. The compound of claim 44, wherein m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

47. The compound of any one of claims 44-46, wherein Y is a phenyl ring.

48. The compound of any one of claims 44-46, wherein Y is an optionally substituted thiophenyl ring.

49. The compound of claim 26 or 44, wherein the compound comprises one of the following:Attorney Docket No. 10877-004W01Attorney Docket No. 10877-004W0150. A pharmaceutical composition comprising a compound of any one of claims 26-49.

51. A method of treating cancer in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound defined by Formula I or Formula II:or a pharmaceutically acceptable salt or prodrug thereof, whereinQ is selected from one of the following:Z is selected from -CH₂-, -CH2CH2-, and -C(=O)~;Attorney Docket No. 10877-004W01A is, individually for each occurrence, selected from N and CH;R1is selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, a 5-membered heteroaryl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxy carbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC( =O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=())R'R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, and the 5-membered heteroaryl ring are each optionally substituted with from 1 to 4 RAgroups, or R!and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R2is selected from halogen, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkoxy, -P(=O)R'R8, and -L-RB, wherein the C1-C4 alkoxy group is optionally substituted with from 1 to 4 RAgroups, or wherein R2and R4, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R‘ is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy;R4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy;R5and RDare independently selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or R7and Rb, together with the atoms to which they are attached, form a 5-7 membered carbocyclic or hetercyclic ring optionally substituted with from 1 to 4 RAgroups, or R7is selected from hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R6and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;R7and R8are independently C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups, or Rzis C1-C4 alkyl, wherein the C1-C4 alkyl group is optionally substituted with from 1 to 4 RAgroups and R8and R3, together with the atoms to which they are attached, form a 5-7 membered hetercyclic ring optionally substituted with from 1 to 4 RAgroups;RAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkyl carbonyl, C1-C4 alkoxycarbonyl,Attorney Docket No. 10877-004W01aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 di alkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7R8;L is a bivalent linking group comprising from 2 to 10 atoms;RBis selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkyl sulfonyl, a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, - NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, -S(=O)(=NR5)R7, -NH-S(=O)(=NR5)R7, and -P(=O)R7R8, wherein the C1-C4 alkyl, the C1-C4 alkoxy, the 5-7 membered aryl ring, the 5-7 membered heteroaryl ring, the 3-7 membered cycloalkyl ring, and the 3-7 membered heterocycloalkyl ring are each optionally substituted with from 1 to 4 RAgroups;n is an integer from 0 to 4; andm is an integer from 0 to 4.

52. The method of claim 51, wherein A is CH.

53. The method of any one of claims 51 -52, wherein R2is a halogen, such as fluoro.

54. The method of any one of claims 1-52, wherein R2is hydroxyl.

55. The method of any one of claims 1-52, wherein R2is one of the followingAttorney Docket No. 10877-004W0156. The method of claim 55, wherein R2is one of the following57. The method of claim 56, wherein R2is58. The method of any one of claims 1-52, wherein R2is -P(=O)R7R8.

59. The method of any one of claims 1-58, wherein m is 0.Attorney Docket No. 10877-004W0160. The method of any one of claims 51-58, wherein m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

61. The method of any one of claims 1 -60, wherein n i s 0.

62. The method of any one of claims 51-61, wherein R1is a cyano group63. The method of any one of claims 51-61, wherein R1is -P(=O)R'RS.

64. The method of any one of claims 51-61, wherein R1is a sulfonamide group, a methanesulfonamido group, a protected amino group, or a carbamate group.

65. The method of any one of claims 1-61, wherein R1is a carboxy group, an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

66. The method of any one of claims 51 -58, wherein R1is a C1-C4 alkoxy group substituted with a carboxy group, a sulfonamide group, a methanesulfonamido group, an amino group, a protected amino group (e.g., an alkyloxycarbonylamino group such as -NH-CO-O-tBu), an alkylcarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, or an alkylaminocarbonyl group.

67. The method of any one of claims 51 -58, wherein R1is a tetrazole ring.

68. The method of any one of claims 51-58, wherein R1is -O-CH2-CO2H, -CH2-NH- SO2Me), -NHSChMe), -CH2CO2H), or carboxy.

69. A method of treating cancer in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound defined by Formula III:Attorney Docket No. 10877-004W01Formula IIIor a pharmaceutically acceptable salt or prodrug thereof, whereinR4is selected from halogen, cyano, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy; m is an integer from 0 to 4;Y is selected from a 5-7 membered aryl ring, a 5-7 membered heteroaryl ring, a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocycloalkyl ring, each optionally substituted with one or more substituents individually selected from RA; andRAis, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, carboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, aminocarbonyl, C1-C4 alkylaminocarbonyl, C1-C4 dialkylaminocarbonyl, -SO2NR5R6, -NHC(=O)OR7, -NHC(=O)R5R6, -NHSO2NR5R6, and -P(=O)R7RS.

70. The method of claim 69, wherein m is 0.

71. The method of claim 69, wherein m is 1 and R4is C1-C4 alkyl group, such as a methyl group.

72. The method of any one of claims 69-71, wherein Y is a phenyl ring.

73. The method of any one of claims 69-71, wherein Y is an optionally substituted thiophenyl ring.

74. The method of any one of claims 1-73, wherein the method further comprises co¬ administering an additional anticancer agent.

75. The method of claim 74, wherein the additional anticancer agent comprises a small-molecule chemotherapeutic selected from the group consisting of platinum-based compounds (e.g., cisplatin, carboplatin, oxaliplatin), taxanes (e.g., paclitaxel, docetaxel,Attorney Docket No. 10877-004W01cabazitaxel), antimetabolites (e.g., 5 -fluorouracil, capecitabine, gemcitabine, pemetrexed), and anthracy clines (e.g., doxorubicin, epirubicin).

76. The method of claim 74, wherein the additional anticancer agent comprises a targeted-therapy agent selected from the group consisting of a tyrosine-kinase inhibitor, a PARP inhibitor, an mTOR inhibitor, a STAT inhibitor, a KRAS inhibitor, and a PI3K inhibitor.

77. The method of claim 74, wherein the additional anticancer agent comprises an immunotherapy agent selected from the group consisting of an immune-checkpoint inhibitor (anti-PD-1, anti-PD-Ll, or anti-CTLA-4 antibody), a chimeric-antigen-receptor (CAR) T-cell therapy, a bispecific T-cell engager, an oncolytic virus, a therapeutic cancer vaccine, and a cytokine therapy.

78. The method of claim 74, wherein the additional anticancer agent comprises a hormone-therapy agent selected from the group consisting of a selective estrogen-receptor modulator, an aromatase inhibitor, an androgen -receptor antagonist, and a gonadohopin-releasing-hormone agonist or antagonist.

79. The method of claim 74, wherein the additional anticancer agent comprises a biologic anticancer agent selected from the group consisting of a naked monoclonal antibody, an antibody-drug conjugate, a fusion protein, a therapeutic cancer vaccine, and a cell -based therapy (e.g., CAR-T, tumor-infiltrating lymphocyte).

80. The method of any one of claim 51-79, wherein the compound defined by Formula I, Formula II, or Formula III is administered in an effective amount to inhibit SIN3A expression, thereby reducing immune suppression by T regulatory and Thl7 cells and increasing expression of MHC-1 (HLA-1, HLA-2).

81. The method of any one of claims 51-80, wherein the cancer is selected from brain cancer, breast cancer, colorectal cancer, esophageal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, melanoma, pancreatic, prostate and GI cancer.